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ABSTRACT 
THE SYNTHESIS AND CHARACTERISATION OF NEW 
MACROCYCLIC COMPLEXING AGENTS FOR USE IN TUMOUR 
TARGETING 
Macrocyclic complexing agents have been synthesised for the 
binding of indium(III), gallium(III), 3^trium(III), gold(I), silver(I) and 
rhenium(V) and a comparative study has been made between the 
macrocyclic complexing agents, I8N4S2, 18N4S2Me4, I8N4O2 and 
18N402Me4 and their ability to bind silver (I). 
The gallium(III) and indium(III) complexes of 9N3C3Me3 and 
9N3C3PI13 have been investigated extensively both in vitro and in vivo. 
The stability of the complexes have been characterised using ^iGa NMR, 
1 H NMR, U.V. spectral analysis, ligand protonation constants, and 
complex binding constants. A full X-ray crystallographic structural 
determination has been obtained for the indiima-9N3C3Me3 complex. 
Following confirmation of the excellent binding characteristics of the 
9N3C3Me3 and 9N3C3Ph3 complexing agents, the in vivo kinetic 
stability of the indiimi and gallium complexes has been investigated. The 
9N3C3Me3 complexes were exceptionally stable and cleared rapidly (99% 
within 24 hrs) via the renal excretion pathway. The complexes of the 
9N3C3Ph3 were less stable and also showed a preference for clearance 
via the kidneys. Further to this, the timiour localising properties in a 
human melanotic melanoma has been investigated for the 6 7 Q Q . 
9N3C3Ph3 complex. The complex has shown a preference for. tumour 
localisation, although a low tumour: blood ratio (1:1) may prohibit its 
application for ttmiour targeting. 
The stability constants of the silver(I) complexes of I8N4S2, 
18N4S2Me4, I8N4O2 and 18N402Me4 have been measured both in 
methanolic and aqueous media. The [Ag-18N4S2Me4]+ complex stability 
(log K M L = 14.6) is the highest stability constant recorded in methanol. In 
aqueous media, of the four complexes, the [Ag-18N4S2]'*" is the most stable 
(log K M L = 1 0 . 4 ) a reversal of the observed order of complex stability in 
methanol. 
The stability of the new jrttriumdll) complexing agent has been 
ascertained using ^H NMR and HPLC radiometry and proved to be 
insufficiently stable for in vivo use, and was easily displaced by DTPA in 
a trial experiment. 
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X I V 
CHAPTER ONE 
INTRODUCTION 
1.0 INTRODUCTION 
1.1 THE NEED FOR IMPROVED CANCER THERAPY 
1.1.1 What Is Cancer?(l,2) 
Cancer is a disease of the cell. It normally appears as a 
growth or tumour, a large mass of tissue cells. The tumour is the 
result of a multi-stage process known as carcinogenesis. 
Carcinogenesis involves, firstly, an initiation step by a carcinogen, 
followed by the second stage, the activation of the damaged cell. The 
time span between the appearance of the tumour and the initiation 
step may be many years. Carcinogens can be physical (e.g. U.V. or 
X-Ray radiation) or chemical (e.g. benzene). What is common to 
both is the ability to severely damage celliilar DNA. 
The activation step is less well understood and may be the 
result of environmental factors (e.g. diet, exposure to sunlight, 
nicotine and alcohol abuse). However there is some evidence that 
susceptibility runs in families, suggesting genetic inheritance. 
Another possibility is the effect of certain viruses oh the 
immune system which may inhibit the body's natural defence 
against a mutant cell. Although there is much research and 
debate over the actual cause of the cell activation, it is clear once 
the cell is activated a tiunour will begin to grow. 
The cells of a tumour no longer respond to normal growth 
mechanisms and may replicate -their natural function, at a rate 
which far exceeds the normal rate, producing a growth and 
possibly damaging the surrounding tissues. If the tumour 
remains in a fixed position, it is known as a benign tumour. If the 
tumour fragments and invades other organs, it is a malignant 
2 
tumour. The process of fragmentation is known as metastasis. 
Metastasis is very difficult to control, and is responsible for the 
major number of deaths of those people that die from cancer. 
1.1 .^ The Incidence Of Cancer(3) 
Cancer is a very common disease and was responsible for 
163,000 deaths in the U.K. in 1990. In the U.K. alone, more than 
250,000 people are diagnosed with cancer each year. The incidence 
of the ten most common forms of cancer are given in figure 1.1 (A). 
Present statistics show that one in three people will develop cancer 
during their lifetime. Most (70%) of the people who contract cancer 
are over 60 years old. 
INCIDENCE: Number of New Cases, U.K. 1986 
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Figure 1.1(A) The Incidence Of The Ten Most Common Forms Of 
Cancer In The U.K., 1986.(^^ * "Skin" does not include malignant 
melanoma. 
Survival from cancer depends greatly on the stage at which i t 
is diagnosed; the more advanced the disease, the more likely i t is 
that metastasis has occurred and that other tumours are 
developing away from the primary site. Figure 1.1(B) shows the 
five year relative survival rates for the ten most common forms of 
cancer. 
SURVIVAL: 5 Year Relative Survival Rates, 
England and Wales, 1981 
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Figure 1.1(B) The Five Year Survival Rate For Patients With The 
Ten Most Common Forms Of Cancer. England and Wales, 1981/^^ 
*"Skin"'does not include malignant melanoma. 
Figure 1.1(C) shows the ten cancers which cause the most 
deaths in men and women. With men, lung cancer is the major 
cause of death from cancer (one third), whereas with women, 
breast cancer is the largest cause of death for women who contract 
cancer (one fifth). 
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Figure 1.1(A) The Number Of Deaths From The Ten Most Common 
Forms Of Cancer In The U.K., 1990.(2) 
1.1.3 The Treatment Of Cancer(l) 
Surgery can be used to remove a tumour, and is very effective 
in the treatment of benign tumours. Radiotherapy - the use of X-
rays and Gamma-rays, and chemotherapy - the use of drugs (e.g. 
cis-platin and 5-fluorouracil) are used to combat benign tumours in 
situ. These techniques do meet with some success, for example, 
more than 80% remission is occurring for testicular and ovarian 
cancers, but this degree of success is limited to the treatment of a 
small group of cancers. In fact lung, colon, rectum and prostate 
cancers, are virtually untreatable using chemotherapy. Because 
chemotherapy involves the destruction of the DNA of tumour cells, 
a side effect of the technique is the destruction of healthy tissue and 
possibly vital organs. 
The need for new treatment is clear. Those cancers which are 
currently untreatable, surgery aside, call for new methods for their 
treatment, and the intrinsic danger of chemotherapy puts the 
emphasis on finding a new cell-selective approach to the treatment 
of cancer. One such approach is to specifically target the cancer 
cells using the molecular blood hounds - monoclonal antibodies. 
1^ ANTIBODIES 
1^ .1 Introduction 
Antibodies are proteins known as immunoglobulins. They are 
produced in vertebrates by white blood cells called B-lymphocytes in 
response to invading pathogens or other foreign substances. T-
lymphocytes alert the B-cell to the presence of the foreign substance; 
the B-cells produce huge quantities of antibodies which recognise 
and subsequently give rise to their destruction by the white killer 
cells, or macrophages^^\ The mechanism of antigen recognition is 
achieved by binding to the surface with partial structures 
(determinants) in a highly specific fashion. 
—- Binding Sites 
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Figure 1.2 Schematic Diagram Of An Antibody 
Antibodies, in their simplest form, consist of two identical 
heavy chains and two identical light chains linked together by 
disulphide bridges in a complex three dimensional structure. The 
antibody has three regions: of these two are Fab regions (ab stands 
for antigen binding), consisting of one light chain and part of the 
heavy chain. Each Fab is a single binding site, thus each molecule 
is bivalent, giving rise to two identical binding sites. The third 
region is the Fc or constant region, consisting of two parts of the 
heavy chains. The Fc fragment mediates the effector functions by 
initiating a sequence of immunological reactions which lead to the 
elimination of the antigen. I t is the spatial arrangement of the 
amino acid residues in the Fab fragments that determine the 
individual binding specificity of the antibody. 
1.2.2 Monoclonal Antibodies And Cancer Therapy 
Altered Carbohydrate^ ^ Mutant protein 
Proliferation-linked 
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Figure 1.3 Target Antigens 
A tumour cell expresses glycoproteins and glycolipids (Figure 
1.3) on its surface which are not normally expressed. The body's 
immune system should recognise these as antigenic and the 
response process described above should take place. Often this is 
not the case and the mutant cell is allowed to proliferate causing 
the growth of a tumour. This fact in itself demands to be 
understood. Why is i t that the cell is not recognised and destroyed? 
Aside from this apparent malfunction of the immune system, 
the presence of these glycolipids and glycoproteins can be 
advantageous. I f an antibody, specific to these unique antigens. 
could be labelled with an imaging agent (Radioimmuno-
scintigraphy, RII) or a therapeutic agent (Radioimmunotherapy, 
RIT), this would provide us with a cell selective approach to the 
treatment of cancer. 
The Radiolabelled 
Macrocycl ic-Antibody 
Conjugate Delivers a 
Potentially Sterilising 
Dose of Radiation 
Tumour Cell 
Figure 1.4 Radioimmunotherapy 
radioactive 
antibody injocted 
into t/Bliont 
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metastasis surgical removal 
detected of primary tumour 
and metastasis 
Figure 1.5 Radioimmunoimagingf^^ 
Nearly one hundred years ago, Ehrlich postulated that i t may 
be possible to target therapeutic agents at specific tissues. He 
suggested that antibodies would be likely agents for the job, but vmtil 
the 1970's this was an impossible task. At that time, i t was 
impossible to raise a specific antibody for a specific antigen - a 
monoclonal antibody. 
In 1975, Kohler and Milstein(7) were responsible for solving 
this problem. They discovered, that i f a plasma-B-cell could be 
immimised against one antigen and fused to a malignant myeloma 
cell (a hybridoma), the resultant hybrid is capable of maintaining 
the characteristics of both cells, namely, to produce an abundance 
of antibodies specific to one antigen, (Figure 1.6). Since then, this 
hybridoma technology has made i t possible to produce large 
quantities of monoclonal antibodies. 
Immunize mouse 
myeloma 
cells in 
^ ^ ' i:;] culture 
\
isolate / 
spleen / 
cells / 
e c3 c» % mixture of hytjrid 
• • ^ » » ; and unlused cells 
\ 2. HAT SELECTION 
• • many clones of 
, • , hytjridoma cells 
/ / 3. CLONING & 
|-7rhr1-rrsl SCREENING 
. o o 
single done of 
hytmdoma cells 
—^-v-*"C growth of hybridoma cells 
mice or m culture 
monodonal 
antibody 
Figure 1.6 Hybridoma Technology(^) 
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1 .^3 Chimaeric Antibodies(8,9) And Antibody 
Fragments(lO) 
Kohler and Milstein used mice for their initial work. From the 
diagram, i t is shown that part of the process involves injecting a 
tumour antigen into a mouse, from which the resultant 
lymphocytes are taken. The antibodies produced by a mouse are 
murine antibodies and are recognised by the human immune 
system as foreign or immunogenic. I f they are used in vivo they 
may cause an immune response that would obliviate the desired 
process. I f a fully human antibody is required, somebody must be 
inoculated with the tumour antigen. This obviously poses a severe 
difficulty. 
This problem has been partially overcome by employing 
humanised or chimaeric antibodies. These antibodies have the 
hypervariable region of the mouse for the tumour antigen, but 
human constant and variable regions. These antibodies should 
prove less immunogenic than the murine antibodies. 
Important advances have also taken place in the production of 
antibody fragments directly from E-colidO). An antibody fragment, 
as the name suggests, is just the binding part of the antibody. 
Figure 1.7 shows the possible fragments. As the constant region 
does not take part in the recognition process, i t is disposable. Apart 
from reducing immunogenicity, their smaller size should improve 
transport time to the tumour site and also allow better access into 
more hindered sites. These antibody fragments are also cleared 
more rapidly from the blood and eventually from the body, and 
should improve the tumour : background ratio. 
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Figure 1.7 Antibody Fragments of an IgG 
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1.3 RADIOIMMUNOTHERAPY AND 
RADIOIMMUNOIMAGING 
1.3.1 Introduction 
Tumour targeting employing antibody conjugated radiolabels, 
allows both therapy and imaging to be achieved within a single 
treatment protocol(ll'l2). The use of monoclonal antibodies provides 
a method of achieving a high target: non-target ratio. To facilitate 
the successful use of these techniques a n;imber of factors must be 
addressed. The method of radiolabelling is of crucial importance 
(sectionl.3.3), as is the choice of a suitable radiolabel. 
1.3.2 The Choice Of RadionucUde (13,17) 
1.3.2.1 Radioimmvinoimaging 
When imaging is intended, what is required is a high photon 
density to maximise the resolution of the image produced (^3)^ For 
therapeutic use, a radionuclide with high energy is required. 
More specifically, for imaging, the minimum possible 
interaction with the tissue is crucial. Also the nature of the 
radiation emitted must allow an easy and preferably cheap method 
of detection. As most in-house detectors are tuned for the detection 
of technetiimi 99m (E = 141 keV), a photon energy close to this value 
would be beneficial. Gamma and positron emitting isotopes of 
sufficient energy fall into this category. Detection of a single photon 
emitter can take place using a conventional Anger camera, with a 
resolution of 1 cm, which can be improved using a tomographic 
detector. A positron colliding with another electron creates two 
13 
colinear photons of 511 keV, and gives improved resolution (3mm) 
using a positron emission tomography scanner^"^). 
Common requirements for both imaging and therapy isotopes are 
as follows: 
1) A half-life of between 6 hours and 8 days. The 
physical process of getting the conjugated antibody 
(mass = 150000) is relatively slow, ty2 = 24 hours. 
2) The production of stable daughter products. 
3) Must be cheap and readily available. 
4) Must be carrier free (not contaminated with stable 
isotopes of the element) to achieve maximum dosage for 
the tumour. 
5) The radionuclide must possess the appropriate 
chemical properties to enable its attachment to the 
antibody with a specially chosen complexing agent. 
A list of possible isotopes is given below. 
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Radionuclide Tl /2 E photon 
(%) 
123l 13.2 hr 159 (83) 
125l 60.0 days 27(138) 
35(7) 
131p 8.05 days 364(82) 
113min 1.68 hr 391(66) 
Hlln 2.83 days 171(88) 
247(94) 
99mxc 6.02 hr 141(89) 
67Ga 3.25 hr 184(24) 
82Rb (PET) 1.4 hr 511 
64Cu**(PET) 12.8 hr 511(120) 
68Ga (PET) 1.20hr 511(178) 
* 1311 has an accompanying P' emission Emax 0-188 MeV 
** 64cu has an accompanying p ' emission Emax 0-^ '^  
Table 1.1 List Of Candidates For Tumour Imaging 
Gallium 67 And Indium 111 
Despite being more expensive and less easy to detect than 
technetium 99m, both of these isotopes have a convenient 
coordination chemistry, and suitable half-lives making them very 
strong candidates for imaging. 
1.3 .^2 Radioimmunotherapy 
For radioimmunotherapy, the antibody-radiolabel conjugate 
needs to be able to deliver a sterilising dose of radiation 4;hat is of 
sufficient energy to cause cleavage of the cellular DNA. This 
constitutes a dosage of between 600 to 40000 rads. This suggests that 
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an alpha or beta emitter is the most suitable. There is one more 
consideration that must be borne in mind -that of the tumour 
morphology(^'^^\ I t is impossible for any one nuclide to meet the 
morphological demands of every tumour. For instance, leukaemia 
is a single cell cancer, and i f a long range emitter was employed, 
many healthy cells in the local environment would be damaged. In 
this case i t would be best to employ a short range beta or alpha 
emitter. For large and dense tumours, a long range beta emitter 
woiild be best. This would enable the whole tumour to be irradiated, 
even when antigen distribution is non-uniform. Figure 1.7 
The Area is Irradiated 
by Crossfire from 
Adjacent Sites 
No Glycolipids 
Expressed in 
this Area 
Figure 1.7 The Remote Part Of The Tumour Where No Tumour 
Specific Antigens Exist Is Irradiated By The Long Distance Beta 
Emitter - Crossfire. 
The problem with alpha emitters is that they have a very short 
range (1 to 2 cell diameters), and therefore are not suitable for most 
tumours. Also, many alpha emitters produce potentially harmful 
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daughter products, or possess undesirable chemical properties. 
Beta emitters that may be suitable are given in table 1.2. 
Isotope Half Life Bmax Mean Gamma 
hr (Mev%) Range 
mm 
(KeV %) 
67Cu 62 0.40 (45) 0.2 93 (17) 
0.48 (35) 184(47) 
0.58 (20) ^ 
90Y 64 2.25 (100) 3.9 — 
l l l A g 179 1.04 (93) 1.1 342(6) 
0.69 (6) 
1311 193 0.61 (90) 0.4 364(79) 
16lTb 166 0.45 0.3 75 
0.57 57 (21) 
0.58 
188Re 17 1.96 3.3 155 
2.12 
199AU 75 0.25 (22) 0.1 158 (76) 
0.3 (72) 
Table 1.2 Possible Isotopes For Use In RIT 
Rhenium 188 
Of these candidates, rhenium 188 is a potential candidate. 
Unfortunately, the low oxidation state chemistry is rather complex 
and difficult synthetically, although stable cationic Re(V)02 
complexes wi th 1,4,8,11- tetrazaundecane have been 
characterised^ 
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Gold 199 And SUver 111 
Gold 199 has similar problems to the rhenium 188 isotope 
associated with its usage, in that its coordination chemistry is 
complicated by the fact that whilst Au(III) complexes are 
kinetically inert, they are strongly oxidising and Au(I) complexes -
preferring a linear coordination geometry - tend to disproportionate 
readily. However, silver 111 is much more amenable to 
complexation. I f a more stable complex can be made^l^)^ this 
isotope could prove to be a very effective therapeutic agent. 
Yttrium 90 
Yttrium 90 is particularly well suited to therapy. It has a 
suitable half life (ti/2 = 64 hours) and is a pure beta emitter of 
intermediate energy (2.3 MeV). The daughter products are stable 
and i t is readily available from a generator from its parent 
strontium 90. 
Because yttrium 90 has a range of 3.9mm, i t is very suitable for 
lung, ovarian(19,20)^ colorectaK^D and breast cancer. However i f i t 
becomes dislodged from the antibody, i t can build up in the bone 
marrow causing the potentially lethal myelosuppression. I t is 
crucial that the radiometal is bound irreversibly to the antibody. 
1.3.3 Bifimctional Complexing Agents 
In order to achieve successful tumour targeting the radiolabel 
must be irreversibly bound to the antibody. To achieve this a 
bifunctional complexing agent is required (22,23). A bifunctional 
complexing agent consists of an activated moiety that can be 
conjugated to an antibody, possibly via the NH2 group of a lysine 
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residue. This is combined with a complexing agent specifically 
chosen to bind the radionuclide irreversibly. (Figure 1.8) 
H 
I 
-N 
O 
Antibody 
NH2 o 
O R 
Radiometal-Macrocycle 
Conjugate 
Antibody 
Figure 1.8 Radiolabelling A Monoclonal Antibody 
The choice of complexing agent is governed by the radiometal 
ion that will be used as the radiolabel(24) ig impossible for any 
one complexing agent to form stable complexes with all of the 
choice radiometals. Each metal ion will have a distinctive 
coordination requirement comprising of a specific ntmiber and type 
of donor atoms with a suitable spatial arrangement to achieve 
coordination saturation. Previous workers concentrated on this one 
ligand approach employing functionalised EDTA(25,26) or DTPA(27) 
as the complexing agent for all choice radiolabels. The instability of 
such complexes in vivo predetermined the use of selectively tailored 
complexing agents. The problems encountered with EDTA and 
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DTPA, namely acid catalysed decomplexation in vivo, may be 
partially or completely solved by a judicious choice of a macrocyclic 
complexing agent(28,29). 
20 
1.4. MACROCYCLIC COMPLEXING AGENTS. 
1.4.1 Introduction 
A macrocycle is a polydentate ligand, accommodated by a 
cyclic array of atoms containing at least three donor atoms; the 
macrocyclic ring containing at least nine atoms, (Figure 1.10). 
Macrocyclic complexing agents (29) are a better choice for in vivo 
work for a number of reasons. 
1.4.2 Macrocycles - Superior Complexing Agents ? 
Macrocycles form complexes with metals that are usually of 
greater thermodynamic stability than their acyclic counterparts(32) 
such as EDTA and DTPA. 
Figure 1.10 A Macrocyclic Complex 
We should expect an extra increase in the stability constant, 
due to the formation of another chelate ring - the chelate effect. 
Polydentate chelating agents are always thermodynamically more 
stable than monodentate ligands. The example below clearly 
demonstrates this effect: 
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Ni2+(aq) + 6NH3(aq) ^ Ni(NH3)62++ aq logK=8.6 
Ni2+(aq) + 3en(aq) ^ Ni(en)32++aq logK=18.2 
The introduction of three chelate rings produces a large 
increase in the stability constant (K) and therefore a large decrease 
in the Gibbs free energy(AG°), 
AG° = - RTlnK = AH° - TAS° 
The free energy of a reaction is a combination of the enthalpy 
(AH°) and the entropy (AS°) of the reaction. The enormous increase 
in the stability constant is a combination of these parameters. 
Although the main effect, in this case, is due to the increase in 
translational entropy of the system when monodentate ligands are 
replaced by the polydentate ligand. 
1.4^  The Macrocyclic Effect 
Macrocyclic complexes are, almost always, kinetically and 
thermodynamically more stable than their acyclic analogues. The 
increase in stability found with a macrocyclic ligand far outweighs 
that which might be expected with the addition of another chelate 
ring. Cabbiness and Margerum(33) have reported that the 
copper(II) complex of tet-a was 10,000 times more stable than the 
copper(II) complex of the acyclic of 2,3,2-tet. 
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NH HN. ^ N H H N ^ 
NH HN NH HN 
Cyclam tet-a 
NH HN 
NH2 H2N 
2,3,2-tet 
Complex LogK 
Cu(2,3.2-tet)2+ 23.9 
Cu(tet-a)2+ 28 
This effect has been primarily ascribed to an increased entropy 
of complexation. 
The Ni(II) complex of cyclam and its acyclic analogue have 
also been compared by Margerum(33). 
Complex logK AH/kcalmol-1 AS/calK-^ mole-^  
Ni(2,3,2-tet)2+ 
Ni(cyclam)^+ 
15.8 
22.2 
-13.0 
-19.4 
7.4 
-2.0 
In this case the enthalpic factor dominates and the 
macrocyclic effect results in a stability that is of the order of 10"^  
greater than its acyclic analogue. 
The extra stability of macrocyclic complexes may be attributed 
to either favourable enthalpy or favourable entropic contributions. 
In many cases it is a mixture of both, but often the entropie factor is 
the main contribution. The conformational change an acyclic 
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complexing agent must undergo to form the complex, far 
outweighs that of the already pre-organised macrocycle. 
Kinetic Stability is also associated with macrocyclic 
complexing agents. Most macrocycles show a kinetic inertness and 
do not readily dissociate, even in acidic conditions. These kinetic 
properties may also effect the equilibrium constant of such 
complexes. For instance, it is possible with the open chain series to 
undergo S N I displacements, where the displaced donor can be 
readily solvated. With the macrocyclic ligand, this is much more 
difficult because of the rigidity. The cycle does not allow the 
passage of incoming ligands, or the subsequent solvation and 
stabilisation of the displaced donor moiety. 
1.4.4 Specific Tailoring Of The Macrocycle 
Because each macrocycle can be synthesised specifically, 
containing the required number and type of donor atoms to 
coordinately saturate the metal ion, this considerably reduces the 
risk of competitive demetallation in vivo. Also, macrocyclic 
complexes are less sensitive to acid catalysed dissociation(30,3l), and 
therefore tend to be more kinetically stable in vivo (the pH in the 
region of the liver may be as low as 2). 
In addition, each macrocycle can be designed to form a neutral 
or cationic complex, which will not attract protons and other 
cations encountered in the blood stream, again reducing the chance 
of the formation of mixed complexes with metals already in 
relatively high concentration in the body (Ca2+ is 1.26 rmnol dm-3, 
Mg2+ is 0.8 mmol dm-3, and Zn is 10-5 mmol dm-3 in human 
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serum). The overall charge on the complex may also influence its 
excretion pathway in the body. 
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1.5 THE SCOPE OF TfflS WORK 
1.5.1 Introduction 
As previously discussed, stable complexes of the chosSTTradio-
metals are of primary importance for tumour targeting and in vivo 
work in general. This research aims to synthesise a number of 
macrocyclic complexing agents and the subsequent complexes, in 
order to clarify whether the complexing agents are viable 
candidates for in vivo use. _ 
Selected methods of investigation have been employed, 
including NMR studies, protonation constant measurements, 
calorimetric determination of binding constants, crystallographic 
determination of structure, and biodistribution studies. 
The remainder of this chapter is concerned with a brief 
description of the relevant coordination chemistry of the chosen 
radiolabels, leading to our choice of proposed macrocycle for 
synthesis. 
1.5.2 Indium(III) And Gallium(III) -Coordination 
Chemistry And Proposed Macrocycles For Synthesis 
Indium is a group I I I metal possessing the electron 
configuration (Kr)4dl05s25pl. The +3 ion is the common oxidation 
state. Many examples(34) of neutral octahedral complexes exist 
with both mono and polydentate ligands. 
Indium complexes of EDTA and DTPA have been used in 
Radioimmunoimaging(35). These anionic complexes, despite being 
stable at pH 7, readily protonate at a lower pH and as suggested 
earlier, are susceptible to competitive demetallation in vivo. 
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Gallium possesses similar coordination chemistry to indium, 
the tripositive ion being the most stable. Both the DTPA and EDTA 
complexes readily protonate at a lower pH. 
Both gallium(III) and indium(III) readily hydrSt^s'e in 
aqueous media. Thus the ligand employed should be tri-basic in 
order to neutralise the resultant complex. As suggested the 
complex ought to be hexadentate in order to coordinately saturate 
the ion. 
Complexes of indium(III) and gallium(III) with (3) (page 28) 
have been reported(35)^ and indium is bound very rapidly under 
ambient conditions. This suggests that the carboxylate or similar 
acid donor groups allow fast complexation, a prerequisite for radio 
isotopic tumour targeting. Also acid donor groups like the 
carboxylate group or alkylphosphinic acid group(36), will also resist 
protonation of the complex. The stability of the complexes of 9 N 3 C 3 
(3) has been studied and it has been shown that the complexes are 
very stable with respect to acid-catalysed dissociation, therefore 
being suitable for in vivo use. 
Bearing this in mind, it was decided to synthesise (4), (5) and 
(6) (page 28). The addition of the methyl and phenyl groups with (4) 
and (5) should radically alter the lipophilicity (and the solubility) of 
the complexes, compared to (3), and should produce some 
interesting characteristics. 
It was hoped in the synthesis of (6) that a successful synthetic 
route to phosphinic acid - polyazacycles could be found. 
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COaH CO2H 1 
CO2H I \ X ^ C O ^ H 
COsH-^ CO2H Me 
9N3C3-(3) 9N3C3Me3-(4) 
P02H{0Me) 
N 
N 
P02H(0Me) 
C a O H ^ ^ P h PC^H(OMe) 
9N3C3Ph3-(5) (6) 
1.5.3 Yttrium Coordination Chemistry And Proposed 
Macrocycles For Synthesis 
Yttrium has the electronic configuration (Kr)5s24dl. It lies 
above L a in the transition group 3. The values of the atomic and 
ionic radius lie close to the corresponding values for terbium and 
dysprosium (the lanthanide contraction). Yttrium resembles the 
lathanides in its chemistry, forming a very stable tripositive ion. 
The yttrium(III) ion has low polarisability and tends to form 
electrostatic bonds with hard donors like 0 and N. The coordination 
of the tripositive ion is characterised by octadentate complexes^ "^^ ). 
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DTPA is an acyclic complexing agent which forms a 
thermodynamically stable (logKML = 22.1) complex with 
yttrium(III). 
H C ^ 
H C ^ ^ C O g H \ f 
DTPA (7) 
The good thermod5nnamic stability is not sufficient for in vivo 
use and the complex undergoes measurable demetallation in the 
human bod5K49). 
J .P .L . Cox(38) has compared the stabilities of the complexing 
agents on page 30, concluding that Y(DOTA)- is the most stable 
complex. Therefore it was decided in the light of this work to 
prepare ligand (7), which may be considered as a macrocyclic 
analogue of DTPA. In Chapter 5 the background chemistry is 
discussed in more detail. 
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CO2H HOaC, 
^ N 
CO2H HO2C 
DOTA 
HO2C 
CO2H HO2Q j.^^.. U U 2 H nu2U ^r^/ lr\) 
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CO2H HO2C 
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CO2H 
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O 
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N 
CO2H 
CO2H 
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CO2H 
C02H H02C 
DTCTA 
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1.5.4 Rhenium And Technetium Coordination Chemistry 
And Proposed Macrocycle for Synthesis. 
The extensive use of the metastable isotope 99™TC(Y = 140 keV, 
ti/2 = 6.02 h) in medicine as a scanning agent for specific -vital 
organs has been documented^^ )^^  In recent years ^^^Re (p- = 1.07 
MeV, ti/2 = 90 h) and l88Re ((3- = 2.12 MeV, ti/2 = 17 h) have been 
suggested as suitable candidates for diagnostic work.(47) A s 
mentioned earlier in this chapter these isotopes may be suitable for 
RIT if they can be irreversibly bound to a bifiinctional complexing 
agent and subsequently attached to an antibody. 
Parker and Roy^^S) have made stable complexes with 
rhenivmiCV) of the type [LRe02]X, (where X = C1-, CH3COO2-, PFeO 
where L is either L i or L2 from below. 
NH2 H2N NH2 H2N 
(9) 
It was decided to synthesise an analogue of L2, functionalising 
the ligand at the 6 position to allow attachment to an antibody. 
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Therefore it was proposed to synthesise (9) as a suitable complexing 
agent for rhenium and technetiima. 
1.5.5 Gold Coordination Chemistry And Proposed 
Complexing Agents For Synthesis. 
Gold(I) readily disproportionates unless stabilised by strong 
complexing agents. GoldCIII) is more stable but may be unsuiteble 
for in vivo use, as it carries a +3 charge that cannot easily be 
neutralised by the complexing agent. In addition, complexes of 
gold(III) are strongly oxidising. 
Gold(I) forms many complexes - linear, trigonal and 
tetrahedral. Linear complexes are favoured eg, [Au(PPh3)2]+. There 
is a strong tendency for the gold atoms in linear complexes to 
interact with one another to produce polymeric chains^^D, and for 
this reason it is necessarily difficult to form macrocyclic complexes. 
Gold(I) forms a stable complex with ethylenethiourea (Figure 
1.11) and an X-ray structure has been determined '^^ lb). However, 
the complex is susceptible to nucleophilic attack and is unstable at 
low and high pH^^lc). 
H 
\ 
N-/ 
H 
+ 
Figure l . I l The Gold(I) - Ethylenethiourea Complex 
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After carrying out some modelling studies, using information 
gained from the aforementioned crystal structure, we proposed to 
synthesise two acyclic complexing agents (56) (figure 1.12)ttnd (57) 
(figure 1.13). The 'bite' of the two complexing moieties is sufficient 
to fit the gold(I) ion and the use of a bidentate chelate should provide 
an advantage i-the chelate effect) over monodentate ligands, and 
may produce a more thermodynamically, as well as more 
kinetically stable complex. _ 
- I -
Figure 1.12 The Proposed Gold(I) Complex Of (56) 
+ 
Figure 1.13 The Proposed Gold(I) Complex Of (57) 
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To begin with it was decided to synthesise (12) (figure 1.14), the 
lipophilic phenyl groups providing us with a monodentate molecule 
functionalised in such a way as to resemble the bidentate ligands 
(56) and (57). We hoped, due to the bulky side-arms, ^y*at the 
complexing agents would protect the gold ion from nucleophilic 
attack providing a more stable complex. Also if (12) was successful 
as a complexing agent for gold(I) we would synthesise (56) and (57). 
=< 
Figure 1.14 The Proposed Gold(I) Complex Of (12) 
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1.5.6 Silver Coordination Chemistry And Proposed 
Complexing Agents For Synthesis. 
Silver prefers the unipositive oxidation state. The SilveKI) ion 
is large and polarisable, has a d^^ electron configuration-and an 
ionic radius of 1.15A°. From ligand field considerations, no 
coordination geometry is preferred, but in practice, linear and 
tetrahedral coordination are the most abundant. With macrocyclic 
complexing agents five and six coordinate complexes are common, 
and seven and eight coordination numbers are also known^^ )^ 
Silver(I) shows a preference for soft donor atoms eg. sulphur and 
nitrogen(43), and prefers the 18-crown cavity size(44). Even though 
silver(I) has a greater preference for sulphur over nitrogen, 
because polysulphur cycles tend to adopt an 'endodentate' 
conformationC*^)^ a mixed sulphur and nitrogen cycle will be 
preferred. Taking these points into consideration we proposed to 
synthesise (13) and (14). 
Me ^ 
r ~ \ H 
S N 
S N; 
(14) (13) 
To further investigate the thermodynamic properties of the 
silver complexes of (15), (48), (49) and I8N4S2 these macrocycles 
were synthesised. 
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I \ Me I \ / 
n-S N - — \ / — O N — ^ 
^ - - - M e H - N N - ^ Me-N N 
< > ^ > 
Me' \ / H ' \ \ 
(15) (48) 
/ \ Me I \ H 
O N — \ N \ ^ 
Me^N N^Me H N N ' " 
Me' \ / H \ I 
(49) I8N4S2 
36 
1.6 REFERENCES 
1. a) "Introduction To The Cellular and Molecular Biology of 
Cancer" , Ed. L.M. Franks and N. Teich. 
b) J . Cairns, 'The Cancer Problem', Scientific American-64, 
233. (1978). 
2. MRC, Private communication 
3. J . Cairns, Nature, 2SH , 359, (1991). 
4. "Biochemistry", L . Stryer, Freeman, New York, (1988). 
5. C. Milstein, Sci. Amer., 243(4). 56, (1980). 
6. D. Parker and K. Jankowski, 'Advances In Metals In 
Medicine', ed. M.A. Abrahms, P.A. Murrer, Volume 1, 29-73, 
(1993), Jai Press, New York. 
7. G. Kohler and C. Milstein, Nature, 256 , 495, (1975). 
8. J . L . Marx, Science, 222 ,455, (1985). 
9. L . Riechmann, M. Clark, H. Waldman, and G. Winter, 
Nature, 332 , 323, (1988). 
10. E .S . Ward, R. Gussow, A.D. Griffiths, P.T. Jones, and G. 
Winter, Nature, 341, 544, (1989). 
11. D. Parker, Chem. Soc. Rev., 19 , 271, (1990). 
12. D. Parker and K. Jankowski, 'Advances In Metals In 
Medicine', ed. M.A. Abrahms, P.A. Murrer, Volume 1, 29-73, 
1993), Jai Press, New York. 
13. B. W. Wessels and R.D. Rogus, Med. Phys., 11(5). 638, (1984). 
14. R. P. Spencer, Therapy in Nuclear Medicine, 3, (1978). 
15. J . L . Humm, J . Nucl. Med., 27(9), 1490, (1986). 
16. R.D. Neirinckx, Chem. Br., 335 , (1986). 
17. M.E. Phelps and J.C. Mazziotta, _228, 799, (1985). 
18. D. Parker and P.S. Roy, Inorg. Chem., 21, 4127 (1988). 
37 
19. D. J . Hnatowich, M. Chinol, D.A. Siebecker, M. Gionet, T. 
Griffin, P.W. Doherty, R. Hunter and K. R, Kase, J . Nucl. 
Med., 29(8), 1429, (1988). 
20. L . C . Washburn, Y.C. Lee, T.T.H. Sun, B. Byrd, J . E . Crook, 
M.G. Stabin and Z. Steplewski, Nucl. Med. Biol., 15(6). 707, 
(1988). 
21. R. M. Sharkey, F.A. Kaltovich, L.B. Shih, I. Fand, G. GoveHtz, 
and D. M. Goldberg, Cancer Res., 48 , 3270, (1988). 
22. C.F. Meares, Acc. Chem. Res., 17 , 202, (1984). 
23. C. F . Meares, Nuc. Med. Biol., 13(4) ,311, (1986). 
24. R.D. Hancock, and A.E. Martell, Chem Rev., 89 , 1874, (1989). 
25. S.M. Yeh, D.G. Sherman, C.F. Meares, Anal. Biochem., lOjO, 
152, (1979). 
26. C.F. Meares, and T.G. Wensel, Acc. Chem. Res., 17, 202, 
(1984). 
27. M.W. Brechbiel, O.A. Gansow, R.W. Atcher, J . Schlom, J . 
Esteban, D.E. Simpson, and D. Colcher, Inorg. Chem., 25 , 
2772, (1986). 
28. D. Parker, Chem. Soc. Rev., 19 , 271 (1990). 
29. S.V. Despande, S.J. DeNardo, C.F. Meares, M.J. McCall, G.P. 
Adams, M.K. Moi, and G.L. DeNardo, J . Nucl. Med., 29 , 
217, (1988). 
30. D. Parker, Adv. Inorg. Chem. Radiochem., 26 , 1, (1983). 
31. L . H . Chen, C.S. Chung, Inorg. Chem., 27 , 1880, (1988). 
32. "Stereochemical and Stereophysical Behaviour of 
Macrocycles", J.C.A. Boeyens, and S.M. Dobson, ed. L 
Bemal, Elsevier, Oxford, 2 , 1, 1987). 
33. a) D.K. Cabbiness, and D.W. Margerum, J . Am. Chem. Soc, 
a i , 6540, (1969). 
38 
b) D.K. Cabbiness, and D.W. Margerum, J . Am. Chem. Soc, 
22,2151, (1970). 
34. A.J. Carty, and D.G. Tuck, Prog, Inorg. Chem., 19 , 243, 
(1975). — -
35. A.S. Craig, D. Parker, H. Adams, N.A. Bailey, J . Chem. Soc. 
Chem. Commun., 1793, (1989). 
36. C. J . Broan, R. Kataky, K. Jankowski and D. Parker, J . Chem. 
Soc. Chem. Commun., 1738, (1990). 
37. a) M.F. Loncin, J .F . Desreux, E . Merciny, Inorg. Chem., 2^, 
2646, (1986). 
b) "Comprehensive Coordination Chemistry", Vol. 3, P. 1059, 
ed. G. Wilkinson, R.D. Gillard, Pergamon (1987). 
38. C.J. Broan, K. Jankowski, R. Kataky, D. Parker, A. Harrison, 
and A.M. Randall, J.Chem. Soc. Chem. Coomun. , 1738, 
(1990). 
39. a) M.R. Spirlet, J . Rebizant, J .F . Desreux, and M.F. Loncin, 
Inorg. Chem., 23 , 359, (1984). 
b) M.K. Moi, C.F. Meares, and S.J. DeNardo, J . Am. Chem. 
Soc, m., 6266, (1988). 
40. "The Chemistry of Gold", R. J . Puddephat, Elsevier, (1978). 
41. a) D. Parker, P.S. Roy, Inorg. Chim. Acta., 155 , 227, (1988). 
b) P.G. Jones, J . J . Guy and G.M. Sheldrick, Acta Cryst. 3321, 
B32, (1976). 
c) D.Parker, Unpublished Data. 
42. D. Parker, and K . E . Matthes, Ch. 3 in "Stereochemical and 
Stereophysical Behaviour of Macrocycles", ed. I. Bernal, 
Elsevier, New York, (1987). 
43. a) H.K. Frennsdorf, J.Am. Chem. Soc, ^ , 3533, (1963). 
b) C.J. Pedersen, J . Org. Chem., 36 , 254, (1971). 
39 
44. A.S. Craig, PhD Thesis, University of Durham, (1989). 
45. R.E. Wolf, J.R. Hartman, S.M.E. Story, B.M. Foxman, S.R. 
Cooper, J.Am. Chem. Soc, 1Q£ , 4328, (1987). 
46 a) A. Davison, A.G. Jones, Int. J . Appl. Radiat. Isot Mr^75, 
(1982) 
b) D. Brenner, J , Lister-James, A.G. Jones, Inorg. Chem. 
22,3793, (1984). 
c) S. Jurrisson, E . G . Slemper, D.E. Troutner, L.R. Canning, 
D.P. Nowotnik, R.D. Neirinckx, Inorg. Chem. 25, 543, (1986) 
47. E . Deutsch, K Libsow, J . L . Vanderheydon, A.L. Ketring, H.R. 
Marxon, Nucl. Med. Biol. 13, 465, (1986) 
48. D. Parker, P.S. Roy, Inorg. Chem., 127, 23, (1988) 
49. A. Harrison, D.Parker, Int. J . Nucl. Med (1991) 
40 
CHAPTER TWO 
SYNTHESIS AND CHAEACTERISATION 
OF COMPLEXING AGENTS 9N3C3Me3 
AND 9N3C3Ph3 AND THE ATTEMPTED 
SYNTHESIS OF A PHOSPHINIC ACID 
POLYAZACYCLE. 
2.0 SYNTHESIS AND CHARACTERISATION OF 
COMPLEXING AGENTS ONsCsMes AND 9N3C3Ph3 
AND T H E A T T E M P T E D S Y N T H E S I S OF A 
PHOSPHINIC ACID POLYAZACYCLE. ^ 
2.1 THE SYNTHESIS OF THE COMPLEXING 
AGENTS 
2,1.1 Introduction 
The synthesis of 9N3C3 (3) was first reported in 1973(1). The 
subsequent formation of neutral stable complexes with Fe(III) and 
Cr(III) was reported in 1977(2). 
CO2H 
CO2H 
CO2H' 
9N3C3-(3) 
Stable complexes of (3) with indium and gallium have been 
synthesised in this laboratory(3). As mentioned in the introduction 
(4), (5) and (6), are excellent models for the N-functionalised ligands 
(54) and (55) that may be attached to tumour-localising antibodies 
and rapidly radiolabelled with indium or gallium isotopes^ )^. 
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Me pf, 
CO2H 1 CO2H I 
M e ^ N Ptr N 
CO2H Me 
9N3C3Me3-(4) 9N3C3Ph3-(5) 
P02H(0Me) 
C / \ / / ^ P 0 2 H ( 0 M e ) / ^ 
N \ / \ 
\ N 
\ / 
N 
P02H(0Me) C 0 2 H > ^ V NHCOR 
(6) (54) 
CO2H ' - NHCOR 
•CO2H 
•N N 
N 
C O g H ^ V NHCOR 
(55) 
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2.1.2 The Synthesis Of (R)-l, 4, 7 -Tris (2'-
Methylcarboxyinethyl)-Triazacyclononane(4) 
Desreux has reported '^*) the synthesis of the supposedly 
enantiopure tetraazacycle (17). — -
PO2H \ 
N N, 
CO2H 
Me HO2C " Me 
12N4C4(17) (19a, Hal=Br) 
(19b, Hal=Cl) 
The synthesis involves the nucleophilic attack of the tetra-
amine's nitrogen atoms on the electron deficient carbon of the 
substituted acid (19a). The configuration of the stereocentre at C-2 is 
inverted during the concerted Sn2 reaction. 
For our synthesis, we used 1,4,7-triazacyclononane (22) with the 
enantiopure a-chloropropanoic acid (19b). 
•N N- ° " 
HO2C 
Me 
H "^^^ H 
9N3(22) (18) 
The liberated proton from the amine lowers the pH of the 
reaction mixture as the reaction proceeds, and is a suitable method of 
monitoring the reaction. The initial pH of the reaction was adjusted 
44 
to pH 10, with lithium hydroxide and the pH was maintained 
throughout the reaction by adding solid lithium hydroxide. If the pH 
falls too low, protonation of the nitrogen occurs inhibiting alkylation. 
I f the pH was taken much higher than pHlO, the possibility of 
competitive nucleophilic attack by hydroxide ions is increased (Figure 
2.1), resulting in the formation of the unwanted alpha-hydroxy acid 
(18). Concurrent base catalysed racemisation of the enantiopure 
alpha-chloro acid is also more likely at elevated pH (Figure 2.2). 
HOOC 
COOH 
OH- Me 
Figure 2.1 Competitive Nucleophilic Substitution From Hydroxide 
Ions 
CO2H 
H Me 
(R) 
CO2H 
Figure 2.2 Base Catalysed Racemisation 
Purification was attempted by recrystallisation at pH 12, 7 and 
3. These attempts proved fruitless, and the complexing agent was 
purified by column chromatography as the tri-ester (MeOH/H+), 
followed by hydrolysis giving the hydrochloride salt, (HC1(6M) 120°C, 
18h). 
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2.1.3 The Synthesis of 1,4,7-Tris (2'-Phenylcarboxy 
methyl)-1,4,7-Triazacyclononane (5) 
The synthesis of (5) was approached in a similar manner^o that 
of (4). However, the partial insolubility of the phenyl substituted acid 
(20) in aqueous methanol retarded the progress of the reaction, 
(followed as a function of the pH of the reaction mixture). 
Br Br 
H O s C ^ \ MeOaC-^ > H 
(20) (21) 
Therefore the synthesis of the methyl ester (21) of (20) was 
undertaken and (21) was purified by column chromatography. The 
reaction of 9N3 (22) with the racemic ester in a suitable polar solvent 
(CH3CN)^ was successful, and the compound was purified with 
column chromatography, followed by acidic hydrolysis. 
At this stage, it must be noted that the purified compoimd was 
most probably a mixture of the four possible stereoisomers, RRR, 
SSS, SRS, RSR (i.e. two chiral diastereoisomers). 
1 This reaction was tried in a number of solvent/base systems in order to improve 
the relatively slow rate of alkylation. Acetonitrile and LiOH (pH maintained at 8 -
9 ) or THF/methanol/ CH3CN with K2C03were both tried, the latter proved to be 
the best system and was chosen for further syntheses of this molecule. 
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N N 
N 
R 
•N N' 
N 
R 
N N 
N 
N N 
N 
The Possible Stereoisomers 
2.1.4 The Attempted Synthesis of 0,0',0"-Trimethyl-
1,4,7-tris (phosphonatome thy 1) -triazacy clononane (6) 
The proposed synthesis of (6) is in Scheme 2.1. The initial 
reaction of 9N3 with formaldehyde and H3PO3 to form (22) has been 
used in this laboratory previously (5) with success. 
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P0(0H)2 
^ I \ H C I V X ^ P 0 ( 0 H ) 2 
•^-N I.HCHO/H3PQ3 N 
H ) (22) 
(H0)20P 
1. H+/MeOH 
; ^ 0 M e \ V 
/ I ^ / — P — O M e 
N 
t 
0 = P . 
(6) 
Scheme 2.1 
Following formation of (22) and purification by recrystallisation, 
the amino phosphinic acid was boiled vmder reflux in methanol in the 
presence of sulphuric acid. According to the 3ip and NMR and 
mass spectral analysis, the nitrogen-carbon bond had cleaved under 
these conditions. 
An alternative route was attempted, (Scheme 2.2). 
48 
PO(OMe)2 
^ I ^ / ^ P O ( O M e ) 2 
l.(HCHO)„/P(OMe)3 
PO(OMe)2 
(23) 
A. MeOH/KOH 
B. IMeaSi/HjO 
CCu^VMeOH 
D.H*/MeOH 
O OH o OH 
r°A/--p'-OMe 
o=p. 
(6) 
Scheme 2.2 
The first step involving the formation of (23) was successful. 
Selective hydrolysis was attempted by the following four methods: 
a) The use of MeOH/KOH was entirely unsuccessful and 
produced no detectable reaction (NMR and Mass Spectrum). 
b) Dealkylation using Me3SiI, involving alkyl-oxygen cleavage, 
yielded a large mixture of species as deduced by 31P and ^H NMR. 
If this reaction had been selective and therefore successful, in so 
much as it was mainly the desired product, simple base hydrolysis 
should have resulted in the target molecule. 
c) The use of copper to control the base hydrolysis was suggested 
by Thomas Kaden and co-workers(6), who achieved selective 
hydrolysis of diethyl phosphonate moieties attached to tetraazacycles. 
With or without the copper present, no reaction could be detected 
even at elevated temperature. This result could be explained as an 
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effect of the smaller ring size of the 9-membered cycle, and thus the 
proximity of the copper to the reaction site would be very different 
than the case with the 12-membered cycle. 
d) Finally, acid hydrolysis (H2S04/MeOH) was attempted which 
produced a large mixture of inseparable products as deduced from 
and 3lp NMR spectra. 
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2.2 C H A R A C T E R I S A T I O N O F 9N3C3Me3 AND 
9N3C3Ph3 
2.2.1 Introduction 
This section reports the information acquired about the two new 
hexadentate ligands QNsCsMes and gNsCaPhg. The structures of the 
new complexing agents and of selected complexes (Cu(II), Ca(II), 
Ga(II), In(III)) were determined using and ''iGa NMR, mass 
spectral analysis and X-ray crystallographic methods of analysis. 
Binding constants of 9N3C3Me3 with Ca(II) and Cu(II) were 
measured by pH potentiometric titrations, as were the pKa values of 
the ligands. Having gained the confidence that the gallium and 
indium complexes were of similar stability to the parent ligand 
(9N3C3), the in vivo kinetic stability was investigated through 
biodistribution studies of the ^'^Ga-ligand complexes in mice. 
Further to this, an assessment of the localising properties of the 
complexes in a xenograft of a human tumour in mice was 
investigated. The details of that investigation are reported in chapter 
3. 
2.2.2 Synthesis And Structural Analysis Of 
[In(III).9N3C3Me3] 
The neutral indium(III) complex was prepared at pH 2 following 
admixture of equimolar quantities of 9N3C3Me3 and indium 
trinitrate solutions. The complex readily crystalised at room 
temperature, producing clear and colourless crystals. The crystals 
showed unusual insolubility and would not dissolve in any common 
laboratory solvent. 
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X-ray analysis^ (figure 2.4) revealed that indium is very tightly 
bound by the oxygen and nitrogen donors, with shorter In-0 and In-N 
bond lengths than any previously reported hexacoordinate indium 
complexes). The crystal possesses an orthorhombic space group 
(P22i2i) and takes the form of a distorted trigonal prism. The angle 
of distortion (twist angle, figure 2.3) is 20.8°, This value is 
approximately the same as that found for the ferric complex of the 
parent triacetate ligand(8) 
/ 
\ 
Figure 2.3: The Twist Angle (0) - A measure Of The Distortion 
From Cs Symmetry 
^The X-ray crystal structure was determined by Professor George Ferguson 
(Department of Chemistry, University of Guelph, Ontario, Canada). 
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C11 
Figure 2.1 Perspective (ORTEP) View of the Indium -SNsCsMes 
Complex. Selected bond lengths and bond angles: In-N(l) 2.258(4), In-N(4) 
2.270(5), In-N(7) 2.254(5), In-O(l) 2.101(4), In-0(3) 2.094(4), In-0(5) 2.094(4)A°; 
N(l)-In-N(4) 79.2(2), N(l)-In-N(7) 79.7(2), N(4)-In -N(7) 79.3(2), 0(l)-In-0(3) 
93.6(2), 0(l)-In-0(5) 93.9(2), 0(3)-In-0(5) 94.1(2), N(4)-In-0(3) 77.0(2), N(7)-In-
0(5) 77.0(2), N(l)-In-0(1) 77.7(1). 
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It is the first structural analysis of a neutral indium(III) complex 
with hexacoordinate geometry which possesses non-crystallographic 
C3 symmetry. 
Using a similar method to that described above, an attempt was 
made to crystalise 9N3C3Me3 with galliiun(III) and copper(II). The 
admixture of the ligand with galliima trinitrate solution produced an 
unusual resiilt. After 60 minutes the solution became viscous and 
opaque. Presumably, this was caused by the insolubility of the 
complex. The reason why it should show a marked difference to the 
indivun-ligand complex is unclear. The difference in the ion size and 
thus the polarising strength may render the complex more lipophilic 
causing it to come out of solution so quickly that it has no time to 
crystallise uniformly as in the case of the corresponding indium 
complex. 
The copper complex did not crystallise. Changes in the 
concentration of the solution and in the pH made no difference and 
the solution did not produce any crystals. 
Similar attempts were made with the complexing agent 
SNaCaPhs and gallium, indium and copper. With gallium and 
indium, the complex was very insoluble -similar to the gallixmi-
9N3C3Me3 complex, and it did not prove possible to grow any crystals 
for X-ray analysis. With copper(II), crystals have been grown but 
they were deliquescent and it was not possible to analyse them using 
X-ray methods. 
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2.3 7 l G a NMR I N V E S T I G A T I O N O F T H E 
STRUCTURE O F THE GALLIUM COMPLEXES OF 
9N3C3Me3 AND 9N3C3Ph3 
Using 7lGa NMR, [QNaCsMes.Ga] can be observed in 6M HNO3 
as a singlet at +149 ppm (CO 1/2 = llOOHz). The investigation was 
problematic due to the aforementioned solubility of the gallium 
complexes of these ligands. The solution had to be introduced to the 
NMR probe immediately after mixing, to enable enough time for the 
measurement to be taken before the complex came out of solution. 
Figure 2.5 ^iQa NMR of the Gallivun Complex of QNaCsMes 
The reference signal is Gallium trinitrate in 6M HN03 
55 
Figure 2.5 shows the "^ iQa spectrum, and it can be seen that the 
signal width of the complex at the baseline is broader than that of the 
reference complex Ga(H20)63+, The origin of line broadening with 
quadrupolar nuclei is related to the interaction of the electric field 
gradient with the quadrupolar moment at the nucleus. Any 
distortion of the field gradient away from cubic symmetry results in 
an interaction with the nuclear quadrupole causing an increase in the 
relaxation times T i and T2. The effect of this is to produce line 
broadening as illustrated in figure 2.5. The gallitim ion in the nitric 
acid solution is symmetrically surrounded by water molecules 
producing minimal interaction of the electric field gradient and 
quadrupole at the nucleus resulting in a very sharp signal peak. The 
fact that the complex gives such a broad signal would suggest that 
the symmetry of the complex is distorted fi^om the C3 symmetry as we 
might expect fi-om a comparison with other similar complexes. 
Complexing NMR 0)1/2 Complex Twist Angle 
Agent Signal Hz Symmetry degrees 
ppm 
(pH) 
9N3C3Me3 +149 (0.7) 1100 non C3 20.5 
9N3C3(9) +171 (0.7) 210 C3 0 
9N3P3Ph3^ 9^  +132 (0.7) 560 = C3 7.9 
Table 2.1: A Comparison Of^^Ga NMR Signals And Complex 
Symmetry For Related Complexes 
Table 2.1 shows the relationship between line width ((O1/2) and 
the symmetry of the complex in its crystalline form. 
Complexes of 9N3C3 possess crystallographic C3 symmetry(^) 
and the SNsCs-gallium complex produces a sharp signal with similar 
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line width to [Ga(H20)6]^'^ ion. Crystallographic analysis of Ga-
9N3P3Ph3(10) complex shows the complex possesses only approximate 
crystallographic C3 symmetry and the ^iGa NMR signal is rather 
broad ((O1/2 = 560Hz). The 9NC3Me3 complex shows even greater 
line broadening and this may suggest that the departure from C3 
symmetry in solution is even greater than that of 9N3P3Ph3. 
Comparing the twist angle (the angle between the oxygen donor and 
the nearest nitrogen donor in the ring, (Figure 2.3) of the crystals of 
each complex (Table 2.1), a similar trend is apparent, suggesting^that 
the solid state conformation is similar to the average conformation in 
solution. 
The insolubility of the gallivun complex of 9N3C3Ph3 prevented 
any determination of the "^ G^a NMR spectrum. 
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2.4 DETERMINATION OF PROTONATION AND 
BINDING CONSTANTS OF 9N3C3Me3 
Using pH potentiometric titrations, the protonation and selected 
binding constants have been obtained for 9N3C3Me3. The 
experimental procedure (Section 5.5) employed was similar to that 
used by Zompa^O) in his investigation of the parent ligand 9N3C3. 
The ligand or 1:1 complex of known concentration was titrated 
against an accurately calibrated alkaline solution and the ..data 
analysed using SCOGS to obtain the required equilibrium constants. 1 
Ligand 
pKi pK2 pK3 logKCaL logKcaLH logKCuLHZ* 
9N3C3 (7a) 11.2 6.10 3.48 10.8 5.75 2.9 
9N3C3Me3 11.7 5.74 3.16 8.92 5.06 2.77 
Difference 0.5 0.36 0.32 0.12 0.69 0.13 
Table 2.2 The pKa and Stability Constants ofdNsCs and SNsCsMes 
* From spectraphotometric analysis of the 780 nmand 660 nm bands 
The results of our investigation show that complexing agent 
9N3C3Me3 shows similar complexing behaviour to the parent 9N3C3. 
The steric effect of the methyl group in the alpha position is limited 
as it is exocyclic. The bond attaching it to the cycle may freely 
rotate so that the methyl moiety does not interfere with complexation 
(Figure 2.6 and Figure 2.1). 
iThe analysis of the data was carried out at the University of Durham by Dr Ritu 
Kataky. 
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Free Rotation 
Figure 2.6 The Alpha-Methyl Group May Rotate Freely 
The electronic effect of the methyl group, may slightly increase 
the electron density at the carbonyl, although the measurements 
suggest the effect is negligible. 
From this comparison, it is clear that 9N3C3Me3 possesses 
similar complexing abilities to the parent 9N3C3 and the effect of the 
methyl group on the ability to form complexes is minimal, although 
the change in the solubility of the resultant complexes is marked. 
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2.5 V I S I B L E S P E C T R U M A N A L Y S I S O F 
[Cu.9N3C3Me3]2+ AND [Cu.9N3C3Ph3]2+ 
The copper(II) complexes of QNsCsMes and 9N3C3Ph3 are blue. 
The parent ligand complex [Cu.9N3C3]2+ forms two distinct species 
with copper(II) between pH 1.8 and 3.5. Within this pH range, the 
protonation of the species [CU.9N3C3]- occurs forming H[Cu.9N3C3] 
(10) (equation 2.1). 
[Cu.9N3C3]- + H + = ^ — HCU.9N3C3] 
Equation 2.1 
ABS 
630 710 
Figure 2.7 The Visible Spectrum Of The QNsCs-CopperdI) Complex 
At Various Values OfpH^O). 
The two species possess different absorption maxima and are 
distinguishable using visible spectroscopy. Zompa used this 
quantifiable difference to determine the pKa value for the equilibrium 
shown in equation 2.1. Using accurately known concentrations of 
ligand and copper (II) solutions, the pH was varied between pH 1.8 
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and pH 3.5 in small accurate increments and the visible spectrum 
was recorded. 
The two distinct peaks at either side of the figure correspond to 
the two distinct species. Situated between them is the isosbestic 
point (720 nm), which is related to the equilibrium of the two 
complexes. Using the information from the visible spectrum and the 
exact concentrations of the reagents, the pKa of the protonation can 
be calculated as follows: 
If the extinction coefficients of the species are calculated using 
the Beer-Lambert equation (1): 
log I°/I = A = e.l.c (1) 
Where the optical density, A, can be measured at m^ax ^or a 
known concentration, c, to give a value for e at Imax- Therefore at an 
accurately known value of pH the concentration of each species can 
be calculated, using the Beer-Lambert relationship, by measuring the 
absorption value at either value of m^ax and combining this result 
with (2). 
[Cu.L] + [Cu.LH] = [Cu.L]° (2) 
Where [Cu.L]° is the initial concentration of copper complex 
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The pKa of the protonation (2), can then be calculated from (3); 
Kcu.LH = [Cu.L]. [H *] 
[Cu.LH] 
(3) 
When I = l.OM 
The pH gives a value of [H+] (1=1.0), and the concentrations of 
species can be calculated as described above. Therefore at different 
values of pH a value for the pKa can be calculated. 
abs 
600 700 
Wavelength (nm) 
800 
Figure 2.8 The Visible Spectrum Of The Copper - SNsCsMes Complex 
Between pH 2.0 And pH 3.2 
Using a similar but less rigourous method to Zompa's, the 
experiment was repeated to estimate the pKg of this protonation for 
the two new complexing agents. 
The visible spectrum, of a known concentration of the Cu-
9N3C3Me3 complex at a known value of pH(2.0-3.4), was measured, 
(1=1.0 M, NaC104). The pH was adjusted in small increments and the 
spectrum measured again. The visible spectra are shown in figure 
2.8 and figure 2.9. 
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abs 
600 700 
Wavelength (nm) 
800 
Figure 2.9 The Visible Spectrum Of The Copper • SNsCsPhs Complex 
Between pH 2.0 And pH 3.2 
As with 9N3C3-copper complex , the isosbestic points are clearly 
visible at 720 nm as are the peaks corresponding to the individual 
species, within this pH range. 
From this information, using the procedure outlined above, we 
estimated that this pKa for the two new complexing agents is 
approximately 2.9+0.2 @ 25°C, very similar to that for the 9N3C3-
copper complex. 
The method Zompa used was extremely thorough, using 
SQUAD, to analyse his data. Our investigation experiment was 
much less rigourous, and the value calculated for both values of the 
pka carries an error of ± 0.2. 
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CHAPTER T H R E E 
BIODISTRIBUTION STUDIES OF THE 
GALLIUM AND INDIUM COMPLEXES OF 
9N3C3Me3 AND 9N3C3Ph3 IN ATHYMIC 
NUiNUMICE 
3.0 BIODISTRIBUTION STUDIES OF THE GALLIUM 
AND INDIUM COMPLEXES OF 9N3C3Me3 AND 
9N3C3Ph3 IN ATHYMIC NU.NU MICE 
3.1 INTRODUCTION 
Interpretation of the U.V spectra, NMR data, crystal analysis 
and stability constant measurements of the two new complexing 
agents 9N3C3Me3 and 9N3C3Ph3, suggests that both ligands form 
stable indium(III) and gallium(III) complexes and possess similar 
coordination chemistry to the parent 9N3C3('*). As mentioned 
previously the in vivo kinetic stability of the complexes is of the 
upmost importance to their suitability for use in diagnostic and 
nuclear medicine ( l^In, y, ty2 = 2.83 days; 67Ga, y, ty2 = 3.25 days; 
68Ga, p+, ty2 = 68min). 
With variable pH (2-8) and a high concentration of cations in 
vivo, it is crucial that the complex remains stable despite the in vivo 
environment. We knew from the results of previous 
biodistribution(2) investigation that the parent gallium complex, 
gallium-9N3C3, possesses high stability in vivo, with virtually no 
decomplexation occurring. A further biodistribution study was 
undertaken to test and compare the in vivo kinetic stability of 
gallium and indiimi complexes of 9N3C3Me3, 9N3C3Ph3, 9N3P3Me3* 
and 9N3P3Ph3** with that of the parent complex. 
Later in this chapter, localising properties of the complexes 
within a human melanotic melanoma implanted in mice, are 
reported. 
* 9N3P3Me3 wase synthesised by C. Broan at the University of Durham. 
** 9N3P3Ph3 were synthesised byT. Norman at the University of Durham. 
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3.1.1 The Phosphinic Acid-9N3 Complexing Agents 
All these complexeing agents are derived and synthesised from 
the cyclic polyamine 1,4,7-triazacyclononane. The physical and 
chemical properties of SNsCaMes and SNaCsPha have already been 
discussed in chapter 2. The other two complexing agents, BNaPsMea 
and 9N3P3Ph3 are aminoalkylphosphinic acids and possess distinct 
chemical differences to the carboxylic acid analogues^^'^). Compared 
to a carboxylic acid, the phosphinic analogue is usually more acidic 
and the complex is more resistant to protonation and acid-mediated 
decomplexation. In addition, when the oxygen of the phosphinic acid 
is interacting with a metal, the position of the phosphinic acid is fixed 
and a new stereogenic centre is produced at the pentavalent 
phosphorus, allowing the possibility of stereoisomeric complexes. 
Similarly to the two carboxylate complexing agents they are 
hexadentate, and possess strong complexing characteristics. 
PO2H R 
/ 
"PO2H 
N 
R=Me 9N3P3Me3 
R=Ph 9N3P3Ph3 
PO2H 
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3.2 E X P E R I M E N T A L METHOD O F 
INVESTIGATION! 
Scheme 3.1 shows an overview of the experimental procedures. 
Details are given in section 5.3. 
Stagel: The addition of Ga, 
buffered at pH 5 and incubated 
for 15 minutes. 
R' = COOH, R = Me or R = Ph 
R' = POOH(Me) and R' = POOHPh 
R . A R 
Radiometal Complex 
and uncomplexed^^Ga. 
Stage 2: The addition of 
DTPA followed by 15 
minute incubation 
"Clean" ^^Ga-Ligand 
Complex 
Stage 3: Separation of *^Ga-ligand 
from unwanted *''Ga-DTPA and 
uncomplexed DTPA 
4^ 
Stage4: The mouse is injected 
with the '^Ga-Ligand complex. 
I— l _ Stage 5:The mouse is terminated 
by lethal injection (t= 1,4,24 h) 
Radiolabelled Mouse 
Radiometal complex, 
^•'Ga-DTPAandXS 
DTPA 
— • 
Biodistribution Data 
Stage 6: The mouse is dissected 
and the radiation levels in the 
vital organs are measured. 
LL 
Scheme 3.1 Experimental Method 
^These experiments were carried out by A. Harrison and L . Royle, MRC, Radiobiology 
Uni t , Didcot, Oxon. 
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3.3 B I O D I S T R I B U T I O N DATA F O R T H E G A L L I U M 
C O M P L E X E S IN NON-TUMOUR B E A R I N G M I C E . 
3.3.1 The Data 
Gallium 
One Hour 
Citrate 9N3 9N3P3-
Me3 
9N3C3-
Me3 
9N3P3-
Ph3 
9N3C3-
Ph3 
Tissue %dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
blood 1155 
39.13 
0.15 
0.53 
0.09 
0.31 
0.11 
0.41 
0.12 
0.40 
0.15 
035 
kidney 3.92 
2.04 
4.57 
3.28 
3.18 
1.89 
8.37 
5.20 
3.49 
1.97 
5.78 
455 
liver 2.61 
4.89 
0.65 
1.18 
0.14 
0.26 
2.10 
4.01 
0.65 
1.32 
0.41 
0.87 
lung 5.20 
0.98 
0.42 
0.08 
0.24 
0.05 
0.17 
0.03 
0.14 
0.03 
0.14 
0.030 
spleen 2.26 
0.27 
0.11 
0.02 
0.07 
0.01 
0.10 
0.01 
0.08 
0.01 
0.07 
0.011 
salivary glands 2.83 
0.62 
0.08 
0.03 
0.07 
0.02 
0.08 
0.02 
0.05 
0.01 
urine 19.4 449.8 257.4 
0.28 
268.8 119.00 146.3 
brain 0.017 
0.008 
0.010 
0.0047 
0.009 
0.0045 
femur *2 3.16 
0.56 
0.07 
0.01 
0.07 
0.01 
0.07 
0.01 
0.05 
0.10 
0.07 
0.014 
gall bladder 
0.034 0.185 0.471 
muscle skel. 1.18 0.06 0.08 0.06 0.05 0.06 
stomache 
0.80 0.05 0.03 0.03 
0.13 
0.07 
0.07 
0.05 
sm. intestine 
4.92 0.61 0.36 0.79 
15.7 
31.87 
25.2 
57.39 
caecum 
1.03 0.06 0.08 0.11 
4.6 
3.45 
0.07 
0.06 
la. intestine 
1.65 0.08 0.04 0.10 
1.04 
0.70 
0.06 
0.05 
no. of mice 4 5 7 4 4 3 
34.0 36.7 35.2 37.2 33.5 36.9 
Table 3.1 The Biodistribution at 1 Hour 
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Gallium 
4 Hours 
Citrate 9N3 9N3P3-
Me3 
9N3C3-
Me3 
9N3P3-
Ph3 
9N3C3-
Ph3 
Tissue %dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
blood 8.26 
30.37 
0.005 
0.021 
0.005 
0.018 
0.023 
0.081 
0.058 
0.02 
0.121 
0.420 
kidney 4.63 
2.95 
1.11 
0.76 
1.86 
1.21 
3.74 
2.39 
0.75 
0.47 
0.551 
0.293 
liver 3.09 
6.44 
0.29 
0.73 
0.084 
0.17 
1.34 
2.8 
0.3 
055 
0.216 
0.367 
lung 3.62 
0.97 
0.05 
0.01 
0.05 
0.011 
0.06 
0.013 
0.05 
0.01 -
spleen 3.17 
0.47 
0.04 
0.006 
0.033 
0.005 
0.07 
0.008 
0.036 
0.004 
0.055 
0.006 
salivary glands 2.32 
0.62 
0.03 
0.008 
0.05 
0.012 
0.032 
0.008 
urine 7.49 165 15 18 2 32 10 
0.7 
brain 0.009 
0.004 
0.005 
0.002 
0.007 
0.003 
femur *2 3.39 
0.67 
0.019 
0.003 
0.022 
0.004 
0.036 
0.006 
0.035 
0.007 
0.082 
0.014 
gall bladder 
0.001 
0.05 1.35 
0.018 0.100 
muscle 0.92 0.016 
0.02 
0.015 0.029 
0.006 
stomach 
0.90 0.02 0.069 0.014 
0.05 
0.033 0.09 
small intestine 
7.44 0.17 0.21 0.36 
0.37 
0.74 1.35 
caecum 
2.79 0.28 0.19 0.52 
13.3 
11.4 19.46 
large intestine 
2.24 0.30 0.12 0.51 
16.7 
15.3 21.19 
no. of mice 3 4 3 4 3 4 
mean weight g. 36.2 41.5 38.3 34.7 34.7 34.9 
Table 3.2 T/ie Biodistribution at 4 Hours 
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24 Hours Citrate 9N3 9N3P3-
Me3 
9N3Me3-
C3 
9N3C3-
Ph3 
9N3P3-
Ph3 
Tissue %dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
blood 1.66 
623 
0.002 
0.007 
0.001 
0.004 
0.0245 
0.089 
0.122 
0347 
0.0195 
0.0701 
kidney 3.46 
2.10 
0.021 
0.012 
0.359 
0.208 
0.107 
0.062 
0J296 
0.153 
0.121 
0.0716 
liver 3.39 
7.18 
0.124 
0.235 
0.0385 0.124 
0.251 
0.342 
0.602 
0.161 
0.32 
lung 1.81 
0.42 
0.037 
0.009 
0.0157 
0.0031 
0.059 
0.01 
0.180 
0.048 
0.027 
0.0057 
spleen 2.53 
0.33 
0.028 
0.004 
0.0226 
0.003 
0.0527 
0.007 
0.169 
0.017 
0.028 
0.0035 
salivary glands 2.32 
0.60 
0.025 
0.0059 
0.024 
0.0056 
urine 3.35 0.22 0.186 
0.22 
0.22 0.064 
brain 0.0067 
0.0029 
0.006 
0.003 
0.017 
0.0008 
femur *2 4.41 
0.82 
0.015 
0.002 
0.0164 
0.003 
0.0978 
0.0166 
0.278 0.0437 
0.0074 
gall bladder 
0.001 
0.09 
0.0007 
muscle 0.43 
0.005 
0.0078 0.0193 0.026 0.0062 
stomach 
1.21 0.006 0.1036 0.036 0.084 
0.017 
0.012 
small intestine 
659 0.03 0.0603 0.14 0.322 
0.045 
0.1 
caecum 
2.13 0.03 0.0234 0.21 0.279 
0.083 
0.081 ; 
large intestine 
2.87 0.03 0.0234 0.16 0.162 
0.072 
0.068 
no. of mice 3 3 4 5 4 3 
mean weight g. 37.9 375 34.8 36.1 30.6 35.8 
Table 3.3 The Biodistribution at 24 Hours 
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6RAPH la: Biodist r ibut ion (% Dose) 
of the Gallium Complexes at 1 hour 
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GRAPH 2a: B l o d i s t r l t l o n (%dose) of the 
Ga l l ium Complexes At Four Hours 
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Gallium Complexes at Four Hours 
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GRAPH 3a: Blodlstr lbutlon (%(iose) of the 
Gallium Complexes At 24 Hours 
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GRAPH 4a: Biodist r ibut ion of Gal1um-9N3 
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GRAPH 5a: Blodlstr lbut lon of 
Ga-9N3C3Me3 
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GRAPH 6a: Biodistr ibut ion (% dose) of 
Ga-9N3P3Me3 
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GRAPH :7a Blodlstr lbut lon (%dose) of 
Gall1um-9N3C3Ph3 
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GRAPH 7b: Blodlst r lbut lon (%dose/g) 
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GRAPH 8a: Biodistr ibut ion (% dose) 
of Ga-9N3P3Ph3 
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3.3.2 The Stability Of The Gallium Complexes In Vivo 
During the preparation of the the complexes (Section 5.3), the 
uncomplexed 67Ga is removed from the sample using a ten-fold excess 
of DTPA. All the complexes remained intact in the presence of the 
DTPA, This confirmed our previous experimental measurements and 
also demonstrates the high kinetic stability of all the complexes. 
The stability of the complexes in vivo can be ascertained 
visually when comparing the graphical data for the gallium-citrate 
complex (graph 9) with that of the gallium-SNaCa complex. _ 
CH2CO2H 
H 0 2 C - ^ C ? I ? C 0 2 H 
C I T R A T E 
The biodistribution of the weak gallium-citrate complex was 
undertaken to compare the results against and provide a bench mark 
for assessing the stability of the complexes. The citrate complex 
readily dissociates in vivo. Therefore much of the gallium-67 localises 
in the body (liver and skeleton) and clears more slowly from other 
tissues than a stable complex. 
The new complexing agents contrast well with the citrate 
complex and have almost completely cleared after 24 hours. This 
indicates that the complexes remain intact in vivo. 
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GRAPH 9: B i o d i s t r i b u t i o n of 
G a - C l t r a t e Complex 
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3.3.3 The Fate OfThe 67Ga-Complexes 
The parent 9N3C3 complex (graph 1 and 4) is cleared mainly 
through the renal pathway (kidneys). The activity of the complex in 
the kidneys is 4.57, 1.11, and 0.021 % dose g-1 at 1, 4, and 24 hours 
respectively. The measured activity that remains at 24 hours is very 
small indicating the complex has mostly been excreted, presumably 
intact. 
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H E F A T O 
BULIARY 
IMffiDiBidt 
SMSIM Mtesilajiii® 
F i g u r e 3.1 Renal And Hepato-Biliary Excretion Pathways 
The ^^Ga-QNsPaMea complex is excreted via the kidney and the 
biodistribution is very similar to the parent complex, 6'^Ga-9N3C3. 
After 24 hours most of the activity has cleared. 
The 6'^Ga-9N3C3Me3 also shows a substantial concentration (8.37 
% dose g"l) in the kidney at one hour. I n addition, graph lb indicates 
that, after one hour, there is a substantial amotmt of ^^Ga-SNsCsMes 
in the liver. On closer inspection of graph 2a, there is no indication 
of the complex in the small and large intestine. Figure 3.1 describes 
the two main excretion pathways. It is slightly surprising that the 
high concentration of the complex in the liver is not mirrored with a 
proportionally high concentration in the small and large intestine -
the hepato-biliary excretion pathway. The explanation for this 
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anomaly may be that the complex is unstable in vivo. Graphs 5a and 
5b show that in femur, kidney, liver and blood there is a little activity 
(= 0.25 % dose g-l). Comparing this to the activity of the other 
complexes at 24 hours (graph 3a and 3b), the concentration of the 
S^Ga-SNaCsMes is less than that of the other complexes. Therefore i t 
is unlikely that decomplexation is the cause of this phenomenon. The 
presence of the ^VGa-QNaCsMea complex i n the liver i n such a 
relatively high concentration cannot be explained at present. . 
After one hour, the STGa-gNsCaPha and eTQa-gNsPsPhs 
complexes show a comparatively lower concentration i n the kidney 
than the other complexes. I n addition, high concentrations i n the 
small and large intestines (graph l a and 8a) have been observed. 
This indicates that a proportion of the complex is passing through the 
liver and bile duct and into the intestines to be excreted i n the 
caecum. This preference for the hepato-biliary route may be related 
to the lipophilicity of these complexes. The addition of phenyl groups 
to the complex, does alter the solubility characteristics of their 
complexes, and may be expected to influence the in vivo 
pharmacokinetics of these complexes as well. 
The clearance of all the complexes is fast, after 24 hours less 
than 1 % of each complex remains in the body. 
3.3.4 Conclusions 
The experiment was designed to determine the eligibility of the 
gallium complexes of the new complexing agents for use in vivo. Al l 
the complexes demonstrated excellent in vivo stability, and all of 
them cleared quickly f rom the body, wi th l i t t le evidence of 
dissociation. 
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Secondly, the modification to the hpophihcity of the complexes 
introduced by the presence of the methyl and phenyl groups affects 
the way the complexes are processed by the body. The more lipophilic 
complexes tend to excrete via the hepato-biliary route, whereas the 
parent and 9N3P3Me3 are mainly excreted through the kidneys. 
The following list shows the order which is observed. 
gNaCaPhs 
The application of the new 67Ga(Y) complexes for in vivo imaging 
of the liver, bile duct and small intestine is feasible as the 
concentration i n these organs, although small, compared to the 
background may be within the lower limits that allow successful 
imaging. Also the use of 68Ga for positron emission tomography 
(PET) or stable gallium for in vivo NMR detection may also be 
feasible. 
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3.4 B I O D I S T R I B U T I O N O F T H E INDIUM 
COMPLEXES IN ATHYMIC NU:NU MICE 
3.4.1 Introduction 
I n chapter 1 (1.3.2), i t was noted that m i n is a good imaging 
isotope. This gamma emitter has a half-life of 2.83 days and is a 
potential candidate for single photon emission computed tomography 
(SPECT). 
Although indi\mi(III) has a larger ionic radius than the gallium 
ion, indium forms strong complexes wi th the 9N3C3 family of 
complexing agents.^ '*^ 
Gallium(m) Indium(III) 
Ionic Radius A° 
(hexacoordinate) 0.76 0.94 
A second set of biodistribution experiments, similar to the 
gallium work, was made using indiimi 111 as the radiometal. 
Once again the aim of the investigation was to determine the 
stability of the indium complexes in vivo and observe i f the 
complexes displayed a preference for a particular excretion pathway, 
i.e. whether the more lipophilic indiimi complexes were excreted via 
the hepato-biliary route. 
3.4.2 Experimental Method Of Investigation 
The experimental details were analogous to those used i n the 
gallium work. 
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3.4.3 The Data 
In (1 Hour) 9N3 9N3P3-
Me3 
9N3C3-
Me3 
9N3P3-
Ph3 
9N3C3-
Ph3 
Tissue %dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
Blood 028 
1.08 
1.38 
4.95 
0.38 
1.37 
2.06 
7.79 
0.12 
0.38 
Brain 0.024 
0.010 
0.049 
0.02 
0.028 
0.013 
0.055 
0.026 
0.011 
0.005 
Femur 0.34 0.45 0.21 0.64 0.134 
Kidney 4.55 
2.99 
13.81 
8.91 
4.81 
196 
353 
2.04 
4.2 
2.38 
Liver 0.25 
0.28 
0.39 
0.79 
0.29 
0.58 
0.68 
1.40 
23.3 
40.50 
Lung 0.33 
0.07 
0.74 
0.13 
0.4 
0.08 
1.03 
0.20 
0.20 
0.03 
Muscle 0.12 0.30 0.13 0.33 0.04 
Skeleton 
1.28 1.62 0.73 2.41 0.42 
Spleen 0.12 
0.02 
0.35 
0.05 
0.14 
0.02 
0.42 
0.05 
0.14 
0.02 
Gall Bladder 
0.02 0.01 0.28 056 1.15 
Stomach 
0.08 0.11 0.33 0.8 0.45 
S.Intestine 
1.08 0.78 9.18 30.21 29.8 
Caecum 
0.09 0.17 0.14 4.18 1.87 
L.Intestine 
0.09 0.19 0.12 0.45 0.03 
Urine Via 
Kidney 79.77 69.77 70.59 27.85 16.6 
Total Gut 
1.35 1.25 9.77 35.64 32.16 
no. of mice 9 4 4 8 4 
mean weight 38g 34.9 35.2 37.2 31.9 
Table 3.4 The Biodistribution Of The Indium Complexes At One 
Hour 
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In (24 Hours) 9N3 9N3P3-
Me3 
9N3C3-
Me3 
9N3P3-
Ph3 
9N3C3-
Ph3 
Tissue %dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
%dose/g 
%dose 
Blood 0.002 
0.009 
0.31 
0.99 
0.002 
0.007 
0.25 
0.93 
0.034 
0.105 
Brain 0.001 
0.0006 
0.03 
0.013 
0.0008 
0.0003 
0.03 
0.013 
0.004 
0.002 
Femur 0.05 0.67 0.019 0.80 0.10 
Kidney 0.19 
0.13 
2.78 
1.74 
0.17 
0.10 
2.89 
1.81 
1.02 
055 
Liver 0.05 
0.10 
1.09 
1.84 
0.04 
0.07 
0.84 
1.73 
14.72 
24.28 
Lung 0.02 
0.004 
0.56 
0.09 
0.010 
0.002 
0.43 
0.08 
0.073 
0.012 
Muscle 0.004 0.21 0.002 0.19 0.024 
Skeleton 
0.17 2.13 0.065 1.18 0.31 
Spleen 0.02 
0.002 
0.44 
0.05 
0.012 
0.001 
0.47 
0.06 
0.124 
0.01 
Gall Bladder 
0.0004 0.02 0.0005 0.007 0.13 
Stomach 
0.008 0.11 0.004 0.12 0.16 
S.Intestine 
0.05 2,.19 0.04 1.11 0.67 
Caecum 
0.11 0.31 0.14 0.4 11.37 
L.Intestine 
0.05 0.41 0.05 0.34 0.74 
Total Gut 
0.21 3.01 0.23 1.97 
2.94 
no. of mice 4 4 4 7 4 
mean weight g. 38.3 32.0 34.1 - 31.0 
Table 3.5 The Biodistribution Of The Indium Complexes At 24 
Hours 
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GRAPH 10a: Blodlstr lbut lon of (% dose)the 
Indium Complexes 1 hour af ter Introduction 
Urine via kidney 
Large Intestine 
Caecum 
S. Intestine 
Stomach 
Gall Bladder 
liver 
kidney 
Femur 
blood 
r 
r 
• ' I 
5 10 
% Dose 
15 
' - I — ' 
20 25 
GRAPH 10b: Blodlstr lbut lon (% dose/g) of the 
Indium Complexes 1 hour af ter Introduction 
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GRAPH 11a: The Blodlstr lbut lon {% dose) of the 
Indium complexes 24 hr af ter their Introduction 
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GRAPH 12a: Blodlstr lbut lon ( % dose) 
of ind1um-9N3C3 
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GRAPH 13a: Biodist r ibut ion (% dose) 
of lncl1um-9N3C3Me3 
to 
o 
T3 2 H 
<i> 
CO 
o 
•o 
6e 
• 
blood 
kidney 
liver 
stomach 
s.intestine 
caecum 
1.intestine 
I 24 
Hours Af ter Introduction of the Complex 
GRAPH 13b: Biodist r ibut ion (% dose/g) 
of lnd1um-9N3C3Me3 
4 -\ 
3 H 
2H 
I H I m • blood brain femur kidney liver spleen 
1 24 
Hours Af ter Introduction of the Complex 
91 
to 
O 
6e 
GRAPH 14a: Blodlstr lbut lon (% dose) of 
lnd1um-9N3C3Ph3 
40 
30 H 
20 H 
10H 
1 24 
Hours Af ter Introduction of the Complex 
GRAPH Mb: Blodlst r lbut lon (% dose/g) 
of lnd1um-9N3C3Ph3 
20 
</> 10 H 
o 
•a 
1 24 
Hours Af ter Introduction of the Complex 
• blood 
0 kidney 
M liver 
0 stomach 
• S.Intestine 
M caecum 
M 1. intestine 
• blood 
0 brain 
1^ femur 
0 kidney 
\3 liver 
M spleen 
92 
tn 
o 
•o 
v> 
o 
•a 
GRAPH 15a: Biodist r ibut ion (% dose) 
of lnd1um-9N3P3Me3 
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GRAPH 16a: Blodlst r lbut lon (% dose) 
of lnd1unn-9N3P3Ph3 
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3.4.4 The Stability Of The lUln-Complexes In Vivo 
Comparing graphs 11a and l i b wi th graphs 3a and 3b (the 
biodistribution of the gallium and indium complexes at 24 hours), 
the amount of radioactivity stil l present wi th some of the indium 
complexes is greater by almost a factor of 10 i n certain organs 
(kidney, liver, femur) and this effect is most notable with the 
9N3P3Ph3 indivmi complex. 
This suggests that, i n general, the indium complexes are less 
stable in vivo than the analogous galUum complexes. An explanation 
for this may lie in the size of the ion. The larger indium(III) ion may 
be too large to allow the macrocycle to bind properly. I t is possible 
that the indiimi ion is less well bound by the 'tighter bite' of the 9N3 
moiety. The position of the pendant acid groups wil l be affected and 
they may not be able to bind cooperatively at their optimum In-0 
distances. 
3.4.5 The Fate Of The Indium Complexes. 
Graph 17 compares the biodistribution data at one hour to see i f 
the indium complexes are excreted i n a similar manner to those of 
gallium. 
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GRAPH 17: Biodistr ibut ion in the Liver 
and Kidney after 1 Hour 
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The parent indium-SNsCa complex is excreted via the renal 
pathway (Graphs 10 and 12). 
The lllIn-ONaCsMea and min-QNaPsMea complexes also show 
renal excretion, with very little activity detected in the liver, (Graphs 
10, 13 and 14). The imexplained presence of a large concentration of 
the 67Ga-9N3C3Me3 complex i n the liver does not occur with the 
indium analogue. However graph l a shows, after one hour, a 
relatively large concentration i n the intestines indicating that a 
proportion of the complex is passing through the liver, and excreted 
via the hepato-biliary pathway. 
The lilIn-QNaCsPhs and min-QNsPaPhs complexes display a 
preference for the hepato-biliary pathway (Graphs 1, 14 and 15). 
After one hour, graph 10a shows that both complexes were present in 
the caecum. This gives an indication of the rate at which the 
complexes are cleared via the hepato-biliary route (< 1 hour). 
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3.4.6 Conclusions 
The experiment was designed to determine the eligibility of the 
indium(III) complexes for their use in vivo.. The complexes 
demonstrated less adequate in vivo stability than the analogous 
gallium complexes and there is evidence for dissociation with activity 
present in the liver, in particular, after 24 hours. The In-9N3C3Ph3 
complex appears to be the most unstable, the high concentration of 
indium in the liver after 24 hours is probably due to the free indium 
being scavenged by transferrin and deposited in the liver. _ The 
modification to the lipophilicity of the complexes introduced by the 
presence of the methyl and phenyl groups affects the way the 
complexes are processed by the body. With the gallium complexes, 
the more lipophilic complexes (phenyl) tend to excrete via the hepato-
biliary route, whereas the parent, 9N3P3Me3 and 9N3C3Me3 are 
mainly excreted through the kidneys. The indium complexes show a 
similar order of preference which is shown below. The only difference 
is that the iilIn-9N3C3Me3 shows a slight preference for the hepato-
biliary route, although it is excreted mostly via the renal pathway. 
The excretion preferences for the complexes are summarised below. 
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3.4.7 A Second Investigation Of The Biodistribution 
Of The lllln-9N3C3Ph3 Complex 
Graphs 14a and 14b, indicated that the lUln-eNsCsPhs 
complex was xmstable in vivo. A second sample of the DNsPsPhs was 
submitted for biodistribution to clarify this. 
98 
3.4.8 The Data 
The experimental details are the same as those used in the 
previous experiments. The data is presented below (Table 3.6): 
9N3C3Ph3 
One Hour 
9N3C3Ph3 
24 Hours 
Tissue %dose/g 
%dose 
%dose/g 
%dose 
Blood 0.694 
2.70 
0.115 
0.478 
Brain 0.036 
0.017 
Femur 0.234 
0.038 
0.247 
0.039 
Skeleton 
0.915 1.03 
Heart 0.219 
0.034 
Kidneys 12.0 
8.935 
1.48 
0.96 
Liver 0.821 
1.77 
0.664 
1.4 
Lungs 0.446 
0.095 
0.177 
0.036 
Spleen 0.166 
0.019 
0.17 
0.016 
Gall bladder 
0.100 
Stomach 
0.095 0.038 
S. Intestine 
8.86 0.437 
Caecum/L.Int 
-estin 1.638 0.425 
Urine 
66.3 0.08 
Table 3. 6 The Biodistribution Of The l^Un-SNsCsPhs Complex 
99 
GRAPH 18a: Blodlstr lbutlon i% dose) of the 
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lndium-9N3C3Ph3 complex (second investigat ion) 
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3.4.9 Discussion 
The new results indicate that the complex was excreted quickly 
and remained stable. The excretion pathway is similar to the 
analogous gallium complex and travels via the liver (Hepato-biliary) 
with some going via the renal pathway. This is substantially 
different to the results of the previous experiment, where we 
concluded that the complex was imstable. 
This difference may be explained by the influence of the ligand's 
stereochemistry. The sample, used in the second experiment^ was 
from the first batch of elutants, containing the triester, taken off the 
alumina column. The previous sample had been from the main 
fraction of elutants. If the diastereoisomers have different polarities, 
then it is possible that each sample may have contained a larger 
amount of either diastereomeric pairs, e.g. SSS and RRR or SRS and 
RSR. If that was the case, the results indicate that the isomer present 
in the first experiments forms a less stable complex with indium, 
than the predominant isomer used in the second experiment. 
Figure 3.3 represents the possible solid state conformation of the 
two diastereomers. The drawing is based on the conformation of the 
SNsCsMes ligand when complexed with indium (Section 2.3). Phenyl 
groups have been added in place of the methyl groups. 
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RSR 
Figure 3.3 Schematic Representation of the Complex's Solid State 
Conformation 
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With the RSR (and SRS) isomer, the acid group attached to the 
carbon with the S configuration is twisted in the opposite direction to 
the other carboxylate groups (Figure 3.3) The effect of this may 
influence the ability of the macrocycle to adopt a conformation that 
provides optimum donor-atom-In bond lengths. Therefore it may be 
possible that one of the diastereomeric pairs is less stable than the 
other. 
To summarise, it seems that each experiment was carried out 
using a mixture of the SNaCsPhs isomers which contained more of 
one set of diastereomers than the other. Those diastereomers 
predominant in the second experiment form a much more stable 
complex than those isomers predominant in the first experiment. 
To further investigate this phenomena would necessitate the 
separation of the isomers, identification of the configuration of each 
one, and a further biodistribution study. 
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3.5 GALLIUM-67 C O M P L E X U P T A K E BY 
X E N O G R A F T S O F HUMAN M E L A N O T I C 
MELANOMA IN MICEl 
3.5.1 Introduction 
This section reports on the biodistribution of the gallium 67 
complexes 9N3, SNsPsMes, BNaCaPha, DOTA and citrate in mice 
that had previously grafted with a human melanotic melanoma 
(HX118). 
The incentive for this study arose from the results of a 
investigation into the biodistribution of the gallium-9N3 complex in 
timiour bearing mice. 
The summarised results are as follows; 
67Ga-9N3 complex cleared faster from all tissues (and the 
blood) than from the timiour. 
The concentration ratio xenograft: blood was = 20:1, 4 hours 
after introduction of the complex. 
After 4 hours only 4.5 % of physical decay has occurred 
ensuring near maximum signal: noise ratio. 
This led to a suspicion that the complex was specifically binding 
to melanin and may provide a useful means of detecting melanotic 
melanoma metasteses using SPECT, 
iThe data collection was carried out by A. Harrison and L . Royle, MRC, Radiobiology 
Unit, Didcot 
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3.5.2 Experimental Method 
The experimental method used was similar to that given in 
chapter 5. The major difference is that the mice had been previously 
injected subcutaneously in the flank with HX118 cells. After 6 to 8 
weeks, the timiour volume is large enough (0.05ml) for their use in 
these experiments. At this time the mice are injected with 10-25 |iCi 
of the radiometal complex. A fatal injection of sodimn pentabarbitone 
was administered to kill the mice at 1, 2, 4, 8 and 24 hours. 
Also l53Gd-DOTA was investigated as part of the experiment. 
Because the 153Gd-DOTA complex is anionic and remains 
extracellular, it was hoped to to compare its biodistribution with 
those of the other (charge neutral) complexes, that can diffuse into 
the cells. 
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3.5.3 The Biodistribution of the G^Gallium Complexes 
in Tumour-Bearing Mice 
The results of the investigation are shown in graphs 19-20. 
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Graph 19 (A+B):Concentration of 67Ga-9N3 in blood, HX118 tumour 
and seven other tissues between 1 and 24 h after injection. 
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Tumour And Other Tissues 4 h After Injection. 
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The data from the graphs is summarised below; 
67Gallium-9N3C3 
At all times the the radioactivity produced by the complex, as 
compared to all the other organs, was greatest in the tumour 
(approximately twice), except for the liver and the kidneys, where 
the activity was 2 and 3 times that of the tumour. 
The complex was excreted through the kidneys (RENAL). 
The Other Complexes 
The gallium-citrate complex demonstrates what occurs when a 
weak complex is introduced in vivo and dissociates, clearing slowly 
from all the organs and especially slowly from the liver, lungs and 
femur. At 4 hours the concentration of the gallium in the citrate 
treated mice was very high, and the amount 67Ga in the blood is 
5.8%g-l -this value is higher than in any other tissue and the HX118 
timiour. 
The hpophilic complexes 67Ga-9N3C3Ph3 and 67Ga-9N3P3Ph3 
cleared fi-om the blood comparatively more slowly than Ga-9N3C3 and 
the concentration in the tumour at 4 hours was = 0.13% g-l. Both of 
the complexes cleared quickly and we may conclude that they 
remained intact m vivo. 
The l53Gd-DOTA complex cleared faster than Ga-9N3 in most 
tissues. This resulted in much lower concentrations in these tissues. 
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3.5.4 The Tumour: Blood Ratios At 4 Hours 
The tumour : blood ratios are given in table 3.6. It is essential to 
have a high value for this ratio if the txmiour is to be detected 
successfully (SPECT, PET). 
Of all the complexes tested only the 9N3C3 complex may meet the 
required ratio for successful imaging (timiour: blood = 21). 
Injected Activity % 
67Ga-Complex Blood Tumour Tumour: 
Blood 
Clearence 
9N3C3 0.005 0.127 21.5 Renal 
9N3P3Me3 0.008 0.05 5 Renal 
9N3C3Ph3 0.121 0.13 1.1 H.-Biliary 
DOTA* 0.002 0.055 22 Renal 
Citrate 5.57 3.88 0.64 — 
* 153Gd 
Table 3.6 Concentrations of Radioactivity in Tumour and 
Blood at 4 h. 
The 67Ga-9N3C3 and 67Ga-9N3C3Ph3 complexes, which were 
eliminated via the renal pathway, had the highest tumour:blood 
ratios. The 9N3C3Ph3 complex is excreted via the hepato biliary 
route. As mentioned earlier in this chapter, the rate of clearance via 
the liver is very much fast than renal excretion with these complexes. 
This may partially explain the very low tumourrblood ratio for this 
complex. 
3.5.5 Conclusions 
The results from this investigation confirm the previous 
results(^) that the concentration of 67Ga-9N3C3 complex is greater in 
the HX118 xenograft than in the blood at 4 hours. The mechanism by 
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which the gallium-9N3C3 complex localises in the melanin is not 
understood, but is likely to be related to the slower rate of clearance 
of the complex from the timiour cells. Also this behaviour is not 
specific to the melanotic melanoma^!)- Despite this, the tumour 
localising abilities of the complex in himian melanotic melanoma 
grafted in mice are adequate for in vivo imaging. 
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C H A P T E R F O U R 
SYNTHESIS AND INVESTIGATION OF 
THE COMPLEXING AGENTS I8N4S2, 
18N4S2Me4, I8N4O2, 18N402Me4, N,N-
DIBENZYLETHYLENETHIOUREA (12), 
15N302C3 (7) AND LIGAND (9) AND THEIR 
SILVER(I), GOLD(I), YTTRIUM(III), AND 
RHENIUM(V) COMPLEXES. 
4.0 SYNTHESIS AND INVESTIGATION OF THE 
COMPLEXING AGENTS I8N4S2.18N4S2Me4.18N4O2, 
18N402Me4, N,N-DIBENZYLETHYLENETHIO-UREA 
(12), I5N3O2C3 (7) AND LIGAND (9) AND THEIR 
SILVER(I), GOLD(I), YTTRIUM(III), AND 
RHENIUM(V) COMPLEXES. 
4.1 INTRODUCTION 
This chapter is split into four sections. Each section describes 
the synthesis or attempted synthesis of the macrocycles described in 
section 1.5. Where the synthesis was successful, the results, outlined 
below, of the complexation experiments are reported. 
The first section reports the comparison of the stability of the 
silveKI) complexes of I8N4S2,18N4S2Me4,18N4O2, and 18N402Me4. 
This investigation involves the use of calorimetrically determined 
entropies of complexation and pH - metric determination of 
protonation constants of the ligands and binding constants of the 
complexes. 
The second section describes the complexation of gold(I) by the 
new complexing agent (12). 
The third section reports the characterisation of the 3d;trium(III) 
complex of I5N3O2C3 (7). NMR and HPLC radiometric methods 
were used to determine its possible use for in vivo applications. 
The final section of the chapter reports attempted the synthesis 
of the rhenium complex of (9). 
113 
4.2 T H E S Y N T H E S I S O F T H E S I L V E R ( I ) 
COMPLEXING AGENTS 18N4S2Me4,18N4O2, AND 
18N402Me4, T H E ATTEMPTED SYNTHESIS OF 
LIGAND (13) AND (14) AND THE COMPARISON OF 
T H E STABILITY OF THE SILVER (I) COMPLEXES 
OF I8N4S2,18N4S2Me4,18N4O2, AND 18N402Me4 
4.2.1 The Attempted Synthesis Of 1,7,13-Trithia-
4,10,16-Triazacyclooctadecane (13) 
Aza-thia macrocycles are difficult to prepare by standard 
macrocyclisation methods, but may be made from either 
tosylamide/thiol(lO) or amine/acid chloride^ l^) precursors. 
NHTs 
^ 2. TsCl/Pyridine 
NHTs 
(33) 
SN-TS 
U -T: 
OTs (34) 
l.NaS2/EtOH 
" .Ts 
l.Li/NHs 
(13) 
r 
Ts-N S L 
(39) 
Scheme 4.1 
The original synthetic proposal. Scheme 4.1, resulted in a 
mixture of tosylated material which proved intractable, and it was 
decided to attempt the longer synthesis outlined in scheme 4.2. 
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The esterification of thioglycolic acid with methanol yielded 
compovind (35). Aminolysis (24 hour refliix in ethanolamine) resulted 
in a 43% yield of the diamide (36). Successful reduction was carried 
out with Borane-THF. 
After trying a variety of solvents and temperature variations, 
tetratosylation was achieved with the highest yield using a mixed 
solvent system of acetonitrile and chloroform, with the initial reaction 
temperature at -15°C. The reaction could be monitored by TLC. After 
4 hours, the reaction was allowed to warm up to room temperature, 
and was filtered after a further four hours. Column chromatography 
on alumina purified the reaction mixture. 
Q s - ^ O M e 
^ MeOHffl* L, H2N NH, BH,.THF^ 
^ 8 ,— • ^ c ; — ^ 
(35) 
OMe 
OH 
NH 
S 
NH 
OH 
(36) 
SH 
^SH 
OH 
(37) 
TsQ 
Ts-N 
N—< 3 
(38) 
(38),DMF,CsC03 
(39) 
OTos 
NHTs 
S 
NHTs 
LijWHj/EtOH 
•OTos 
(34) 
H N 
,1 1 
3 
(13) 
Scheme 4.2 
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Synthesis of the dithiol (38) was carried out using a standard 
procedure, (Scheme 4.3)(12) However, this method restdted in a 
mixture of two compounds, presumably the thiol and the related 
disulphide, which coiild not be separated by chromatography. To 
remedy this problem, the reflux time of the intermediate salt (41), 
was reduced to thirty minutes. This resulted in the formation of the 
dithiol, free from the disulphide. 
OH 
NH 
OTs 
NHTs 
S 
>« 
OTs HgN NH2 /Eton 
(22) 
S — Q 
s - c 
(41) 
+ 
.NH2 
NH2 
+ 
.NH2 
\ 
NH2 
K2CO3/30mins 
•SH 
(38) 
Scheme 4.3 
The cyclisation step was attempted in DMF using caesium 
carbonate as the base. The reaction was followed by T L C , and after 
seven days, and elevation of temperature, there was no reaction. If 
more laboratory time had been available, different conditions coiild 
have been tried to facilitate the formation of the cyclic molecule (39). 
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4.2.2 T H E A T T E M P T E D S Y N T H E S I S 1,7-
BIS(DIMETHYLAMINOETHYL)-4,10-DITHIA-1,7-
DIAZACYCLOOCTADECANE (14) 
4.2,2.1 ROUTE 1 
The reaction of (34) with sodium sulphide was attempted, 
Scheme 4.4. The insolubility of sodium sulphide was a concern and a 
mixture of DMF and ethanol seemed to provide slight solubility and a 
finer suspension. The heterogenous reaction mixture was heated to 
80 °C for four days but no chemical change was observed. 
OTos 
^ N H T s 
+ Na2S, EtOH, DMF Ts—N 
N-Ts 
NHTs 
OTos 
(34) 
Me' 
Me 
/ 
O 
(44) 
Li/NHs/EtOH 
N 
CS2CO3/DMF 
2.BH3.THF 
NH HN 
(14) (42) 
Scheme 4.4 
4.2.2.2 ROUTE 2 
Reaction of (22) with the dithiol (38), Scheme 4.5, produced no 
detectable change. Whereas reaction of (43) with the dithiol (38), 
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produced a mixture of products with (45) as the main component of 
the mixture (NMR and mass spectral analysis). The nature of the 
reaction pathway that facilitated the formation of this product (and 
why the reaction conditions favoured (45) is not clear). The 
deprotonation of the thiol and subsequent nucleophilic attack at the 
opposite carbon is the obvious reaction pathway. Displacement of a 
leaving group must have occurred, although the nature of the leaving 
group is unclear. 
R' HS TS 
NTs + TsN 
R-
^ CS.CO3/DMF \ ^ ^ 
^ "^^^-f \ 
(22) R=OTs 
(43) R=Br 
HS 
(38) 
•s-
(45) 
(44) 
Me" 
Me 
/ 
Me^  Me I B r ^ c ^ j ^ e 
W Me 
CS2CO3/DMF 
Li/NHs/EtOH 
2.BH3.THF 
NH HN 
(14) (42) 
Scheme 4.5 
4.2.2.3 Conclusions 
Both of these attempts proved inconclusive. However, other 
similar cyclisation reactions^l'l^) hgye proved successful. With more 
laboratory time, and a variation of the reaction conditions, both of 
these routes may be successful in producing an alternative route to 
the thiol/acid chloride method of producing I2N2S2 
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4.2.3 SYNTHESIS OF N,N',N",N'" - TETRAMETHYL-1, 
lO-DITHIA-4,7,13,16 - TETRAAZA -
CYCLOOCTADECANE (15) 
To further investigate the thermodynamic properties of (15)(12)^  
the tetramethylated I8N4S2 complexing agent was synthesised 
(Scheme 4.6). Tetramethylation was carried out using the Eschweiler-
Clarke methylation procedure. Equimolar quantities of acetic acid 
and formaldehyde (37%) was added with I8N4S2 and heated to 100°C 
for twenty-four hours. Purification of the tetra-amine was achieved 
by a recrystallisation from hexane. 
r - \ . H r 
H N N-l^ 
H V _ / 
HCO2H/HCHO 
^ Me'N l  
"A Me 
N 
N C-Me 
•N S 
Me \ \ 
(15) 
Scheme 4.6 
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4.2.4 SYNTHESIS OF N, N', N", N'" - TETRAMETHYL 
-1,10-DIOXA -4, 7,13,16 -
TETRAAZACYCLOOCTADECANE (49)(12) 
In order to make comparative thermodynamic studies with the 
tetramethylated I8N4S2 (15) and its silver(I) complex, it was 
necessary to synthesise the I8N4O2 macrocycle (48)(12), and its 
tetramethyl derivitives (49) (Scheme 4.7). 
NHTs 
NHTs 
(50) 
CS2CO3/DMF 
I V.TS 
Ts-N N--TS^ 
^ ^ N 0 ~ / 
T S ' ^ 
(51) (52) (53) 
HBr/PhOH/CHsCOjH 
Me 
Me-N N'"^ 
O N \ H C O i H / H C H O ^ O 
A ' Me 
^ ^ N O — ^ 
Me' \ I 
HN 
^ ^ N 0-->^ 
(49) (48) 
Scheme 4.7 
The cycUsation (DMF, caesiiim carbonate) of (50) and (51) gave 
two main products, the 9-membered (53), and the 18-membered (52) 
rings in a ratio of 2:1 respectively. Detosylation was effected using 
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HBr/acetic acid/phenol, followed by recrystallisation from hexane to 
give the I8N4O2 as a colourless solid in 28% yield. Tetramethylation 
was carried out using the Eschwieler-Clarke methodology as with the 
I8N4S2. 
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4.2.5 COMPARISON O F T H E S I L V E R ( I ) 
COMPLEXES OF I8N4S2,18N4S2Me4,18N4O2, AND 
18N402Me4. 
4.2.5.1 Introduction 
This section describes the results of the thermodynamic and pH 
- metric investigation of the silver(I) complexes of (14), (48), (49) and 
I8N4S2. 
I \ Me I V / 
>r--S N — \ N \^ 
Me-N N'Me H -N (^^ 
S - ^ N O - / 
Me' \ / H \ / 
(15) (48) 
I \ Me J \ I 
Me- N N. Me H N N 
Me' V / H ^ 
(49) I8N4S2 
The failed synthesies of (13) and (14) prevented any 
complexation studies with these molecviles. 
I V H 
S \ ^ ^^ e^  Me 
/ Me ^ N 
H-N ' 
S N . - ^ / 
(13) (14) 
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4.2.5.2 Complex Stability As Determined By A 
Thermodynamic Study Of Complexationl 
The entropies of complexation for the silver complexes of 
I8N4S2,18N4S2Me4, I8N4O2 and 18N402Me4 were calculated firom 
calorifically determined enthalpies of complexation. 
Ligand 
log Ks@/ 
dm^ mol"^  
-AH/ 
kJ mol-i 
TAS/ 
kJ mol-i 
N4S2 14.1 77.0 + 3.3 
N4S2Me4 14.6 102.1 -18.7 
N4O2 11.2 59.5 + 4.4 
N402Me4 13.4 84.3 -7.8 
N2O4* 10.0 51.4 + 5.7 
N2S4* 13.7 83.2 -5.0 
S2O4* 10.3 64.0 -5.3 
4.6 38.3 -12.1 
* Data from ref. 3. " Data from ref.4. 
@ Errors in log K are typically (± 0.1) Or less, and for AH ± 0.3 kJ mol-1 or less 
Table 4.1 Stability Constants, Entropies And Enthalpies Of 
Complexation 
4.2.5.3 Discussion 
The data in table 4.1 indicates that the silver (I) complex of 
18N4S2Me4 possesses the highest stability constant of all the 1:1 
complexes with these ligands. It is 10 times greater than the oxygen 
analogue and slightly more stable than the unfunctionalised parent 
macrocycle, (I8N4S2). 
The extra stability as a result of tetra methylation (as also seen 
with the I8N4O2 complex) can be explained in terms of an increase in 
the enthalpy of complexation (table 4.1, third colimin). This suggests 
ICarried out by H. Schneider, Max-Planck Insitut fur Biophysikalische Chemie, D-
3400, Gottingen, FRG. 
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that a tertiary nitrogen is a superior a-donor for silver(I) in methanol 
solution. 
Closer scrutiny of the table also shows that the enthalpic 
advantage afforded by the tertiary amine is offset by the decrease in 
the entropy of complexation for these methylated macrocycles. A 
difference of 22 k J mol-1 and 12.2 k J mol-1 between the I8N4S2, 
I8N4O2 complexes and the methylated analogues may be xmderstood 
as a result of two factors: 
Firstly, the presence of the methyl groups causes a strained 
transition state leading to the complexation, which forces the 
macrocycle into an xmfavourable conformation before complexation is 
attained. The obvious reason for this is that the methyl groups are 
interacting unfavourably with their neighbours. 
Secondly, the desolvation of the ligand is an important 
contributory factor in the AS term. The secondary amines of (14) will 
form stong hydrogen bonds with the solvent whereas the methylated 
macrocycle cannot, and futhermore solvation is inhibited by the 
presence of the bulky methyl groups. Undoubtedly the higher 
(unfavourable) enthalpy of ligand desolvation for the secondary 
amine cycles compared to the tertiary amine analogues is also 
contributing to the observed AH differences. 
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4.2.5.4 Complex Stability As Determined By A Study 
Of The Protonation Constants Of The Ligands And 
The Binding Constants Of The Silver Complexes^. 
The protonation and binding constants of the silver (I) complexes 
of I8N4S2 and 18N4S2Me in aqueous solution were measured (298K, 
0.05 mol dm-3 NMe4N03) (Table 4.2). The method employed was to 
use pH-metric titrations in the absence and presence of Ag+. 
Ligand pKi pK2 pKs pK4 log log log log 
KAgL KAgLH KAgLH2 KAgLH3 
N4S2 9.26 8.45 5.81 4.88 10.4 9.05 6.00 4.13 
(7.91) (5.40) (3.94) 
N4S2. 8.82 8.35 4.13 3.71 9.47 8.06 4.31 
Me4 (7.41) (4.60) 
N402* 9.67 8.85 6.61 3.21 - - - -
Table 4.2 Protonation for the ligands and binding constants for the 
silver(I) complexes, (298K, H2O, I =0.1 iVMe^ATOj). Values in parenthese 
refer to protonation constants of the complexes (±0.1). * Ref5. 
Two experimental points worthy of note are that firstly, the 
protonation constants were obtained using SCOGS and formation 
constants by SUPERQUAD and also all the pH-Metric data was 
analysed by SCOGS and SUPERQUAD 
iData analysed by R. Kataky, Unversity of Durham , Durham. 
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4.2.5.6 Discussion 
The protonation constants for I8N4S2 and 18N4S2Me4 are 
similar to those for the I8N4O2 which have been reported 
previously^^\ 
The effect of the siilphur atoms has little effect on the basicity of 
the nitrogen atoms. The methylated molecule shows a slightly lower 
pKg value which is accounted for by less effective solvation of the 
conjugate acid. 
However, the binding constants for the 1:1 complexes in water 
are of the order of 10'* times lower than those recorded in methanol 
(Table 4.3). The explanation for this lies in the better solvation of the 
cation and of the ligand provided by the water molecules. 
LogK LogK 
AlogK dm3 mol-1 dm3 mol-1 
Complex (methanol) (water) 
N4S2 14.1 10.4 3.7 
N4S2Me4 14.6 9.47 5.13 
Table 4.3 A Comparison Of The Silver(I) Complex's Binding 
Constants In Water And Methanol 
Also the order of the magnitude of the binding constants for 
I8N4S2 and 18N4S2Me4 is reversed in water. The explanation for 
this is in accord with the previous discussion: an enhanced negative 
entropy of complexation, whose main contributory factor is the ligand 
desolvation. In the case when water is the solvent, the non-
methylated ligand is more highly solvated by water, and the increase 
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in entropy when these molecules are released (complexation), 
outweighs the loss of enthalpic energy needed to remove them. 
4.3 SYNTHESIS AND CHARACTERISATION OF THE 
COMPLEX OF GOLD(I) WITH THE NEW 
COMPLEXING AGENT N,N-DIBENZYLETHYLENE -
THIOUREA(12) AND THE ATTEMPTED 
SYNTHESIES OF LIGAND (56) AND LIGAND (57) 
4.3.1 The Synthesis Of The Complexing Agents For 
Gold(I). 
4.3.1.1 Introduction 
It was decided to synthesise (12), in the hope that the addition 
of the lipophilic phenyl groups would provide us with a monodentate 
molecule functionalised in such a way as to resemble the bidentate 
ligands (56) and (57), (Section 1.5.5). The synthesis of (12) was 
successful and two methods were employed to attempt the formation 
of the gold(I) complex. The failed syntheses of (56) and (57) 
prevented any complexation studies with these molecules. 
H 
N. 
/ = \ .s r x \ / 
(56) 
(57) 
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4.3.2 The Attempted Synthesis of (57) 
The S5nithetic route outlined in scheme 4.8 begins with the 
selective mono-bromination of 2,9-dimethyl-l,10-phenanthroline 
using NBS. This was unsuccessful and the reaction produced mixed 
products of the di- and tri-brominated species, despite varying the 
reaction time and concentration of the reactants. 
1. NaCN l .NBS 
l.EtOH/H* 
l . N H j / E O I 
(57) 
Scheme 4.8 
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Another approach, to synthesis (58), was attempted^S) (Scheme 
4.9). 
l . S e O j 
CHO 
l . N a B H , 
(62) 
CHO 
(63) HBr 
(58) 
Scheme 4.9 
The difficulty in this scheme was the use of borohydride to 
reduce the carbonyl to the alcohol. The reaction was very unreliable 
and the yield always unpredictable and small. Work up conditions 
were optimised to give the maximum and cleanest yield, but the 
product was always contaminated by an unknown species. We 
presumed that the boron from the reducing agent was binding to the 
phenanthroline ring and this was the cause in yield fluctuation and 
contamination of the product. Bromination was successful, and 
cyanation (Scheme 4.8) was attempted using sodium cyanide. The 
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micro-analysis confirmed that the mono nitrile was the major isolated 
product. The synthesis was not completed due to more emphasis 
being placed on the synthesis and data collection for the 9N3 
complexing agents. 
S3Tithesis of ligand (57) has also been attempted using a 
different strategy involving the use of lithiimi amide (Scheme 4.10). 
The monoalkylated phenanthroline (65) was detected in a low 
yield, but the subsequent di-alkylation was vmsuccessful. 
H 3 C - ^ L D A m ^ ^ ! ! ^ 
CH3 
H//, , a O L i 
"OH 
(64)/rHF 
Scheme 4.10 
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4.3.3 The Attempted Synthesis Of Ligand (56) 
Our initial strategy was to synthesise the diamide (68), and 
reduce this to give the tetra-amine (69), followed by cyclisation to 
give the desired ligand (56), (Scheme 4.11). 
I—NH2 
L N H 2 / C H 2 C H 2 
. S O C I 2 / D M F 
0 tJHo 
I.BH3.THF 
H 0 lilH2 
H NH2 2 . H C 1 
2 . H C 1 
( 5 6 ) 
Scheme 4.11 
Unfortunately, the formation of the amide via the diacid 
chloride, was unsuccessful. There was IR and I.R. evidence that the 
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monoalkylated species had formed but no indication of the formation 
of the dialkylated molecule. We were conscious of the possible 
intramolecular reaction forming camphoric anhydride (Figure 4.1). 
An I.R of the reaction mixture showed the distinctive stretch at 1770 
cm -1 
Figure 4.1 The formation of Camphoric Anhydride. 
We proposed a different synthetic pathway, firstly forming the 
ester of the camphoric acid to inhibit anhydride formation (Scheme 
4.12). 
l .EtOH/HCl 
J I.BH3.THF 
2.HC1 
( 6 9 ) (7t) 
Scheme 4.12 
This esterification was successful (50% yield) but the conversion 
of (70) to the diamide took 14 days and the reaction mixture still 
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contained starting material. The reduction was problematic also, as 
the diamide did not dissolve in THF. The reduction took 3 weeks at 
reflux and resulted in a complex mixture which proved intractable. 
Formation of the diacid chloride was attempted again, this time 
using oxalyl chloride; the infra red spectnun (I.R. 1750,1810 cm^l) of 
the product suggests that the anhydride had formed. A new synthetic 
sequence was scheme 4.13. 
^ l.(C0C1)2 
l.MeOH/H 
0 NH 
I.RCl/Pyr (73) 
2.0H"/H20 
3.oxayl chloride 
I.HBr/Acetic Acid 
, O ^ H R 
(75) H ( 69 ) H 
Scheme 4.13 
The reaction of the anhydride (72) with ethylenediamine may 
give (73), which may be protected by forming the methyl ester (74). 
The reaction of (21) with methoxybenzenesulphonyl chloride, followed 
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by saponification and treatment with oxalyl chloride and ethylene 
diamine would give (75). Deprotection of the amine followed by a 
reduction may gives us (69), which should be readily cyclised, using 
the C S 2 reaction, to give ligand (56). 
This synthetic scheme was not carried out as the synthesis of the 
polyaza and polyoxaaza ligands took precedence. 
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4.3.3 T H E SYNTHESIS O F N,N-
D I B E N Z Y L E T H Y L E N E T H I O U R E A (12) 
N-alkylation of thiourea, a more direct route to (12), was not 
attempted as i t was assumed that S-alkylation would occur 
preferentially. 
N-benzoylation of ethylenediamine, followed by subsequent 
reduction with BH3 .THF yielded (32) in a modest yield. The 
cyclisation step(16) (Scheme 4.15) involves nucleophilic attack on the 
electron-deficient carbon centre of the carbon disulphide, followed by 
protonation and a second nucleophilic attack resulting in the 
formation of (12) (Scheme 4.14). 
• N H 2 
T H F / w a t e r 
JH f ^ N H 2 l .PhCOCI ^ p N  1.BH3.THF ^ p N H ^ P h 
^ K i u „ 10% KOH i n ^Ph 2 .6M HCl ' — ^ ^ P h 
0 
( 3 1 ) ( 3 2 ) 
1. CS2 
2. HCl 
( 1 2 ) 
Scheme 4.14 
^ C — S - / ^ P h 
I—NHR r -NHR 1HC1 
NHR ^ l_NHR -HoS " - - M ^ 
R=CH2Ph 
Scheme 4.15 
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4.3.4 Complexation Of Gold(I) By N,N-
Dibenzylethylenethiourea (12) 
Parker and RojKl^) have shown that thiodiglycol is a smtable 
reducing agent for gold(III). The propensity for thiodiglycol to reduce 
gold(III) is coupled with its ability to form a stable gold(I) complex in 
water. The complex is strong enough to stop the disproportionation 
of the gold(I) ion, but is easily displaced by a stronger donor. It was 
for these reasons that thiodiglycol was chosen as the reducing agent 
which permitted an attempt to form the complex of (12) with the 
gold(I) ion stabilised and reduced in one step. Evidence for the 
reduction and stability of the gold ion is given by NMR and is also 
indicated by the lack of appearance of a gold mirror. 
The experimental procedure (Scheme 4.16) involved mixing of 
the gold(III) precursor with three equivalents of thiodiglycol. Gentle 
warming of the solution is all that is necessary to form the gold(I) 
precursor. 
+ Gold(III) H O . 
H O 
O H 
O H 
+ 
o 
I I 
s. 
O H 
Scheme 4.16 
After the formation of the intermediate, one equivalent of (12) 
was added. At this stage no reaction could be observed (precipitation, 
colour change, etc ) and to facilitate the precipitation of the complex a 
large anion was added (BPh4-, PFe"). After the addition of these 
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anions, no precipitation was observed. ^NMR showed that the 
complex in solution was the gold complex of thiodiglycol. This 
suggested that the thoiodiglycol was in some way preventing (12) 
from binding. The possible reasons for this may have been that (12) 
was thermodynamically a weaker ligand and thiodiglycol binds in 
preference (Equation 4.1). 
K,>>K 2 
j ^ h ^ - - - ^ p r n 
^ P h ^ ^ P 3 ^ 
K, 
Equation 4.1 
Another possible reason may be that the presence of the bulky 
benzyl moiety could be causing a steric hindrance and creating an 
energy maximvim in the kinetic profile which drastically slows down 
the rate of complexation. 
After incubating the solution at 40°C for 24 honrs no precipitate 
was observed. 
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4.3.5 Use Of N,N-Dibenzylethylenethiourea (12) To 
Reduce Gold(III) To Gold(I). 
Another attempt was made to form the complex using (12) itself 
to reduce the gold(III) in situ (Scheme 4.17). 
•Ph 
=S +Au( l l l ) - Au( l ) + 
•Ph 
Ph-A 
Scheme 4.17 
After warming the coloured solution of gold(III) with (12) the 
solution became colourless^ NMR showed the characteristic 
signal shift for (12) indicating that the change in colour of the 
solution was due to the reduction of the gold(III). The addition of the 
larger anion, tetraphenylborate caused the precipitation of a pale 
yellow solid. Microanalysis, NMR and FAB mass spectral analysis 
indicated that the complex had formed, although i t was contaminated 
^Prolonged or excessive heating resulted in disproportionation, suggesting that the 
complex was unstable. 
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with a coprecipitate, probably a salt of teraphenylborate. NMR 
indicated that the previously equivalent protons of the Hgand had 
become nonequivalent upon complexation. 
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4.4 S Y N T H E S I S O F I 5 N 3 O 2 C 3 (7 )AND 
C H A R A C T E R I S A T I O N O F T H E Y T T R I U M C O M P L E X 
4.4.1 Introduction 
As mentioned briefly in chapter 1, a substantial amount of 
research has taken place in the use of polyaza and polyazaoxa 
macrocycles to complex yttrium(III)(6). The work of Cox and Parker 
is briefly summarized below and gives a formative overview of the 
precedent set by their extensive research. 
4.4.1.1 Stability Constants Of TetraazatetracarboxyUc 
Acid Macrocyclic Complexes of Yttrium(III) 
Cox reports the stability constants of five known yttrium 
complexes given in table 4.4 
Complex DOTAa TRITAa TETAa DTPA(«> EDTA^S) 
Y L 24.9 19.6 16.3 22.1b 18.1b 
Table 4,4 Stability Constants (LogK) of the Yttrium Complex. 
a) T = 298 ±0.1K 1=0. IM [(CH^^NOsJ. 
b) T = 298K I =0.1M [KNO3] 
The order of magnitude of the stability constants measurements 
are: 
Y(DOTA)- > Y(DTPA) > Y(TRITA)- > Y(EDTA)2- > Y(TETA)-
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In a summary of this work. Cox discussed the possible reasons 
for this trend. He suggested the following explanations: 
The propylenediamine groups of the six-membered 
chelate rings are more sterically crowded, due to 
unfavourable eclipsing interactions, than the smaller five-
membered chelate rings. 
The macrocyclic conformation - that is the position 
adopted by the macrocycle after complexation - is 
dependent on the size of the chelate rings. The 
conformation adopted by Y(DOTA)- is the antiprismatic 
quadrangular [3,3,3,3] conformation. This is known to be 
the most stable conformation for octadentate yttrium 
complexes, as the repulsion energy between donors is 
minimised. The other possibility is a dodecahedral 
conformation, which is a less stable structure due to 
unfavourable steric interactions. 
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4.4.1.2 Measurement Of The Rate Of Uptake Of 
Yttrium(III) By The Macrocyclic Complexes 
I f the eventual use of the yttrium complexes is the specific 
targeting of radionucleides in vivo, the rate of uptake by the 
complexing agent is a critical factor in a successful application. This 
becomes obvious when taking into consideration the half-life of the 
)rttriiam nuclide and the time taken for the radio-conjugate to localise 
at the tumour site. (90Y: p- (2.3 MeV), ty2 = 64 hours) 
Using I H NMR, Coxd) was able to estimate the rate of uptake of 
the yttrium complexes of DOTA, TRITA, ODOTRA, and DTCTA. His 
results show that all the complexes are fully formed within ten 
minutes. 
Further to this, the rate of forward binding was assessed by 
HPLC radiometry. He concludes that the approximate order for the 
extent of yttrium uptake is: 
DOTA > DTCTA > ODOTRA = TRITA » TETA 
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4.4.1.3 I 5 N 3 O 2 C 3 • A New Macrocyclic Complexing 
Agent For Yttrium(III). 
CO2H HO2C 
I 5 N 3 O 2 C 3 (7) 
The yttrium complex of DTCTA which was synthesised by 
Cox(6), proved to be a poorer complexing agent than DOTA. The 
presence of the five-membered chelates and the overall neutrality of 
the complex appeared to be offset by the presence of the harder 
oxygen donors and possibly a more strained conformation. 
It was decided to prepare I5N3O2C3, which could be considered 
as a macrocyclic analogue of DTPA, with three contiguous nitrogen 
donors. The macrocycle was synthesised and characterised by FAB 
MS, IH NMR and HPLC radiometry. 
4.4.2 SYNTHESIS O F 7,10,13-TRIS(CARBOXY 
METHYL)-1,4 -DIOXA-7,10,13-TRIAZACYCLOPENTA 
-DECANE (7) 
The crucial step in this synthesis (Scheme 4.18) is the cyclisation 
step (Scheme 4.19), and a judicious choice of base is requiredC *^^ ^ It is 
thought that because of the size of the caesium ion, the use of 
caesium carbonate is advantageous. The reaction proceeds via the di-
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caesium salt followed by two nucleophilic displacements of the tosyl 
groups . 
NHTs 
NHTs 
I ! 
N 
f 
Ts 
^2Cs"] + 
-OTs 
-OTs 
SM2 
SM2 
Scheme 4.18 
An excess of base is required, as the bicarbonate ion is not 
sufficiently basic to deprotonate the tosyl-amide at a reasonable rate. 
I t has been suggested that the ion-pairing ability of caesium 
carbonate in DMF (caesium is a large ion and is poorly solvated by 
such dipolar solvents) causes contact pairs to be formed rather than 
purely solvated ions. The effect of this is to bring caesium into close 
proximity to the counter-ions and to promote intramolecular 
reactions as opposed to oligomer-forming intermolecular reactions. In 
addition, due to the large size of the caesium ion, i t enables the SN2 
reaction to occur on the surface of the ion, with a prearranged 
position, creating a favourable entropy change for the reaction. 
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Scheme 4.19 
Detosylation of (26) was at first attempted with hydrobromic 
acid, acetic acid, and phenol. The isolated yield of this reaction was 
less than 5%. The use of liquid ammonia and lithium metal was much 
more successful, giving yields of up to 80%. The final stages of this 
synthesis involved alkylation followed by hydrolysis of (28), to yield 
the target molecule which was isolated as the hydrochloride salt. 
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4.4.3 Estimation Of The Rate Of Yttrium Uptake 
Using i H NMR 
Using a similar experimental method as Cox(6) a series of 
NMR experiments were made to make a semi-quantitive assessment 
of the forward rate of 3i;triimi uptake by I5N3O2C3. 
An IH NMR spectra was recorded of a 0.028 moh^ dm-^  solution 
of the complex at pD 5 as a comparison for the NMR of the 
yttrium complex. 
Next the solution of the macrocycle was mixed with one 
equivalent of yttriima nitrate (in D2O) and immediately placed within 
the NMR probe and the spectra recorded. After a further 10, 50, 110 
and 170 minutes the spectrum was measured again. After three 
hours, ten more equivalents of yttrium were added and the NMR 
measured after 30 minutes. Figure 4.2 shows some of the spectra. 
The spectriun of the complex is complicated and precludes any 
detailed analysis. The presence of the yttrium metal causes the 
various signals to spread out. The complex pattern suggests that 
previously equivalent methylene protons were diastereotopic and 
once the ligand is bound to the yttrium ion the position of these 
protons becomes fixed and they are no-longer symmetrically 
equivalent. Also the sharpness of the spectral peaks indicate that the 
ring is rigid. 
After ten minutes there was no significant change in the 
NMR spectrum. Neither was there any change when further 
yttriimi(III) was added. Therefore it was concluded that the complex 
must have formed within 10 minutes. 
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Figure 4.2 iH NMR Spectra (400MHz, D2O, pD 5, 298K) of; 
A) I5N3O2C3 B) Y(15N302C3) after 10 min. C) Y(15N302C3) after 
3 hours. D) Y(15N302C3) after 3.5h and with 11 equivs. ofY3+. 
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4.4.4 An Assessment Of The Kinetic And 
Thermodynamic Strength 0f 153Gd(15N302C3) Using 
HPLC Radiometryl. 
Using 153Q(i a semi-quantitive assessment was made of the 
kinetic and thermodynamic stabihty of the new complexing agent. 
Because '^^^Gd is physically and chemically very similar to yttrium it 
was chosen as a suitable radioisotope to test the new macrocycle. 
Gd-15N302C3 was prepared by incubating 2 mmols of I5N3O2C3 
in 200 nM ammonium acetate solution (pH 6.5) with trace amoimts of 
153Gd at 37°C for between 0.5 and 5 hours. 
The l53Gd-15N302C3 was then incubated with DTPA; 
a) Ten-fold excess of DTPA for 5 mins.. 
b) Himdred-fold excess of DTPA for 5 mins.. 
c) One-fold excess of DTPA for 5 mins.. 
d) Ten-fold excess of DTPA for 30 mins.. 
a) 1. The gadolinium and I5N3O2C3 were incubated together for 30 
minutes before the addition of the DTPA. 
a) 2. The gadolinium and I5N3O2C3 were incubated together for 4 
hours before the addition of the DTPA. 
The results of these experiments are given in table 4.6. 
1 Experiments performed by A. Harrison and L. Royle, MRC, Radiobiology 
Laboratory, Didcot, Oxon. 
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Retention 
Time (mins) 
a) 1. a) 2. b) c) d) Species 
Detected [DPTA} 10 X 10 X 100 x Ix 10 x* 
4.4 6.04 6.49 5.70 4.73 Gd-15N302C3 
4.9 4.35 4.60 36.64 Gd-15N302C3 
6.8 0.08 Intermediates 
7.5 1.35 0.89 10.91 Intermediates 
9.9 35.85 Gd-DTPA 
10.2 58.29 Gd-DTPA 
10.9 88.26 87.95 Gd-DTPA 
11.3 52.45 95.27 Gd-DTPA 
14.2 0.16 Gd-DTPA 
Table 4.6 The Retention Times and Peak Areas. * 30 Minutes incubation 
period. The letters a) to d) refer to the preparation conditions described on the 
previous page. 
4.4.5 Discussion 
The HPLC results indicate that the DTPA had stripped the 
gadoliniimi from the Gd-15N302C3 complex with ease. When 10 and 
100 equivalents of DTPA are present, approximately 90% of the 
gadolinium is complexed by the DTPA. When only one equivalent of 
DTPA present 36% of the Gd-15N302C3 complex remains intact. 
The difference in incubation period a) 1. (30min) and a) 2. (4 h) 
made no significant difference to the results, which confirmed the 
results the of NMR experiment i.e that the complex must have 
formed formed quickly (< 30 min). 
DTPA forms a very thermodynamically stable complex with 
yttrium(III) (log K M L = 22.1)(8). The successfiil challenge by DTPA 
on the Gd-15N302C3 complex indicates substantial kinetic instability 
in the (Jd-15N302C3 complex. 
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4.4.6 Conclusions 
The IH NMR experiment gave evidence to suggest that the 
Yttrium-I5N3O2C3 1:1 complex is formed quickly (< 10 min) at pH 5. 
This was confirmed (for Gd) by HPLC radiometry. 
The kinetic instability of the complex has been demonstrated 
using a DTPA challenge and the complex is therefore deemed 
unsuitable for in vivo use. 
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4.5 T H E SYNTHESIS OF LIGAND (9) AND THE 
A T T E M P T E D SYNTHESIS OF T H E RHENIUM 
COMPLEX OF (9). 
4.5.1 Synthesis Of (9) l,9-Diamino-(5-p-
aminomethylbenzyl) -3,7-diazanonane(9) 
The first step in this reaction scheme (Scheme 4.20) had been 
previously carried out in this laboratoryd^). The same procedure was 
followed. The formation of the di-amide was achieved by reaction of 
the diester (48h, 60°C) using dried ethylene diamine as the solvent 
and reactant. 
+ 
.COaEt 
COaEt 
Br l.EtOH/Na 
24h reflux 
-* -NC 
(29) 
NHo H2N 
BHo.THF 
Scheme 4.20 
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|—NH2 
— NH2 
(30) 
The following reduction reduces both the amide groups and the 
nitrile in a single step. BH3.THF was the reducing agent used, and 
completion of the reaction was deduced by monitoring the infra-red 
spectrum of quenched samples of the reaction mixtvire. However, the 
work up and extraction of the amine (9) proved not to be 
straightforward. The work-up begins with the cooling of the reaction 
mixture followed by the quenching of the excess borane by adding 
methanol dropwise. Next, the solution was refluxed in HCl (6M) for 2 
hours, and the water removed imder reduced pressure. 
This procedure is followed with a methanol wash to convert any 
of the boron species to the volatile B(0Me)3, which can be removed, 
alongside the methanol, under reduced pressure. In most cases, the 
residue is dissolved in a sodium hydroxide solution bringing the pH to 
14, thereby freeing the amine. Extraction is achieved using 
dichlorome thane. 
At this point, the mixture containing (9) was a white emulsion 
which would not separate. With the other half of the reaction 
products, the same procedure was repeated. After washing with 
methanol, instead of basifying the solution to pH 14, a different 
method of extraction was used. The approximate quantity of sodium 
hydroxide needed to neutralise the salt was dissolved in the 
minimum quantity of water. This was added to the solid residue. The 
mixture was warmed and the pH monitored and maintained (addition 
of sodium hydroxide), above pH 7. When all the residue had 
dissolved, the water was removed under reduced pressure. The 
neutralised amine residue was dissolved in hot dichloromethane, 
filtered, dried over a drying agent and the solvent removed under 
reduced pressure. 
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It is important to note that the solvent used to extract the 
compound was dichloromethane as opposed to chloroform, the reason 
being that at pH > 7, there is a possibility of the chloroform losing H-
Cl, and forming the highly reactive dichlorocarbene, which may have 
reacted with the amine and contaminated the product. 
Recrystallisation from chloroform /methanol gave the pure product. 
The next stage in the synthesis was to fimctionalise the pendant 
arm, so it may be attached to an antibody. Selective acylation 
(PhCOCl) of the primary amine was attempted using a Hpes buffer 
(pH 6.4) to selectively protonate the ring amine groups to allow for 
selective acylation. Unfortunately the pentaamine (9) would not 
remain in solution with the pH stabilised below pH 7. Dioxan was 
added to aid the solubility of the compound but was unsuccessful. 
Selective acylation was not achieved using this strategy. 
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4.5.2 T H E ATTEMPTED SYNTHESIS OF T H E 
RHENIUM COMPLEX OF (9) 
This section reports the attempted synthesis of the rhenium 
complex of (9). 
NH^ ^NH2 
(9) 
The synthetic method that was used was similar to the method 
employed by Parker and Roy^ )^, 
The complexing agent was dissolved in chloroform and the 
rhenium was added as trans-ReOCl3(PPh3)2. The mixture was 
stirred at room temperature and a small quantity of a yellow/green 
solid precipitated and was collected by filtration. 
Micro-analysis of this compoimd showed it to contain less than 
5% rhenium, suggesting a 1:1 complex had not been formed. 
NMR showed no indication of complexation. 
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CHAPTER FIVE 
EXPERIMENTAL PROCEDURES 
5.0 EXPERIMENTAL PROCEDURES 
5.1 INTRODUCTION 
Throughout this work, temperatures are quoted in °C, and 
pressures in mbar. The alumina used in chromatography was Merck 
alumina, activity II-III, 70-230 mesh and unless stated always pre-
soaked in ethyl acetate to deactivate it. 
Proton and carbon-13 NMR spectra were recorded on a Varian 
400, Varian Gemini 200, or a Bruker AC250 spectrometer. Proton 
and carbon chemical shifts are quoted in ppm to higher frequency of 
TMS. Coupling constants are given in Hz. 
Infrared spectra were recorded on a Perkin-Elmer 577 
spectrometer, as a thin film for liquid samples or a Nujol mull for 
solids, between NaCl plates. Mass spectra were recorded on a VG 
7070E mass spectrometer, using CI, DCI, FAB, or E I ionisation 
modes as stated. 
All solvents were dried using the normal laboratory procedures 
and all reactions were carried out under a dried inert gas (Nitrogen 
or Argon) unless the solvent used is water. "Water" refers to 
deionised water throughout. DMF and BH3.THF refer to Aldrich 
'Sure-Seal' reagents. 
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5.2 T H E SYNTHESIS OF T H E COMPLEXING 
AGENTS 
5.2.1 (R) - l,4,7-TRIS(2'-METHYLCARBOXYMETHYL)-
TRIAZACYCLONONANE(4) 
(R) - ly4y7-Tris(2'-Methylcarboxymethyl)-
Triazacyclononane (4) 
To a mixture of triazacyclononane (1.5g, 11.7mmol) and (S)-(-)-2 
chloropropionic acid (4.44g, 40.95mmol) in water (50 cm3) was added 
lithium hydroxide until the pH reached 10. The mixture was 
vigorously stirred at 45 °C and the pH periodically monitored and 
maintained with the addition of more lithium hydroxide. During the 
reaction, samples were removed and examined using ^H NMR to 
ascertain the amount of acid which had hydrolysed and, if necessary, 
up to 3 equivalents of acid were added. After 10 days, the reaction 
was complete (TLC, NMR). The pH was adjusted to 2 (HCl) and the 
mixture filtered and the water evaporated imder reduced pressure. 
The addition and evaporation of methanol to the residue (x3) ensured 
that it was fi*ee fi-om water. Esterification was achieved by refluxing 
the residue in methanol (20 cm )^ with 1 cm3 of sulphuric acid 
present. After 24 hours the mixture was cooled, neutralised with dry 
sodium bicarbonate, filtered and the solvent removed \mder reduced 
pressure. Purification was achieved on an alumina column using 
methanol (0-2%) / dichloromethane followed by acid hydrolysis (6M 
HCl, 60°C, 4hr) to give a white crystalline solid. (2.3g, 61%) m.p. 
265°C 
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Ester: 
NMR: 5H (CDCI3) 3.6 (9H,s,0CH3), 3.5 (3H,quartet,CH(Me)-C02Me), 
2.7 (12H, m, N-CH2-CH2-N), 1.25 (9H, d, CH3); 6c (CDCI3) 173.86 
(carbonyl), 60.95 (OMe), 52.99 (P-C), 50.1 (N-CH2-CH2-N), 15.7 (-
CH3); m (Nujol) 2900 (CH3), 1730 (CO); MS: m/z (DCI,NH3) 404 
(M+ + 17)100% , 389 (M+ + 2) 22%. 
Acid: 
Analysis found: C, 45.20; H , 7.51; N, 10.40; C15H27N3O6.HCI.H2O 
requires C, 45.06; H, 7.56; N, 10.51 %. NMR: 6H (D2O) 4.0 (3H, 
quartet, N-CH(Me)-COOH), 3.3 (12H, m,(N-CH2-CH2-N), 1,4 (9H,d -
CH3); 5c (D2O) 175.0 (carbonyl), 60.55 (p-C), 46.41 (N-CH2-CH2-
N), 10.51 (-CH3); IR (Nujol) 1740 (carbonyl);MS: m/z (DCI, NH3) 362 
(M++17) 100% . 
5.2.2 l,4,7-TRIS(2'-PHENYLCARBOXYMETHYL)-l,4,7-
TRIAZACYCLONONANE (5) 
(2)-Bromophenylmethylpropanoate (21) 
To a mixture of (2)-bromo-phenylacetic acid (5g, 0.23mol) in 
methanol (50 cm )^ was added sulphuric acid (1 cm3) and the 
vigorously stirred mixture was brought to reflux for 24 hours. The 
cool acidic mixture was neutralised with excess sodium bicarbonate 
and following filtration, the solvent was removed under reduced 
pressure. Purification was achieved on an alumina column eluted 
with CH2Cl2/hexane (1:100) and produced a clear oily residue after 
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the elutants had been removed. (4.3g, 81%). b.p.ll2°C, SmmHg [lit^ )^ 
113°, 3mmHg]; NMR: 5H (CDCI3) 7.4 (5H, s, phenyl), 4.6 (IH, m, 
CH(Ph)-C), 3.71 (3H, s, OMe); 5c (CDCI3): 171.1 (carbonyl), 136.1, 
128.1, 127.9, 126.1 (aromatic), 70.2 (p-carbon); MS: m/z (DCI) 230 
(M++1) 64%. 
lf4j7-Tris(2'-phenylcarboxymethyl)-l,4,7-
triazaxiyclononane (5) 
To a vigorously stirred solution of 1,4,7-triazacyclononane 
(0.200g, 15.6mmol) with potassium carbonate (0.72g, 52mmol) in 
acetonitrile (10 cm )^ was added the ester (21) (1.18g, 51.5 mmol). The 
temperature of the mixture was adjusted to 60°C and maintained for 
7 days. The cooled mixture was filtered and the solvents removed 
under reduced pressure. Purification by an alumina column eluted 
with (0-2%) methanol in dichloromethane resulted in a clear oily 
residue. After checking the purity of the ester using carbon and 
proton NMR, the compound was hydrolysed (6M HCl, 60°C, 24hr), to 
yeild a colourless solid, (3.8g, 48%). 
Ester 
NMR: 5H (CDCI3): 7.35 (15H, s, Phenyl), 4.37(3H,quartet, N-
CH(Ph)-CO), 3.60 (9H, s, OMe), 2.75, 2.99 (12H, d, AA'BB", J=13.1, 
CH2-N ); 5c (CDCI3): 173.68 (carbonyl), 135.9, 128.5, 126.8, 125.3 
(aromatic), 71.49 (|3-C), 52.8, 54.8 (N-CH2-CH2-N); MS: m/z (DCI) 
574 (M++1) 100%. 
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Acid 
Analysis found: C, 61.0; H, 6.11; N, 6.9; C30H33N3O6.HCI.H2O 
requires C , 61.48; H , 6.19; N , 7.17%, N M R : 5H (CD3OD): 7.44 (15H, 
s, Phenyl), 3.8 (3H,quartet,N-CH(Ph)-C ), 3.1 (12H,m ,N-CH(Ph)-C ); 
5c (CD3OD): 173.71 (carbonyl), 137.9, 129.5, 128.8, 128.3 (aromatic), 
72.51 (b-C), 51.9, 53.9 (N-CH2-CH2-N);MS: m/z (DCI, NH3) 532 
(M++1) 100%. 
5.2.3. THE ATTEMPTED SYNTHESIS OF 0,0',0''-
TRIMETHYL-l,4,7-TRIS(PHOSPHONATOMETHYL). 
TRIAZACYCLONONANE(6) 
P02H(0Me) 
N 
P02H(0Me) 
P02H(0Me) 
(6) 
l,4,7-Tris(phosphonoxy methyl)-
triazacyclononane(22) 
To a stirred solution of 1,4,7-triazacyclononane (0.19g, 1.5mmol) 
and phosphorous acid (0.374g, 4.6imnol) in 6M hydrochloric acid (3 
cm3) at 120°C was added aqueous formaldehyde (37%, 0.38g, 
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4.7mmol) dropwise over 2.5 hours. After evaporation the solid was 
redissolved in the minimum quantity of water (0.5 cm )^ and 3 cm^ of 
acetone added. The solution was decanted off; the resulting oil was 
dissolved in the minimimi quantity of water and acetone added until 
the solution became turbid. One drop of water was added and the 
mixture was warmed until clear. The cooled solution was filtered 
and the white crystals collected (0.23g, 47%). NMR: 5H (D2O) 3.55 
(12H, s, N-CH2-CH2-N), 3.31 (16H, d(JpH=11.9 Hz), N-CH2-P); 5p 
(D2O) 11.65 (s). [lit(6)]. 
0,0'fO"-Trimethyl-ly4,7-tris(phosphonatomethyl)-
triazacyclononane(6) 
A stirred solution of (22) (O.lg, 0.2mmol) with 1 cm^ of sulphuric 
acid and methanol, was heated under reflux for 3 days. and 
NMR and mass spectral analysis indicated that the sample had 
degraded. 
Hexamethyl-1,4,7-Tris(phosphonatomethyl)-l,4,7-
triazacyclononane(23) 
To a stirred solution of 1,4,7-triazacyclononane (0.2g, l.Gmmol) 
and paraformaldehyde (0.24g, 5.22mmol) was added 
trimethylphosphite (0.58g) and the mixture was brought to reflux for 
24 hours. After evaporation of the solvent the oil was dissolved in 
dichloromethane, decanted off and evaporated to yield a brown oil . 
The oil was chromatographed on alumina, eluting with 1% methanol 
/ dichloromethane (Rf 0.8) to yield a colourless oil (39%). Found 
495.38649, C27H36N3O9P3 requires495.38538; NMR: 5H (CDCI3) 3.8, 
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3.75 (9H,d,0Me), 3.05, 3.01 (6H, d, CH2-P), 2.95 (12H, s, N-CH2). 5p 
(CDCI3) 31.68 (s); m/z (DCI, NH3) 512 (M++ 17). 
5.2.4 1,4 -DIOXA-7,10,13-TRIS (CARBOXYMETHYL) -
TRIAZACYCLOPENTADECANE(7) 
l,8-Bis(p-toluenesulphonato)-3,6-dioxa-octane (24) 
To a solution of triethyleneglycol (5g, 26mmol) in P3aidine was 
added p-toluenesulphonylchloride (15g, 26mmol). Following 
dissolution of all the solid, the flask was cooled to -18 °C for 48 hours. 
The solution was poured onto ice and filtered, washed with 
hydrochloric acid (IM, 2x50cm3) and water (2x50cm3). The solid was 
dissolved in dichloromethane, dried with potassium carbonate and 
was evaporated to yield an oil which was recrystallised from 
methanol (11.9g, 70%).m.p. 80-83°C [lit(7) 80-82°C]; NMR: 5H 
(CDCI3) 7.34, 7.77 (8H, AA'BB', J= 8, OTs), 4.0 (4H, m, CH2-OTS), 
3.6 (4H, m, O-CH2), 3.4 (6H, s, OCH2), 2.43(6H, s. Me); MS: m/z 
(DCI) 476 (M+17). 
l,4-Dioxa-7,10,13-tris(p'toluenesulphonato)-7,10,13-
triazacyclopentadecane (26) 
To a solution of the ditosylate (24) (3.22g, 5.7mmol) and caesium 
carbonate (3.88g, 11.4mmol) in DMF (250 cm )^ was added a solution 
of the tritosylamide (25) (2.6g, 5.7nmiol) in DMF (100 cm3) over 2.5 
hours. The mixture was heated to 60°C for 24 hours. The DMF was 
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removed under vacuum (150°C, 0.1 nrniHg) and the residue dissolved 
in hot chloroform and filtered while still hot. Following evaporation 
the solid was recrystallised from hot toluene (70%, 2.7g). Analysis 
found: C, 54.70; H, 5.93; N, 6.3; C3iH4iN308S3 requires C,54.77; H, 
6.10; N, 6.18 %. NMR: 6H (CDCI3) 7.83 7.32 (4H, d, AA'BB',.(J=8.1), 
aromatic H), 7.72, 7.32 (8H, d, AA'BB*(J=8.1), aromatic H), 3.58 (4H, 
t, O-CH2-CH2-N), 3.50 (4H, s, CH2-O), 3.39 (4H, m, N-CH2), 3.29 
(8H, m, N-CH2), 2.44 (3H, s. Me) 2.43 (6H, s, CH3).; 5c (CDCI3) 142.3, 
142.1, 141.8,137.9,137.6, 126.9 (aromatic), 68.2 67.3 (O-CH2), 43.5, 
45.6, 42.4 (N-CH2), 23.1, 22.4 (CH3) MS: m/z (DCI) 682 (M++3) 100%, 
680(M++1) 32%. 
l,4,-Dioxa-7,10fl3-triazacyclopentadecane(27) 
To a solution of the tosylamide (26) (0.94g, 1.3mmol) in THF (24 
cm3) was added 5 cm3 of ethanol and the mixture was cooled to -78°C 
under an atmoshere of argon gas. Ammonia was condensed into the 
mixture using a cold finger imtil about 50 cm^ had been added. To 
this was added lithium metal(0.5g). The solution became intense 
blue and was left for 2 hours with the temperature maintained. After 
allowing the temperature to gradually rise and the ammonia to 
bubble off through a trap, water was added (20 cm )^ and the solvents 
were removed imder reduced presure. The residue was dissolved in 
6M HCl (50 cm3) and washed with ether (3x50cm3), The water was 
removed and the residue redissolved in 6M sodium hydroxide 
solution (25 cm )^, washed with dichloromethane (3x50cm3), and 
dried with anhydrous magnesium sulphate. After filtration the 
solvents were removed under reduced pressure and the residue 
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dissolved in chloroform; dried again using anhydrous magnesium 
sulphate, filtered and the solvent was evaporated under reduced 
presssure. The solid residue was recrystallised from 
dichlorometane/cyclohexane to give a white crystalline solid. (0.28g, 
85%). Found (M++1) 218.1832 C10H24N3O2 requires 218.1869. NMR: 
6H (CDCI3): 3.61(4H, m, O-CH2), 3.59 (4H, s, O-CH2), 2.74 (12H, 
mult, N-CH2). NMR 5c (CDCI3): 69.3 (0-C), 69.2 (0-C), 48.5, 
48.4, 47.3 (N-C); MS m/z (DCI) 219 (M++2). 
7,10fl3-Tris(ethoxycarbonylmethyl)-l,4-dioxa-7J0,13-
triazacyclopentadecane (28) 
To a stirred solution of (27) (150mg, 0.68mmol) and caesium 
carbonate (760mg, 2.04mmol) was added ethylbromoacetate (0.28 
cm3, 2.3mmol.) The stirred mixture was heated to 60°C and left for 
24 hr. The alkylation was monitored by TLC. After cooling, the 
mixture was filtered and the solvent removed under reduced 
pressure. The oily residue was purified by column chromatography 
(alumina) using 0-2% methanol in dichloromethane as the elutant, 
giving a clear oil. (134mg, 44%), Analysis found: 476.5763 (M++1) 
C22H42N3O8 requires 476.5891. NMR 6H (CDCI3): 4.15 (6H, m, 0-
CH2-CH3), 3.58 (8H, mult.,0-CH2), 3.44 (4H, s.,CH2-N), 3.39 (2H, s, 
CH2-N), 2.85 (12H, m, CH2-N) 1.27 (9H, m, O-CH2-CH3).; 5c 
(CDCI3): 170.53, 170.49 (carbonyl), 69.87, 69.79, (N-CH2-CO), 
59.49, 59.44, 59.33, 55.41 (O-CH2). 45.1, 46.9, 48.3 (CH2-N), 13.36, 
13.35 (CH3); MS: m/z (DCI) 476 (M++1) 90%). 
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1,4 -Dioxa-7fl0,13-tris- (carboxymethyl) -
triazacyclopentadecane (7) 
Hydrolysis of the triester (28) was carried out in 6M HCl (60°C, 
4hr). The solvents were removed under reduced pressure to yield the 
hydrochloride salt, a glassy solid. NMR 5H (D2O): 4.07 (4H, s, N-
CH2-C=0 or CH2O), 3.82 (6H, s, N-CH2-C=0 or CH2), 3.41-3.63 
(16H, m, NCH2, OCH2); 8c (D2O): 170.5,165.4 (carbonyl), 67.1,66.9 
(CH2-O), 65.3 (CH2-C=0), 47.2, 49.3,52.1, 52.3 (CH2-N). MS (FAB) 
392 (M ++ 1). 
5.2.5 SYNTHESIS OF l,9-DIAMINO-5-(P-
AMINOMETHYLBENZYL) 3,7-DIAZANONANE)(9) 
Diethyl-p-cyanobenzylmalonate(29) 
To a solution of sodium ethoxide in ethanol (1 mol dm-3, 125 
cm3) was added dropwise at room temperature diethylmalonate (20g, 
125mmol) in ethanol (50 cm3). The mixture was stirred for thirty 
minutes. a-Bromo-p-toluonitrile (12g, 61mmol) was added in DMF 
(60 cm3) dropwise, and the mixture refluxed for twenty-four hours. 
After filtration, and the addition of water, an oil formed and the 
water was decanted off. The oil was dissolved in ether, dried over 
potassium carbonate, filtered, and the solvent removed under 
reduced pressure. The product was purified by fractional distillation 
at O.Olmm/Hg at 50°C. (9g, 51%). TLC Rf 0.25 Dit. 0.26(2)] (20% 
EtOAc/petrol); NMR: 5H ( C D C I 3 ) : 7.61, 7.32 (4H, d,J=8, aromatic), 
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4.2 (4H, m, OCH2), 3.4 (IH, t,CH) 3.27 (2H, m, CH2-phenyl), 1.2 (6H, 
t, CH3); 5c 172.3 (CO), 141.2, 139.8, 132.6, 131.1 (aromatic), 
123.5(CN), 63.4 (O-CH2), 41.4, 39.2 (CH2-Ph), 21.3(CH3); 
I.R.(thinfilm): 3010 (CH), 2980(CH), 2230(CN); MS: m/z 276 (M++1) 
100%. 
lf9-Diamino-5-(p'Cyanobenzyl)-4,6-dioxa'3,7-
diazanonane (30) 
To a neat solution of ethylenediamine (100 cm3) was added (29) 
(2.5g, O.llmmol). The mixture was heated to 60°C for 48h. After the 
solution cooled, the ethylenediamine was removed at reduced 
pressure leaving a solid yellow residue. NMR: 6H(MeOD) 7.72, 7.41 
(4H, d, J=8, aromatic) 3.48(7H, m, CH2, CH, N-CH2), 2.9 (4H, m, N-
CH2); 5c (MeOD) 171.8 (C=0), 146.2 , 133.7, 131.5, 120.18, 
(aromatic), 111.8 (CN), 46.9, 45.1(CH2-N), 43.5(C-CO), 37.4 (C-
aromatic); MS m/z (DCI, NH3) 320 (M++17) 100%. 
l,9-Diamino-5-(p-aminomethylbenzyl)-
3,7, diazanonane (9) 
To a solution of BH3.THF (52mmol) was added the diamide (30) 
(Ig, 3.4mmol), and the mixture was heated to reflux for 72h. After 
cooling, the mixture was quenched by the dropwise addition of 
methanol. After the borane was deemed to have been quenched, the 
methanol was removed under reduced pressure, and the residue 
refluxed in 6M HCl (250 cm3) for 3.5 hours. After the solution had 
cooled the water was removed under reduced pressure and the 
residue washed with methanol to convert any of the remaining boron 
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species to the volatile B(0Me)3. After the methanol had been 
removed (rotary evaporator), the estimated quantity of NaOH 
required to neutralise the hydrochloride salt was dissolved in the 
minimum quantity of water. This basic solution was added to the 
solid residue and warmed until all the solid had dissolved, 
maintaining the pH at > 7, The water was removed under reduced 
pressure and the dichloromethane (100 cm3) added to the solid 
residue. This mixture was heated to reflux until the solid had 
dissolved. The cool solution was dried over anhydrous potassium 
carbonate, filtered and the solvent removed under reduced pressure, 
to yield a clear oily residue. The compound was purified by 
recrystallisation from chloroform/methanol to yield a glassy solid, 
(45%, 0.46g). Analysis found: C, 64.38; H, 9.47; N, 25.14; C15H29N5 
requires C, 64.48; H, 9.46; N, 25.06%; NMR: 5H (CDCI3) 7.87, 7.46 
(4H, d, AA'BB", J=8.1, aromatic) 3.4 (4H, m, CH2-phenyl), 3.13-2.51 
(12H, m, N-CH2) 1.3 (IH, m, CH); 8c (CDCI3) 140.71, 138.67,128.74, 
126.759, (aromatic), 52.71, 52.36, 51.06, 45.84, 41.2 (CH2-N, CH2-
phenyl), 21.2 (CH); MS: m/z (DCI, NH3) 296 (M++17) 33%. 
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5.2.6 THE ATTEMPTED SYNTHESIS OF (57) 
1, lO-Phenanthroline-2,9-dicarbaldehyde (62) 
To a stirred solution of selenium dioxide (7.5g, 68mmol) in 
aqueous dioxan (96% w/v) was added 2,9-dimethyl-l,10-
phenanthroline (3.0g, 14.9mmol) and the mixture was heated to 
reflux for two hours. The red solution was filtered hot through celite 
and cooled. The orange precipitate was collected by filtration (3.8g, 
76%). m.p. 231-232. Qit.d) 231°C] Vmax 2900 (br), 1700 (CHO, s)-
N M R 5H ( D M S O ) 10.2 (CHO), 8.81 (2H, AB, aromatic), 8.43 (2H, AB, 
aromatic), 8.25 (2H, s, aromatic); M S : m/e (DCI) 237 (M+1) 100%. 
2,9-Bis(hydroxymethyl)l,10-phenanthroline (63) 
To a stirred solution of (62) (Ig, 4.4mmol) in 50 cm^ of ethanol, 
sodium borohydride (0.45g, 12mmol) was added slowly to prevent 
overheating. The mixture was refluxed overnight. After evaporation 
the residue was redissolved in the minimiun volume of water, filtered 
hot and allowed to cool. The orange crystals were collected by 
filtration (10%). m.p. 196-199° Ditt.d) 197-199°] N M R : 5H ( D M S O ) 
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8.94,(2H, AB, Ar), 8.37 (2H,AB, Ar), 5.31 (2H, s, Ar) 4.9(4H,s,CH2). 
I . R . Vxnax 3600-3100, 1630, 1510, 1170, 850 cm-i; M S : m/z ( D C I ) 241 
(M+-^l), 100%. 
2,9-Bis(bromomethyl)l,10-phenanthroline 
hydrohromide. (58) 
A stirred solution of (63) (1.35g, 5.8mmol) in 48% (w/v) hydrogen 
bromide solution (60 cm )^ was heated to reflux over-night. The 
solution was cooled and solid potassium hydroxide added until 
precipitation was complete (2.5g, 95%). Analysis found; C , 44.2; H, 
3.5; N , 7.3; Ci4Hi2N2Br2 requires C , 43.2; H, 3.15; N , 7.3; m.p. 111-
112°C [lit.(l) 110-111]; N M R : 8H (DMSO) 8.63, 8.04 (2H, AB, J=11.2, 
Ar), 8.12 (2H, s, Ar), 4.93 (4H, s, CH2). M S : m/z ( D C D 359 (M+1). 
2-cyanomethyl-9-bromo-lfl0-phenanthroline (59) 
To a stirred solution of (13) (0.18g, 0.35mmol) in 20 cm3 of 
ethanol was added potassium cyanide (0.056g, 0.87mmol) and the 
mixture heated to reflux overnight. The cooled solution was poured 
onto aqueous sodium carbonate (20 cm ,^ 5%) and extracted with 
dichloromethane (4x20cm3), dried with potassium carbonate and 
evaporated to yield a brown oil (0.06g, 70%).; Analysis found; C, 
56.79; H, 4.05; N, 9.27; CieHioNsBr requires C,57.7; H, 3.3; N, 13.46 
NMR: 8H (DMSO) 7.8, 8.5, 7.95 (6H, mult., Ar), 4.9 (4H, s, CH2-Br); 
4.1 (2H, s, CH2-CN); 5c (DMSO) 150.1, 145.7, 136.5, 125.6, 129.0, 
110 (aromatic) 36.7 (CH2) 34.7 (CH2): I.R:. (thinfilm) 2950, 2220 
(CN); MS m/z312,(M+-Hl)100%. 
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2,9-BIS(N,N-DIMETHYLACETEMIDO)l,10-
PHENANTHROLINE (15) 
2'(NfN-dimethyleneacetamido)-lflO-phenanthroline 
(65) 
1) Preparation ofLDA 
To a solution of diisopropylamine (6.2 cm3,44mmol) in 10 cm^ of THF 
was added butyllithium (17 cm3, 2.55M, 44mmol) and the solution 
stirred for twenty minutes at -78°C. 
2) Preparation ofLithiate (64) 
To a solution of LDA (44mmol) was added N,N-dimethyl 
acetmide (4 cm3, 44mmol) and the solution stirred for sixty 
minutes at room temperature. 
To a suspension of phenanthroline (Ig, 5.1 mmols) in benzene 
(20 cm3) was added (64) (44mmols) and the mixture was stirred 
overnight at room temperature. Water was added (10 cm3) at 0°C 
and the aqueous layer separated and extracted with dichloromethane 
(4x20cm3). After combining organic washings, 20g of manganese 
dioxide was added. The reaction was followed by TLC. When it was 
complete 20g of magnesium sulphate was added and the filtered 
solution evaporated to yield a dark red oil. 5H (CDCI3) 8.7 (2H,m , 
Ar), 7.7 (2H, m, Ar)„ 7.1 (2H, m, Ar), 3.6 (4H, s, CH2-C=0), 2.63 (3H, 
s, CH3), 2.54(3H, s, CH3). MS: m/z (DCI) 266 (M-f-1). 
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2,9-Bis(N,N-dimethylacetamide)-l,10-phenanthroline 
(66) 
Procedures 1), 2) and 3) were repeated substituting the mono-
alkylated phenanthroline (65) for phenanthoHne in procedure 3). No 
further reaction could be detected. 
5.2.7 THE ATTEMPTED SYNTHESIS OF LIGAND (56) 
Diethyl camphor ate (70) 
To a solution of camphoric acid (20g, lOOmmol) in ethanol (500 
cm3) was added sulphuric acid (2 cm )^ and the mixture brought to 
reflux for 48 hours. Sodium carbonate solution (5%) was added to pH 
7 and the mixture evaporated. Water (100 cm )^ and ether (100 cm )^ 
were added forming an inseparable viscous solid. After evaporation 
to give a clear oil, ether was added (100 cm )^, the solution washed 
with water (3x20cm3), dried over magnesium sulphate and 
evaporated to leave a clear oil (lOg, 50%). NMR: 8H(CDC13) 4.12 (3H, 
m, C H 2 ) , 4.15 (3H, m, C H 2 ) 2.3 (IH, m, CH), 1.85 (2H, m, C H 2 ) , 1,63 
(2H, m, C H 2 ) 1.21-0.97 (15H, m, C H 3 ) ; I.R. 2900 (CH,br), 1720 
(MeOC=0) cm-1. M/e (DCD 257 (m+1, 100%). 
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2f5-Bis-(N-2-aminoethylcarbamoyl)-lfl,2-
triinethylcyclopentane(71) 
A solution of (70) (lOg, 50mmol) in dioxan (10 cm3) was added 
dropwise over one hour to 50 cm3 of ethylenediamine. It was heated 
under reflux for 2 weeks. The reaction was followed by its I.R 
spectrum. The solvents were removed under vacuum (20°C, 
0.3mmHg) and a brown gum resulted, which was used directly 
without purification. I.R. 1650 (C=0, sh); MS: m/z (CI) 285 (M++1) 
80%. 
2,5-Bis (4 '-amino-2 *aza-butyl)-l, 1,2-
trimethylcyclopentane(69) 
Borane-THF (150 cm3, 131mmols) was added to (71) (3.7g, 
13mmols) and the mixture brought to reflux for three weeks. The 
reaction was followed by the change in its I.R. spectrum. After 
addition of methanol (50cm-3) followed by evaporation and reflux 
with 6M hydrochloric acid (100 cm3) for two hours, the mixture was 
brought to pH 14 with solid potassium hydroxide and extracted with 
dichloromethane (5x20cm3). The carbon-13 spectrum of the resulting 
oil contained a myriad of signals suggesting the product had 
degraded. 
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Camphoric anhydride (72) 
To a suspension of camphoric acid (Ig, 5mmols) in 
dichloromethane (20 cm3) was added oxalyl chloride (2 cm )^ and one 
drop of DMF. The mixture was stirred at room temperature until the 
suspension became clear. Solvents were removed under vacuum 
(O.lmmHg), dichloromethane added (5 cm )^ and removed under 
vacuum (x3). Dichloromethane (10 cm )^ was added and to this 
solution was added ethylenediamine (1 cm )^ in dichloromethane (10 
cm3). After evaporation, a white gununy solid resulted. I.R. 1650 
(RHN-C=0,HO-C=0, br) cm-1. jviS: m/z (DCI) 243 (M+l).[lit (4)] 
5.2.8 N,N-DIBENZYLETHYLENETHIOUREA(12) 
N,N-Dibenzoylethylenediamine(31) 
To a stirred solution of aqueous KOH in THF (100 cm3, 10% 
KOH w/v, 50% THF) and ethylenediamine (5g, 28mmol) at 0°C was 
added benzoyl chloride (11.9g, 85mmol) over 1 hour. The mixture 
was stirred at room temperature for 24 hours. The white solid was 
filtered off, washed with methanol and dried under vacuum. (4.5g, 
60%). m.p. 75°C; I.R.; Vmax (thin film) 3280 (NH, Br), 1625 (NC=0) 
cm-1; MS: m/z (CD 269 (M+1). 
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N,N-Dibenzylethylenediamine (32) 
BH3.THF (IM, 75 cm3, 75mmol) was added to dry (31) (2g, 7.5 
mmol) and the mixture was stirred at reflux for 24 hours. Methanol 
was added dropwise to quench the excess borane until the 
effervescence had ceased. After evaporation of the solvent, 6M HCl 
(200 cm3 ) was added to the oil eind the mixture left to boil under 
reflux for three hours. After evaporation, 50 cm3 of distilled water 
was added along with solid KOH and the solution brought to pH 14. 
Extraction with dichloromethane (3x20cm3) followed by drying with 
potasium carbonate and evaporation yielded a clear oil. (1.67g, 90%). 
b.p 196°C. 4mmHg ait(7) 195°C]; NMR: 5H (CDCI3) 1.4 (2H, s, N-H), 
2.5 (4H, s, CH2-Ph), 3.6 (4H, s, CH2-N), 7.1 (lOH, s, Ph); 5c (CDCI3) 
141.2,138.6, 132.1,129.3 (aromatic), 65.1 (N-CH2), 54.1(N-CH2-CH2-
N); I.R: v^ax 3000-3500 (NH,Br), 1200 cm-1; MS: m/z (CI) 241 
(M+1). 
N,N-Dibenzylethylenethiourea(12) 
To a stirred solution of (32) (1.81g, 8.6 mmol) in aqueous ethanol 
(150 cm3,1:1) at 0°C was added carbon disulphide (0.65g, 8.6mmol) 
in dioxan (100 cm3) over one hour. After the mixture was heated at 
100°C for three hours, cone. HCl (10 cm3) was added and the mixture 
was heated under reflux for 12 hours. After evaporation the solid 
was redissolved in chloroform (50 cm3) and filtered whilst hot. The 
cooled solution was filtered and the crystals washed with water and 
dried under vacuum. (1.6g, 70%). m.p. 81°C. Analysis found: C, 
71.91; H, 6.42; N, 9.53; C17H18N2O requires C, 72.3; H, 6.42; N, 9.92; 
NMR: 5 H (CDCI3) 3.38 (4H, s, CH2-Ph), 4.89 (4H, s, CH2-N), 7.35 
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(lOH, s, Ph); 8c (CDCI3), 182.8 (C=S), 136.3, 128.5, 128.1, 127.5 
(aromatic), 51.6,45.3 (CH2-N) MS: m/z (CI) 283 (M+1), 100%. 
5.2.9 ATTEMPTED SYNTHESIS OF 1,7,13-TRITHIA-
4,10,16-TRIAZACYCLOOCTADECANE(13) 
l,10-Bis(p-toluenesulphanato)-3,8-NfN-bis(p-
toluenesulphanotoamide) -5-thia-decane(34) 
To a solution of (33) (2.3mmol, Ig) in 50 cm3 DMF was added 2-
bromoethanol (5mmol, 0.36 cm )^. The mixture was heated to 60°C for 
5 days. This resulted in a mixture of tosylated material which proved 
intractable. 
Dimethylthiodiglycolate(35) 
The esterification of thiodiglycolic acid was achieved by 
refluxing the add (0.32mol, 48g) in 100 cm3 of methanol and 5 cm^ of 
acetyl chloride for 48h, Any excess acid was neutralised with 
potassium carbonate. The pure ester was extracted into 
dichloromethane and was isolated as a colourless oil. (0.31mol, 95%) 
b.p 137°C, llmmHg [lit(4) 135°,llmmHg]; NMR: 8 H ( C D C 1 3 ) 
3.2(6H,s,OMe), 2.97(4H,s,CH2); 8c (CDCI3) 169.6(0=0), 51.8(OMe), 
32.8(CH2); IR (thin film), 1730 (carbonyl); MS m/z 179 (M++1). 
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3.8- (N,N'-2'-hydroxyethyl)-thiodiglycolamide(36) 
The diester(35) (32mmol) was added to 100 cm3 of 
ethanolamine. The mixture was reflvixed overnight. The solvent was 
removed under reduced pressure and the pale yellow solid 
recrystallised from ethanol/toluene. (31g, 43%) m.p 245°C; Analysis 
found C, 40.77; H, 6.92; N , 11.74; C8H16N2O4S requires C, 40.69; H, 
6.82; N , 11.85; NMR: 6H (CD3OD) 4.59 (4H, s, S-CH2), 3.31 (4H, t, 
J=5.7, CH2-OH, 2.99 (4H, m, CH2-N), 2.22 (2H, t, OH); 6c (CD3OD) 
172.0 (carbonyl), 61.4 (CH2-OH), 43.2 (CH2-N), 36.5 (CH2-S); IR (thin 
f i lm) 3100-3500 (OH), 1650 (carbonyl); MS m/z (EI) 237 (M++1), 
219.176. 
3.9- Diaza-6-thia-undecan-l,ll-diol(37) 
To a solution of BH3.THF (8 equivalents) was added (36) (15g , 
0.06mol) and the solution was heated under reflux for 4 days. The 
cool solution was quenched by the drop wise addition of methanol. 
Excess methanol was added and removed imder reduced pressure. 
The residue was washed with ether. The residue was refluxed in 6M 
HCl (30cm3) for 2 hours. The water was removed under reduced 
pressure and the residue washed with ether (3x20cm3). The residue 
was dissolved i n a solution of NaOH (25cm3, O.lmol dm-3) and the 
amine extracted with dichloromethane (3x20cm3). The solution was 
dried over K2CO3, filtered and the solvents removed to give a grey oil 
(5g, 33%). An alternative method of extracting the amine from the 
basic solution was the use of a anion exchange column. NMR: 5H 
(CDCI3) 3.4 (4H,t,0-CH2), 2.7 (4H,t,0-CH2-CH2-N), 2.5 (4H,t,S-CH2-
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CH2-N) 2.3 (S-CH2); 5c (CDCI3) 62.7 (CH2O), 61.6 (CH2-N), 48.9 
(CH2-N), 31.1 (CH2-S); MS m/z 209 (M++1). 
3,9-NfN'-Bis(p-toluenesulphanato)-lfll-bis(p-
toluenesulhonyl)-3,9-Diaza'6-thia-undecan-l,ll-
diol(34) 
To a so lu t ion of (37) (lOOmgs, 0.026mmol) i n 
acetonitrile/chloroform (3cm3) (50:50) and EtaN (0.16g, 1.58mniol) at 
-15°C was added tosylchloride (0.3g, l.Smmol). The temperature 
was maintained at -15°C and the reaction vigorously stirred for 4h. 
The reaction mixture was allowed to warm up to room temperature 
and was filtered after a further 4hours. The solvents were removed 
under reduced pressure and the residue purified on an alumina 
column eluted wi th 0.75% methanol i n dichloromethane to yield a 
colourless oil. NMR: 5H (CDCI3) 7.49 ,7.46 (4H,AA'BB",aromatic H), 
7.65, 7.34 (4H,AA'BB',aromatic H), 4.15 (4H,t.J=5.4,CH2-0), 3.41 
(4H, t , J=5 .4 ,0 -CH2-CH2 -N) , 3.25 (4H,t,J=8.4,CH2-N), 2.69 
(6H,t,J=8.4,CH2-S) 2.45, 2.41 (CH3); 6c 145.2, 143.9 ,135.91, 132.16, 
130.06, 129.97, 129.91, 130.6, 127.98, 127.26 (aromatic), 68.9 (CH2-
0) , 50.14, 48.28(CH2-N), 30.41 (CH2-S), 21.66, 21.51 (CHs-aromatic); 
MS m/z 826 (M++1). 
N- (p-toluene-sulphonyl) -S-aza-lf 5-bis(p-
toluenesulphonato)pentane (22) 
To a solution of toluene-p-sulphonyl chloride (107.8g, 0.565mol) 
i n pyr id ine (lOOcm^) was added a solution of bis-(2-
hydroxyethyDamine (16.5g, 0.157mol) i n pyridine (90cm3) dropwise 
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over a period of 30 min. The mixture was left at - 18°C for 48h. After 
pouring the mixture onto ice (400g), with stirring unt i l the ice 
melted, the mixture was left at room temperature for 2h to give a 
yellow-brown solid which was collected by filtration and twice 
recrystallised from ethanol-toluene (5:1) to give a yellow solid (75.0g, 
84%); m.p. 96-97°C nit(7) 96-98°]; (Found: C, 52.5; H , 4.92; N , 1.81. 
C25H29NO8S3 requires C, 52.9; H , 5.11; N , 2.11); NMR: 5H (CDCI3) 
7.75 (2H, d, J=8.1, part of AA'BB' system, aromatic H), 7.35 (2H, d, 
J=8.1, part of aromatic AA'BB' system, aromatic H), 7.28 (4H,d, 
J=8.1, part of AA'BB' system, aromatic ), 4.11 (4 H, t, J=5.9, CH2 -0), 
3.37 (4H, t, J=5.9, CH2-N), 2.43 (3 H, s, CH3), and 2.35 (6H, s, CH3). 
MS: m/z (DCI, NH3) 585 (M++ 18), 568 (M++1). 
N-(Tolyl-p-sulphonyl)- 3-azapentane-l,5-dithiolf (38) 
Thio-urea (22.8g, 0.299mol) was added to a solution of 
compound, (22), (75.0g, 0.136mol) in dry ethanol (500cm3) and the 
solution was heated under reflux, under a nitrogen atmosphere for 
30h. The solvent was evaporated under reduced pressure and the 
residue taken up i n saturated sodium bicarbonate solution (250cm3) 
and heated under reflux for 30 minutes. The cooled solution was 
adjusted to pH 7 with hydrochloric acid ( 6 mol dm-3). The aqueous 
layer was extracted wi th dichloromethane (3x250cm3), dried 
(anhydrous MgS04), filtered and the solute chromatographed on 
"flash" silica gel eluting wi th dichloromethane:methanol, (199:1). 
Evaporation of the elutes gave a clear oil which crystallised over a 
period of 24h(32.7g, 83%); R F O . 5 [silica gel: CH2-Cl2-MeOH (99:1)]; 
Analysis found (M++1) 292.0490. C11H17NO2S3 requires 292.0496; 
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NMR: 5h (CDCI3) 7.70 (2H, d, J=8, part of AA'BB' system, aromatic 
H), 7.33 (2H, d, J=8.1, part of AA'BB'system, aromatic H), 3.28 
(4H.t, J=7.5, N-CH2), 2.74 (4H, m, S-CH2), 2.43 (3H, s, CH3), and 
1.44 (2H, t, J=8.5, SH); 6c(CDCl3) 21.4 (CH3), 23.8 (CH2-S), 52.6 
(CH2-N), and 126.7, 126.9, 129.7, 135.9, 143.6 (aromatic C). MS: m/z 
(DCI, NH3) 292 (M++1). 
l,7yl3-Trithia-4,10,16-N,N,N-(p-toluenesulphonyl)-
4,10,16- Triazacyclooctadecane (39) 
To a solution of (34) (2g, 2.43mmol) and CSCO3 (2g, 6mmol) in 
DMF (80 cm3) was added (38) (0.78g, 2.1 equivalents). The solution 
was heated to 55°C wi th vigorous stirring for 2 weeks. After the 
removal of the DMF under reduced pressure, no signs of reaction 
could be discerned (TLC, i H NMR). 
5.2.10 ATTEMPTED SYNTHESIS OF 1,7-
BIS(DIMETHYLANIMOETHYL)-4,10-DITHIA-1,7-
DIAZACYCLODODECANE(14) 
Route 1 
To a solution of Na2S (0.04g, 0.026mmol) in ethanol (10 cm3) was 
added (34) (220mg, 0.267mmol), and CsCOa (0.09g, 2 equivalents). 
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The mixture was refluxed at 40°C for 4 days with no detectable 
reaction taking place (TLC, ^H NMR). 
Route 2 
N-(p-toluene-sulphonyl)-3-aza-l,5-bis(p-
toluenesulphonato)pentane (22) 
See above i n section 5.2.9. 
N-(p-toluene-sulphonyl)-3-aza-l,5-dibromopentane 
(43) 
To a solution of (22) (2g, 3.52mmols) i n DMF was added 
potassium bromide and the solution stirred at 60°C for 48 hours. The 
DMF was removed under reduced pressure and the residue dissolved 
in dichloromethane and washed with water (3 x 50cm3). The organic 
solution was dried with potassium carbonate, filtered and the solvent 
evaporated to yield a pale yellow solid. Analysis found C, 34.23; H , 
3.97; N , 3.71% CiiHi5NSBr2 requires C, 34.30; H , 3.93; N , 3.63%; 
NMR: 5 H ( C D C 1 3 ) 7.7, (2H,d,J=8, part of AA'BB', aromatic), 7.39 
(2H,d,J=8,part of AA'BB, aromatic H), 2.43 (3H, s, CH3), 2.21 (8H, s, 
CH2-CH2). 5c (CDCI3) 141.6,141.1. 136.7,136.2 (aromatic), 71.3 
(CH2-N-tosyl), 21.5 (CH2-Br). MS: m/z 386 (M++1). 
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If4-Dithia- 7,10-NyN-Bis-(p-toluenesulponyl)-7,10-
diazacyclodecane(44) 
Using reagent (22) 
To a solution of (22) (2.0g, 3.4mmol) and caesium carbonate (2.2 
equivalents) i n D M F (200 cm^) was added a solution of (38) (l.Og, 
3.25mmol) i n D M F (100 cm3) wi th vigorous stirring. The mixture 
was stirred at room temperature for two hours and monitored by 
TLC. The temperature was raised to 80°C after 3 days. TLC showed 
no change i n the starting reagents. 
Using reagent (43) 
To a solution of (43) ( l . l g , 2.65mmol) and caesium carbonate (2.2 
equivalents) i n D M F (200 cm3) was added a solution of (38) (0.8g, 
2.7mmol in D M F (100 cm^) with vigorous stirring. The mixture was 
stirred at 65°C for 4 days. The solvent was evaporared under 
reduced pressure and the residue dissolved i n dichloromethane and 
washed wi th sodium hydroxide solution and dried over potassium 
carbonate, filtered and the solvent evaporated. The residue was 
dissolved in toluene, filtered and the solvent evaporated. The product 
was pur i f ied using an alumina column eluted wi th (1:1) 
dichloromethane:toluene. The oil was recrystallised from a 
toluene/hexane mixture (9:l).(0.3g, 22%).Analysis found; C , 51.24; H, 
5.93, N , 5.44; C11H15NO2S2 requires C , 51.34; H , 5.87; N , 5.44; The 
analysis confirms that the major isolated product is molecule (45): 
N M R : 5H(CDC13) 7.72 (2H, d, ,J=8.1, part of AA'BB' system, aromatic 
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H), 7.31 (2H, d, J=8.1, part of AA'BB' system, aromatic H), 3.65 
(4H,t,CH2-N), 3.01(4H,t, CH2-S). 5c (CDCI3) 142.5, 135.7, 128.8, 
125.9 (aromatic), 50.5 (CH2-N), 38.9(CH2-S); MS: m/z (DCI) 258 
(M++1). 
5.2.11 N,N',N",N'" - TETRA1VIETHYL-1,10-DITHIA-
4,7,13,16 • TETRAAZACYCLOOCTADECANE (15) 
N,N\N",N"' - Tetramethyl-l,10-dithia-4,7a3J6-tetra-
aza-cyclo-octadecane, (15). 
l,10-Dithia-4,7,13,16-tetra-azacyclo-octadecane (80.0mg, 
0.274mmol) was heated at 95°C wi th formaldehyde (0.24cm3, 37% 
solution) and formic acid (0.32cm3) for 20h. To the cooled solution 
was added hydrochloric acid (l.Omol dm-3, 5.0cm3) and the solution 
evaporated imder reduced pressure to give a pale brown residue. 
After dissolving i n water (3cm3) the pH was adjusted to 14 with 
KOH solution and the solution extracted with dichloromethane (5 x 
5cm3), dried (anhydrous K2CO3) and the solvent removed under 
reduced pressure to give a colourless residue. Recrystallisation from 
hexane gave a white solid (52.0mg, 55%); m.p. 43-44°C; (Found: C, 
54.8; H , 10.8; N , 15.5. C16N36N4S2.I/2H2O requires C, 54.6; H, 10.4; 
N , 15.9); NMR: 5H (CDCI3) 2.64 (16H, s, CH2-N, CH2-S), 2.51 (8H, s, 
CH2-N) and 2.27 (12H, s, CH3); 5c (CDCI3) 29.2 (CH3), 43.1 (CH2-S), 
and 55.2, 57.7 (CH2-N). MS: m/z (DCI. NH3) 350 (M++2), 351 (M++3), 
335, 323, 262, 161. 
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5.2.12 N,N',N",N'"-Tetramethyl-l,10-dioxa-4,7,13,16-
tetra-aza-cyclo-octadecane (49) 
N,N',N",N"'-Tetrakis(tosyl-p-sulphony)-l,10-dioxa-
4,7,15,-16-tetra-azacyclo-octadecane, (52), and N,N'-
bis (tolyl-p-sulphonyl)-l-oxa-4,7'diazacyclononane, 
(53). 
Caesiiun carbonate (8.26g, 25.4mmol) was added to a solution of 
3-oxa-l,5-bis (tolyl-p-sulphonyloxy) pentane (5.00g, 12,lmmol) i n 
anhydrous DMF (50cm3) tmder a nitrogen atmosphere. A solution of 
N'N"-bis (tolyl-p-sulphonyl) ethane-1,2-diamaine (4.44g, 12.1mmol) in 
anhydrous DMF (50cm3) was added dropwise over a period of 4h with 
vigorous stirring. The reaction mixture was stirred at room 
temperature for 12h and heated to 60°C for 4h. The solvent was 
removed under reduced pressure, the residue taken up i n 
dichloromethane (lOOcm^) and washed wi th distilled water (2 x 
100cm3). The organic layer was dried (anhydrous MgS04), filtered 
and the solvent removed under reduced pressure to give a pale yellow 
solid. The mixture was taken up in hot toluene (40cm3) and the 18-
membered ring compound was collected as a white solid by filtration 
(warmed filtration apparatus) (1.06g, 20%). The nine-membered ring 
compound was obtained fi:-om the cooled filtrate as a crystalline solid, 
collected by filtration and dried in vacuo (10-2mmHg) (2.17g, 41%). 
Compound (53)- M.p. 160 - 161°C; (Found: C, 54.8; H, 6.02; 
N , 6.34. C20H26N2O5S2 requires C, 54.8; H , 5.94; N , 6.39;) NMR: 5H 
(CDCI3) 7.70 (4H, d , J= 8.1, part of AA' BB', aromatic H), 7.32 (4H, d. 
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J=8.2, part of AA'BB' system, aromatic H), 3.90 (4H, t, J=4.3 Hz, 
CH2-O), 3.47 (4H, s, N-CH2-CH2-N), 3.26 (4H, t, J=4.3, CH2-N), and 
2.43 (6H, s, CH3). MS: m/z (CI, NH3) 440 (M++2), 439 (M++1) and 
283. 
Compound (52) - M.p. 242-244°C; Found: C, 55.0; H , 6.13; N , 
6.12. C40H52N4O10S4 requires C, 54.8; H , 5.94; N , 6.39 ); 5H (CDCI3) 
7.71 (8H, d, J=8.1, part of AA' BB', aromatic H), 7.32 (8H, d, J=8.1, 
part of AA' BB', aromatic H), 3.54 (8H, t, J=4.9, CH2O), 3.32 (8H, s. 
N-CH2-CH2-N), 3.22 (8H, t, J=4.8, CH2-N), and 2.44 (12H, s, CH3). 
MS: m/z (CI, NH3) 880 (M++ 2) and 722. 
lO-Dioxa-d, 7,13,16-tetra-azacyclo-octadecane (48) 
A solution of hydrogen bromide i n acetic acid (45%, lOOcm^) and 
phenol (5.0g, 53mmol) was added to compoimd (52) (1.25g, 1.43mmol) 
and the solution heated under reflux for 6 days. Diethyl ether 
(40cm3) was added to the cooled reaction mixture and a fine white 
precipitate collected by filtration. This was taken up in distilled 
water (40cm3), basified with aqueous KOH (30%) and extracted with 
dichloromethane (4x40cm3). The organic layer was dried (anhydrous 
K2CO3), filtered and the solvent removed under reduced pressure. 
The residue was recrystallised from dichloromethane-hexane to give 
a colourless crystaUine solid (90mg, 25%); m.p. 58 - 60°C; NMR: 5H 
(CDCI3) 3.59 (8H, t, J=4.9, CH2-O), 2.80 (8H, t, J=4.0, CH2-N), 2.78 
(8H, s, N-CH2-CH2-N), and 2.07 (4H, br, s, NH); 6c (CDCI3) 70.0 
(CH2-O) and 49.2 (CH2N); MS: m/z (DCI, NH3) 262 (M++1) and 204, 
131. 
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N,N',N",N"''Tetramethyl-l, lO-dioxa-4,7,13,16-tetra-
aza-cyclo-octadecane (49) 
l,10-Dioxa-4,7,13,16-tetra-azacyclo-octadecane (60mg, 23mmol) 
was heated at 95°C with formaldehyde (37%, 0.20cm3) and formic 
acid (0.27cm3) for 20h. Hydrochloric acid (l.Omol dm-3, 5.0cm3) was 
added to the cooled solution and the solvent removed under reduced 
pressure. The residue was redissolved i n water (3.0cm3) and 
adjusted to pH 14 with potassium hydroxide. After extraction with 
dichloromethane (5 x 5cm3), the organic layer was dried (anhydrous 
K2CO3), filtered and the solvent removed under reduced pressure. 
The residue was treated wi th hexane (3 x 5cm3), the extracts 
combined and the solvent removed under reduced pressure to give a 
clear oil which crystallised on cooling (5°C) (59mg, 80%); m.p. = 23 -
25°C; NMR: 6H(CDC13) 3.55 (8H,t, J = 5.5, CH2-O), 2.63 (8H, t, J=5.5, 
CH2-N), 2.59 (8H, s, NCH2-CH2-N), and 2.28 (12H, s, CH3). 
5.2.13 Indium(III) Complex of (R) - 1,4,7-Tris(2'-
MethylcarboxymethyD-Triazacyclononane (4) 
A solution of indium trinitrate (30.4mgs, IxlQ-'^mols) in 0.001 
mol dm-3 nitric acid (1 cm^) was added to a mixture of (R) - 1,4,7-
Tris(2-Methylcarboxymethyl)-triazacyclononane (4) (34.9mgs, 1x10" 
'^mols) in 0.001 mol dm-3 nitric acid (1 cm3). The solution was gently 
warmed and allowed to cool to room temperature. After 24 hours an 
opaque crystalline solid precipitated. The mother liquors were 
decanted off, and the residue washed with acetone (2 cm^ x 3) and 
the solvent allowed to evaporate. The crystals were insoluble in all 
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common laboratory solvents. Analysis found: C, 38.08; H , 5.38; N, 
8.82; Ci5H24O6N3ln.0.9H2O requires C, 38.12; H, 5.4; N, 8.88 ; MS: 
m/z (FAB) 458 (M++1) 3%. 
5.2.14 SYNTHESIS OF GOLD(I) COIMPLEX OF N,N-
DIBENZYLETHYLENETHIOUREA 
Using N,N-Dibenzylethylenethiourea as the 
Reducing Agent. 
To a solution of the ligand (12) (0.3g, 1.05mmol) in chloroform (5 
cm3) was added potasium tetrachloroaurate (O.lSg, 0.35mmol). The 
mixture was gently warmed and the solution became colurless. After 
cooling, tetramethylammonium tetraphenylborate(0.35mmol) was 
added and a pale yellow solid precipitated, the solution was filtered 
and the solid dried in vacuo. (32%, 0.12g) Analysis foimd C, 59.4; H, 
4.98; N , 6.3 C58H56N4S2AU requires C, 64.4; H, 5.2; N , 5.1%;Analysis 
for Au gave 12.3%, complex requires 18.25 % NMR ^ H (DMSO) 7.13, 
7.12, 7.10, 7.03 (5H, s, aromatic), 4.28, 4.23 (4H, AB,J=20Hz, N-CH2), 
4.15, 3.95, (4H,t,N-CH2); 5c(DMS0) 23.2 (C=S), 135.6, 134.4, 126.4, 
125.3, 125.2, 124.3, 121.5 (aromatic), 56.24, 50.81, 45.50, 44.86, 44.21 
(N-CH2); MS m/z (FAB) 762(M++1) 33%. 
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5.2.15 ATTEMPTED SYNTHESIS OF THE 
RHENIUM(V) COMPLEX OF l,9-Diaimno-(5-p-
AMINOMETHYL-BENZYL) 3,7-DIAZANONANE)(9) 
To a solution of the ligand (9) ( 0.5 mmol) i n chloroform (20 cm3) 
was added trans ReOCl3(PPh3)2 (0.21g, 0.4mmol). The solution was 
stirred at room temperature for 15 minutes. A pale green precipitate 
was collected and washed with chloroform (3x3cm3) and ether 
(3x3cm3) and dried over P2O5 i n vacuo.(0.006g, 5%) Analysis for 
rhenium gave Re (4.9%) 1:1 complex requires 34%. 
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5.3 THE EXPERIMENTAL METHODS USED IN THE 
BIODISTRIBUTION STUDIES* 
5.3.1 Preparation of the 67GalIium and ^ I n d i u m 
Complexes 
The complexes were prepared as follows** 
1. A 250 111 solution of 2nM of the macrocycle is added to 100-
200 |iCi 67Ga and 0.2 M ammonium acetate at pH 5. 
2. The solution is incubated at 37°C for 30 minutes before the 
addition of a ten-fold excess of DPTA for 5 minutes to quench 
any unreacted gallium 67. 
3. The mixture is purified by HPLC on an AX300 anion 
exchange coltunn with 0.2% ammoniiun acetate pH 6.8, 10% 
acetonotrile as the running buffer at Iml/minute. 
4. The peak corresponding to the 67Ga-complex, as measured by 
a radiometer, was collected and left; at 37°C overnight to allow 
the acetonitrile to evaporate. 
5. This solution is then diluted with PBS in preparation for the 
injection. 
* These experiments were carried out by A. Harrison and L. Royle, MRC, 
Radiobiology Unit, Didcot, Oxon. 
** Quantities may differ with respect to each complex 
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5.3.2 The Experimental Details of the 
Biodistribution in Ath5rmic NU:NU Mice* 
The experimental details, as represented i n scheme 3.1 are as 
follows. 
1. The subcutaneous injection of congenitally athymic nu:nu 
mice (8-10 weeks) with a suspension of human melantoic 
melanoma (HX118). After 6 weeks the tumour volume is 
checked (minimimi 0.5 ml) before proceeding.** 
2. The mice were injected with 10-25 \iCi of the radiometal 
complex. 
3. At 1, 4 and 24 hours*** the mice were terminated with a lethal 
injection of sodium pentabarbitone. 
4. Samples of blood and urine were removed and analysed. 
5. Other tissues, as specified i n the results tables, were 
analysed for radioactivity. 
* These experiments were carried out by A. Harrison and L. Royle, MRC, 
Radiobiology Unit, Didcot, Oxon. 
** This only applies to the experiments where the mice had been induced with a 
tumour (4.4.1) 
*** This may vary between experiments 
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5.4 i H NMR DETERMINATION OF THE RATE OF 
YTTRIUM UPTAKE BY (7) 
Spectra were recorded on a Varian 400 spectrometer at 293K. 
The pD was kept constant at 5.0 by a d3-sodivun acetate (0.14 M)-d4-
acetic acid (0.06 M) buffer i n D2O). Ligand and metal ion 
concentrations were both 0.028 M. 
Y t t r i u m ( I I I ) was added to the ligand i n solution as 
Y(N03)3.6D20, and the D2O salt obtained by adding D2O to 
Y(N03)3.6H20, evaporating and repeating this process twice. 
Reagents 
Y(N03)2.6H20 was obtained from Alfa; and used as recieved. 
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5.5 S T A B I L I T Y C O N S T A N T A N D P R O T O N A T I O N 
C O N S T A N T M E A S U R E M E N T S F O R T H E ONsCsMes 
C O M P L E X I N G A G E N T ( I ) 
Potentiometric titrations were carried out at 298 ± O.IK. The 
molarities of tetramethylammonium hydroxide (Sigma) t i t rant 
solutions were corrected for carbonate contamination by previous 
t i t rat ion against dilute hydrochloric acid (0.1 M , BDH). Ionic 
strength was kept constant wi th tetramethylammoniima nitrate (0.1 
M , Sigma). 
The t i trat ion system consisted of a double-walled glass cell 
thermostatted at 298( ±0.1)K containing the ligand solution coupled 
to a Mettler DV401 automatic burette containing the titrant. The pH 
was monitored with a Coming 001854 combination microelectrode. 
Titrations were controlled by a BBC microcomputer which also 
handled data storage. Data were transferred to an MTS mainframe 
computer by the program KERMIT and analysed using the program 
SUPERQUAD. 
194 
5.6 X-ray Crystal Structure Determination's) 
The X-ray crystal structure was determined by Professor George 
Ferguson (Department of Chemistry, University of Guelph, Ontario, 
Canada). The cell and intensity data were collected with an Enraf-
Nonius CAD-4 diffractometer using graphite monochromated Mo-K« 
radiation. All calculations were carried out on a PDP11-73 computer 
system using the SDP-Plus system of programs and data therein. 
The structures were solved by the heavy-atom method. Hydrogen 
atoms (visible in difference maps) were allowed for, and refinement 
was by full-matrix least squares calculations with all non-H atoms 
allowed ansiotropic motion. 
Additional material available from the Cambridge 
Crystallographic Data Centre comprises H-atom co-ordinates, 
thermal parameters and remianing bond length and angles. 
Cell data, experimental details, positional and thermal 
parameters and molecular dimensions for each structure are given in 
the Appendix. 
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5.7 D E T E R M I N A T I O N O F T H E BINDING 
CONSTANTS FOR THE SILVER(I) COMPLEXES 
5.7.1 pH - Metric titrations • Water. 
(i) Apparatus 
The titration cell was a double-walled glass vessel (capacity 5 
cm3) which was maintained at 25°C, using a Techne Tempette Junior 
TE-8J. Titration solutions were stirred using a magnetic stirrer and 
kept under an atmosphere of nitrogen. Titrations were 
performed using an automatic titrator (Mettler DL20,1 cm^ capacity) 
and burette functions (volume increments and equilibration time) 
were controlled by a BBC microprocessor. The pH was measured 
using a Corning 001854 combination microelectrode which was 
calibrated using buffer solutions at pH 4.008 (CO2H. C6H4CO2K, 
O.OSmol dm-3) and pH 6.865 (KH2PO4, 0.025mol dm-3-Na2HP04, 
0.025mol dm-3). Data was stored on the BBC microprocessor and 
transferred to the MTS mainframe using KERMIT and subsequently 
analysed by two non-linear least-squares programs SCOGS and 
SUPERQUAD. 
(ii) Acid-dissociation constants 
Stock solutions of the ligand (0.002mol dm-3) in Milli-Q water 
(25.0 cm3) with nitric acid (Imol equiv. per amine nitrogen of the 
ligand) and tetramethylammonium nitrate (/ = O.lOmol dm-3) were 
prepared. In each titration 3.5 cm3 of the stock ligand solution was 
titrated with tetramethylammonium hydroxide (0.109mol dm-3), the 
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exact molarity of which was determined by titration against 
hydrochloride acid, O.lOOmol dm-3. 
Methanol. Metal binding constants* Stock solutions were 
prepared as above with the addition of one eqviivalent of silver 
nitrate. Titrations were performed as beofre. 
Using the assumption that only 1:1 complex formation was 
occurring we have equations (1) and (2). 
C°Ag = [Ag+] + [AgL+] (1) 
C°L = [L] + [AgL+] (2) 
Here C°Ag was the initial concentration of silver ion and C ° L was 
the overall concentration of ligand in solution (free or complexed). 
Thus: 
Ks = 
C°Ag- [Agl C°Ag- [AQI 
= (3) 
[Agl (C°L-[AgLl) [Ag1(CVC°Ag + [AQ 1) 
Varying the initial silver ion concentration from 5 x 10"'^  to 5 x 
10-4 to 5 X 10-3 niol dm3 did not affect the calculated values. The 
enthalpies of complexation (Ai/) were measured by standard 
calorimetric methods using a Tronac 450 microcalorimeter. 
A solution of silver nitrate (l.Ommol, 20 cm )^ in methanol was 
titrated with a solution of the ligand in methanol (0.02mol dm^). The 
ionic strength was kept constant at / = 0.05 mol dm^ by addition of 
tetramethyl ammonium percholate. The concentration of free silver 
' These analyses by Dr H.J. Buschmann, Krefeld, Germany. 
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ion was measured using a silver ion selective electrode (Metrohm 
EA282) with a second silver electrode as a reference electrode. The 
emf observed coiild be used directly to determine the free silver ion 
concentration, according to the Nernst equation, which simplifies to 
equation (4), 
E = E 0 + AMAg*^] (4) 
where [Ag^] is the concentration of free silver ion and A is a constant 
which may be determined using appropriate cahbration solutions. 
The stability constant iTg which refers to the reaction, equation (5) 
Ag+ + L = AgL+ (5) 
is defined by equation (6) 
[AgLI 
Ks = 
[Ag1[L] 
Kg is the concentration stability constant, assuming that the 
activity coefficients of the three species are equal to unity. 
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UNIVERSITY OF D U R H A M 
Board of Studies i n Chemistry 
CO LLO QUIA, LECTURES A N D SEMINARS G I V E N BY I N V I T E D 
SPEAKERS 
A list of all the research collquia, lectures and seminars arranged by 
the Department of Chemistry dur ing the period of the author's 
residence as a postgraduate student is presented: "*" indicating the 
author's attendance. 
1st October to 31st July 1991 
6th October 1988 
18th October 1988 
18th October 1988 
18th October 1988 
21st October 1988 
27th October 1988 
9th November 1988 
Schmutzler, Professor R. (Technicsche 
Uniersitat Braunschweig) 
Fluorophosphines Revisited - New 
Contributions to an Old Theme * 
Bollen, Mr. F. (Durham Chemistry 
Teachers'Centre) 
Lecture about the use if SATIS in the 
classroom 
Dingwall , Dr. J. (Ciba Geigy) 
Phosporus-containing Amino Acids: 
Biologically Active Natural and Unnatural 
Products* 
Dingwall , Dr. C.J. Ludman (University of 
Durham) 
The Energetics of Explosives * 
von Rague Schleyer, Professor P. 
(Universitaty Erlangen Nurnberg) 
The Frui t fu l Interplay Between 
Calculational and Experimental Chemistry 
Rees, Professor C.W. (Imperial College, 
London) 
Some Very Heterocyclic Compounds * 
Singh, Dr. G. (Teesside Polytechnic) 
Towards Thi rd Generation A n t i -
Leukaemics* 
10th November 1988 Cadogan, Professor J. I . G. (British 
Petroleum) 
From Pure Science to Profit 
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16th November 1988 
24th November 1988 
1st December 1988 
7th December 1988 
9th December 1988 
14th December 1988 
26th January 1989 
1st February 1989 
2nd February 1989 
9th February 1989 
McLauchlan, Dr. K.A. (University of 
Oxford) 
The Effect of Magnetic Fields on Chemical 
Reactions 
Baldwin, Dr. R R. and Walker, Dr R.W. 
(University of Hul l ) 
Combustion: Some Burning Problems * 
Snaith, Dr. R. (University of Cambridge) 
Eyptian Mummies: What, Where, Why 
and How? 
Hardgrove, Dr. G. (St. Olaf College , USA) 
Polymers i n the Physical Chemistry 
Laboratory 
Jager, Dr. C. (Friedrich-Schiller University 
GDR) 
N M R Investigations of Fast Ion Conductors 
of the NASICON Type 
Mortimer, Dr. C. (Durham Chemistry 
Teachers' Centre) 
The Hindeberg Disaster - A n Excuse for 
Some Experiments 
Jennings, Professor R. R (University of 
Warwick) 
Chemistry of the Masses* 
Walters, Mr . D. and Cressey, T. (Durham 
University Teachers' Centre) 
GCSE Chemistry 1988: A Coroner's Report 
Hal l , Professor L. D. (Addenbrooke's 
Hospital, Cambridge) 
N M R - A Window to the Human Body* 
Baldwin, Professor J.E. (University of 
Oxford) 
Recent Advances i n Liv ing Metathesis* 
15th February 1989 Butler, Dr. A. R. (University of St. 
Andrews) 
Cancer in Linxiam: The Chemical 
Dimensions* 
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16th Febraury 1989 
22nd February 1989 
23rd February 1989 
1st March 1989 
9th March 1989 
14th March 1989 
15th March 1989 
20th A p r i l 1989 
27th A p r i l 1989 
3rd May 1989 
3rd May 1989 
10th May 1989 
11th May 1989 
Aylett, Professor B.J. (Queen Mary College, 
London) 
Silicon-Based Chips: The Chemist's 
Contr ibut ion 
MacDoughall, Dr. G. (University of 
Edinburgh) 
Vibrational Spectroscopy of Model Catalytic 
Systems 
Johnson, Dr. B.F.G.(Uruversity of 
Cambridge) 
The Binary Carbonyls 
Errington, Dr. R. J. (University of 
Newcastle-Upon-Tyne) 
Polymetalate Assembly i n Organic Solvents 
Marko, Dr. I . (University of Sheffield) 
Catalytic Asymmetric Osmylation of 
Olefins 
Revell, Mr . P. (Durham Chemistry 
Teachers' Centre) 
Implementing Broad and Balanced Science 
Aveyard, Dr. R. (University of Hul l ) 
Surfactants at your Surface 
Casey, Dr. M . (Uruversity of Salford) 
Sulphoxides i n Stereoselective Synthesis* 
Crich, Dr. D. (Uiuversity College London) 
Some Novel Uses of Free Radicals in 
Organic Synthesis) 
Ashman, Mr . A. (Durham Chemistry 
Teachers' Centre) 
The Chemical Aspects of the National 
Cur r i cu lum 
Page, Dr. P.C.B. (University of Liverpool) 
Stereocontrol of Organic Reactions Using 
1,3- dithiane - 1 - oxides * 
Wells, Professor P. B. (University of Hull) 
Catalyst Characteristics of Activi ty 
Frey, Dr. J. (University of Southampton) 
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Spectroscopy of the Reaction Path: 
Photodissociation Raman Spectra of NOCI 
16th May 1989 Stibr, Dr. R (Czechoslovak Academy of 
Sciences) 
Recent Developments i n the Chemistry of 
Intermediate-Sited Carboranes 
17th May 1989 Moody, Dr. C.J. (Imperial College London) 
Reactive Intermediates on Heterocyclic 
Synthesis * 
23rd May 1989 Paetzold, Professor P. (Aachen) 
Iminoboranes XB=NR: Inorganic 
Acetylenes? 
14th June 1989 Jones, Dr. M.E. (Durham Chemistry 
Teachers' Centre) 
Discussion Session on the National 
Cur r i cu lum 
15th June 1989 Pola, Professor J. (Czechoslovak Academy 
of Sciences) 
Carbon Dioxide Laser Induced Chemical 
Reactions - New Pathways in Gas-Phase 
Chemistry) 
28th June 1989 Jones.Dr. M.E. (Durham Chemistry 
Teachers' Centre) 
GCSE and A Level Chemistry 1989 
11th July 1989 Nicholls, Dr. D. (Durham Chemistry 
Teachers' Centre) 
Demo: Liquid A i r * 
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UNIVERSITY OF D U R H A M 
Board of Studies i n Chemistry 
COLLOQUIA, LECTURES A N D SEMINARS G I V E N BY INVITED 
SPEAKERS 
1st October 1989 to 31st July 1990 
17th October 1989 
25th October 1989 
1st November 1989 
9th November 1989 
10 November 1989 
13 November 1989 
16 November 1989 
29 November 1989 
30 November 1989 
Palmer, Dr. F . (University of Nottingham) 
Thunder and Lightning* 
Floriani, Prof. C. (University of Lausarme) 
Molecular Aggregates - A Bridge Between 
Homogeneous and Heterogeneous 
Systems 
Badyal, Dr. J. P. S. (University of 
Durham) 
Breakthroughs in Heterogeneous 
Catalysis 
Greenwood, Prof. N . N . (University of 
Leeds) 
Novel Cluster Geometries i n 
Metalloborane Chemistry* 
Bercaw, Prof. J. E. (California Institute of 
Technology) 
Synthetic and Mechanistic Approaches to 
Ziegler - Natta Polymerization of Olefins 
Becher, Dr. J. (University of Odense) 
Synthesis of New Macrocyclic Systems 
Using Heterocyclic Building Blocks* 
Parker, Dr. D. (University of Durham) 
Macr©cycles. Drugs and Rock 'n ' Roll* 
Cole-Hamilton, Prof. D. J. (University of St. 
Andrews) 
New Polymers f r o m Homogeneous 
Catalysis 
Hughes, Dr. M . N . (King's College, 
London) 
A Bug's Eye View of the Periodic Table 
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4th December 1989 
6th Decenber 1989 
Graham, Dr. D. (B. P. Research Centre) 
How Proteins Adsorb to Interfaces 
PoweU, Dr. R L. (ICT) 
The Development of C.F.C. Replacement 
7th December 1989 
13 December 1989 
15th December 1989 
24 January 1990 
31 January 1990 
1st February 1990 
7th February 1990 
8th February 1990 
Butler, Dr. A . (University of St. Andrews) 
The Discovery of Penicillin : Facts and 
Fancies* 
Klinowski, Dr. J. (University of Cambridge) 
Solid-state N M R Studies of Zeolite 
Catalysts 
Huisgen, Prof. R. (Universitat Miinchen) 
Recent Mechaiustic Studies of [2 + 2] 
Addi t ions 
Perutz, Dr. R. N . (University of York) 
Plotting the Course of C-H Activations w i t h 
Organometallics* 
Dyer, Dr. U . (Glaxo) 
Synthesis and Conformation of C-
Glycosides 
Holloway, Prof. J. H . (University of 
Leicester) 
Noble Gas Chemistry 
Thompson, Dr. D. P. (University of 
Newcastle upon Tyne) 
The Role of Nitrogen i n Extending Silicate 
Crystal Chemistry 
Lancaster, Rev. R. (Kimbolton Fireworks) 
Fireworks - Principles and Practice* 
12 February 1990 
14th February 1990 
15 February 1990 
Lunazzi, Prof. L. (University of Bologna) 
Application of Dynamic N M R to the Study 
of Conformational Enantiomerism* 
Sutton, Prof. D. (Simon Eraser University, 
Vancouver) 
Synthesis and Applications of Dinitrogen 
and Compounds of Rhenium and I r id ium 
Crombie, Prof. L. (University of 
Not t ingham) 
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The Chemistry of Cannabis and Khat 
21st February 1990 
22nd February 1990 
28th February 1990 
1st March 1990 
8th March 1990 
21st March 1990 
23 March 1990 
9th July 1990 
9th July 1990 
9th July 1990 
Bleasdale, Dr. C. (University of Newcastle 
upon Tyne) 
The Mode of Action of some A n t i -
Tumour Agents* 
Clark, Prof. D.T. (ICI Wilton) 
Spatially Resolved Chemistry (using 
Nature's 
Paradigm in the Advanced Materials 
Arena) 
Thomas, Dr. R. K. (University of Oxford) 
Neutron Reflectometry f r o m Surfaces 
Stoddart, Dr. J. F. (University of Sheffield) 
Molecular Lego 
Cheetham, Dr. A . K. (University of Oxford) 
Chemistry of Zeolite Cages 
Powis, Dr. I . (University of Nottingham) 
Spinning Off in a H u f f : Photodissociation 
of Methyl Iodide 
Bowman, Prof. J. M . (Emory University) 
Fitting Experiment w i t h Theory in A r - O H 
German, Prof. L. S. (Soviet Academy of 
Sciences) 
New Syntheses in Fluoroaliphatic 
Chemistry : 
Recent Advances i n the Chemistry of 
Fluorinated Oxiranes 
Platanov, Prof. V.E. (Soviet Academy of 
Sciences, Novosibirsk 
Polyfluoroindanes : Synthesis and 
Transformation 
Rozhkov, Prof. I . N . (Soviet Academy of 
Sciences, Moscow) 
Reactivity of Perfluoroalkyl Bromides 
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UNIVERSITY OF D U R H A M 
Board of Studies i n Chemistry 
C O L L O Q U I A , LECTURES A N D SEMINARS G I V E N BY I N V I T E D 
SPEAKERS 
1st August 1990 to 31st July 1991 
11th October 1990 
24th October 1990 
26th October 1990 
31st October 1990 
1st November 1990 
6th November 1990 
7th November 1990 
8th November 1990 
Macdonald, Dr. W.A. (ICI Wilton) 
Materials for the Space Age* 
Bochmaim, Dr. M . (University of East 
Anglia) 
Synthesis, Reactions and Catalytic Activity 
of Cationic Titanium Alkyls 
Soulen, Prof. R. (South Western 
University, Texas) 
Preparation and Reactions of 
Bicycloalkenes 
Jackson, Dr. RF.W. (University of 
Newcastle upon Tyne) 
New Synthetic Methods : a-Amino Acids 
and Small Rings * 
Logan, Dr. N . (University of Nottingham) 
Rocket Propellants 
Kocovsky, Dr. P. (University of Uppsala) 
Stereo-Controlled Reactions Mediated by 
Transition and Non-Transition Metals * 
Gerrard, Dr. D. (British Petroleum) 
Raman Spectroscopy for Industrial Analysis 
Scott, Dr. S.K. (University of Leeds) 
Clocks, Oscillations and Chaos* 
14th November 1990 
21st November 1990 
Bell, Prof. T. (SUNY, Stoney Brook, USA) 
Functional Molecular Architecture and 
Molecular Recognition 
Pritchard, Prof. J. (Queen Mary & Westfield 
College) 
Copper Surfaces and Catalysts* 
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28th November 1990 
29 November 1990 
5th December 1990 
13th December 1990 
15th January 1991 
17th January 1991 
24th January 1991 
30th January 1991 
31st January 1991 
6th February 1991 
14th February 1991 
20th February 1991 
28th February 1991 
Whitaker, Dr. B.J. (University of Leeds) 
Two-Dimensional Velocity Imaging of 
State-Selected Reaction Products 
Crout, Prof. D. (University of Warwick) 
Enzymes i n Organic Synthesis 
Pringle, Dr. P.G. (University of Bristol) 
Metal Complexes w i t h Functionalised 
Phosphines* 
Cowley, Prof. A . H . OUniversity of Texas) 
N e w Organometallic Routes to Electronic 
Materials 
Alder, Dr. B.J. (Lawrence Livermore Labs., 
California) 
Hydrogen in all its Glory 
Sarre, Dr. P. (University of Nottingham) 
Comet Chemistry 
Sadler, Dr. P.J. (Birkbeck College London) 
Design of Inorganic Drugs : Precious Metals, 
Hypertension & HTV 
Sinn, Prof. E. (University of Hul l ) 
Coupling of Little Electrons i n Big 
Molecules : Implications for the Active 
Sites of Metalloproteins and other 
Macromolecules 
Lacey, Dr. D. (Uruversity of Hul l ) 
Liquid Crystals 
Bushby, Dr. R. (University of Leeds) 
Biradicals and Orgaruc Magnets 
Petty, Dr. M.C. (Durham University) 
Molecular Electronics 
Shaw, Prof. B.L. (University of Leeds) 
Syntheses w i t h Coordinated, Unsaturated 
Phosphine Ligands* 
Brown, Dr. J. (University of Oxford) 
Can Chemistry Provide Catalysts Superior 
to Enzymes? 
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6th March 1991 
7th March 1991 
24th April 1991 
25th April 19921 
20th June 1991 
29th July 1991 
Dobson, Dr. C M . (University of Oxford) 
NMR Studies of Dynamics in Molecular 
Crystals 
Markam, Dr. J. (ICI Pharmaceuticals) 
DNA Fingerprinting 
Schrock, Prof. R.R. (M.I.T.) 
Metal-Ligand Multiple Bonds and 
Metathesis Initiators 
Hudlicky, Prof. T. (Virginia Polytechnic 
Institute) 
Biocatalysis and Symmetry Based 
Approaches to the Efficient Synthesis of 
Complex Natural Products 
Brookhart, Prof. M.S. (University of North 
Carolina) 
Olefin Polymerizations, Oligomerizations 
and Dimerizations Using Electrophilic Late 
Transition Metal Catalysts* 
Brimble, Dr. M.A. (Massey University, New 
Zealand) 
Synthetic Studies Towards the Antibiotic 
Griseusin-A* 
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R E S E A R C H C O N F E R E N C E S 
1. U.K. Macrocycle Group, Annual Meeting, University of Durham, 
19 April, 1989. 
2 R.S.C. Perkin Division, N.E. Regional Meeting, University of 
York, 16 December, 1989. 
3 RSC Graduate Symosium, University of Durham, 12 April 1989 
4 R.S.C Dalton and Industrial Division, Inorganics In Human 
Health, UCL, 1989. 
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CRYSTAL DATA 
213 
Space Group Cell Dimentions Orthorhombic P22i2i 
a 6.6785(21) b 15.551(3) 
Volume 1803.1(7)A**3 
17.361(3) 
Empirical Formula : C15H25.8OlnN3O6.9O 
Ci'sH25.80l"N3O6.Q0 or Ci5H24lnN3O6 0-9H2O 
Cell dimensions obtained from 25 reflections with 2 theta angle in 
the range 15.00-32.00 degrees. 
Crystal dimensions: 0.29 x 0.22 x 0.08 mm 
FW = 473.41 Z = 4 F(000) = 964 
Dcalc 1.744Mg.m"3. mu = 133mm"^ 
lambda = 0.70930°A. 2Theta(max) = 53.8° 
The inlemsity data was collected on a Nonius diffractometer, 
using the theta/2theta scan mode. 
the h,k,l ranges are: 0 8, 0 18, 0 22. 
No. of reflections measured 2267 
No. of unique reflections 2266 
No. of reflections with Inet > 5sigma(Inet) 1986 
Absorbtion corrections were made. 
The minimum and maximum transmission factors are 0.758165 and 0.896510. 
The last least squares cycle was calculated with 51 atoms, 245 parameters and 
1973 out of 1973 reflections. 
Weights based on counting statistics were used. 
The residuals are as follows: 
For significant reflections, RF 0.029, RW 0.025, GoF 2.28 
For all reflections, 
Where RF = sum(Fo-Fc)/sum(Fo), 
RW = sqrt [sum(w(Fo-Fc)**2)/(No. of reflns - No. of params.)! 
GoF = sqrt [sum(w(Fo-Fc)**2)/(No. of reflins - No. of params.)] 
The maximum shift/sigma ratio was 0.200. 
In the last D-map, the deepest hole was -0.44e/A**3, 
and the highest peak 0.380e/A**3 
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DEPOSITION DATA 90-39 
Table . C a l c u l a t e d hydrogen coordinates (C-H 0.95 A ) 
H2A .4344 .3543 .3587 
H2B .5244 .2934 .2970 
H3A .4379 .4142 .2326 
H3B .2291 .4168 .2716 
H5A .4195 .3100 .0921 
H5B .5192 .2827 .1690 
H6A .4442 .1588 .1081 
H6B .2295 . 1903 .0890 
H8A .4480 .0777 .2608 
H8B .5271 . 1695 .2436 
H9A .4586 . 1667 . 3706 
H9B .2491 .1267 .3562 
HIO . 1151 . 3339 .4058 
H l l C . 1757 . 2720 .5237 
HllA .2946 . 1991 .4833 
HUB . 3739 .2928 . 4810 
H13 . 1000 .3585 . 0868 
H14C . 1361 .5053 .0770 
H14A .2537 .5061 . 1540 
H14B . 3434 .4607 . 0823 
H16 . 1302 . 0376 .2285 
H17C . 1717 -.0443 . 1201 
H17A . 2780 .0325 . .0805 
H17B .3748 -.0111 . 1517 
DEPOSITION DATA 
T a b l e A n i s o t r o p i c t h e r m a l pa r ame te r s (x lO^) 90-39 
"22 "33 "12 "13 "23 
I n 1 . 9 7 1 15) 4 .418( 20) 2 .425 16) .147( 22) . 1 5 1 16) .041( 22) 
N l 2 . 4 2) 3 .7 { 3) 2 . 4 ( 2) - • 1 ( 3) .3 2) • 1 ( 3) 
02 3 . 1 4) 4 .3 ( 4) 3.5 { 4) - . 8 { 3) - • 1 ( 3) - 1 . 1 ( 3) 
C3 4 . 4 4) 3 .7 ( 3) 3.3 ( 4) . 0 ( 3) .8 ( 4) • 1 { 3) 
N4 2 . 8 ( 3) 3 . 1 { 3) 2 . 7 ( 3) - • 1 ( 3) •3 ( 3) - . 3 ( 2) 
C5 2 . 8 ( 3) 5 . 1 ( 4) 2 .7 ( 3) - • 1 ( 3) .8 ( 3) •2 ( 3) 
C6 3 . 1 ( 4) 4 . 2 ( 4) 2 . 0 ( 3) •5 ( 3) •3 { 3) - • 1 ( 3) 
N7 2 . 7 ( 3) 2 .9 ( 3) 2 .6 ( 3) .0 ( 3) - • 1 { 3) •2 ( 2) 
08 2 . 6 ( 3) 4 . 0 { 3) 4 . 1 { 4) •7 ( 2) - . 4 ( 3) - • 1 ( 3) 
09 2 . 8 ( 4) 4 . 4 ( 4) 2 .9 ( 4) - . 6 ( 3) - • 5 ( 3) •3 ( 3) 
010 3 .2 { 3) 6 .0 ( 5) 2 .5 ( 3) •5 ( 3) .2 ( 3) - 1 . 1 ( 3) 
O i l 5 .6 ( 4) 11 .9 ( 7) 3 .0 { 3) - . 2 ( 7) - . 4 ( 3). - 1 . 7 ( 5) 
012 3 .8 ( 3) 5.3 ( 5) 3 .4 ( 3) 1.2 ( 3) 1.2 ( 3) •3 ( 3) 
C13 4 . 5 ( 4) 4 . 0 ( 4) 3 . 1 ( 4) • 1 ( 3) - . 6 ( 3) • 1 ( 3) 
014 7 . 6 ( 6) 5 .7 ( 5) 6 .6 { 6) •2 ( 5) 1 .1 ( 6) 2 .8 { 5) 
015 4 . 2 ( 5) 4 .5 ( 4) 3 .4 { 4) 1.2 ( 4) - . 4 ( 4) - . 8 ( 3) 
016 4 . 7 ( 4) 3 .3 ( 4) 2 . 9 ( 3) - . 7 ( 3) •3 ( 3) •2 ( 3) 
017 7 .9 ( 6) 4 . 0 ( 4) 5.7 ( 5) .5 ( 5) - • 5 ( 5) - 2 . 0 ( 4) 
018 5 . 1 ( 5) 5.7 ( 5) 2 .4 ( 4) - 2 . 4 ( 4) - • 1 ( 4) .8 ( 3) 
O l 2 . 8 ( 2) 6 .8 ( 3) 2 .8 ( 2) - . 5 ( 2) .5 ( 2) •3 ( 2) 
02 5 .7 ( 3) 1 1 . 0 ( 5) 2 .9 ( 2) - . 6 ( 3) 1.7 { 2) - • 1 ( 3) 
03 3 . 2 ( 2) 5.3 ( 3) 4 .5 ( 3) 1.7 ( 2) . 4 ( 2) •4 ( 2) 
04 6 .5 ( 4) 5.9 { 4) 5.3 ( 4) 2 . 7 ( 3) . 1 ( 3) 1.1 ( 3) 
OS 2 . 6 ( 3) 5.3 ( 3) 3 .7 ( 3) - . 4 ( 2) - • 2 ( 2) - . 4 { 2) 
06 6 .9 ( 5) 6 .8 ( 4) 6 .8 ( 4) - 3 . 0 ( 3) - 1 . 1 ( 4) - • 2 ( 3) 
OWl 7 . 1 ( 7) 17 .9 ( 1 7 .9 ( 1 . 1 ) 4 . 6 ( 9) - 2 . 3 ( 9) - 4 . 0 ( 1 •5) 
OW2 1 7 . 2 (2 . 1 ) 32 .2 (9 . 1 ) 7 .9 ( 1 . 4 ) - 7 . 9 (3 . 8 ) - . 3 ( 3) 4 .6 (4 . 9 ) 
A n i s o t r o p i c t e m p e r a t u r e f a c t o r s a r e o f t h e f o r m : 
e x p [ - 2 n - ( h ^ U i i a * 2 + k^Uj^h'- + I - U 3 3 C * - + 2AAU,2a*b* + IhlU^^a-'c* + 2JtiU23b*c*) ] 
DEPOSITION DATA 
T o r s i o n a n g l e s f o r Ci5H24lnN305 x O.SHjO. 90-39 
N4 I n N l 02 7 . 6 ( 3) N4 I n N l 09 - 1 1 1 . 9 ( 4 
N4 I n N l CIO 1 3 0 . 4 ( 4) N7 I n N l 02 8 8 . 4 ( 3 
N7 I n N l 09 - 3 1 . 1 ( 3) N7 I n N l OlO - 1 4 8 . 7 ( 4 
O l I n N l 02 - 1 4 9 . 6 ( 4) O l I n N l 09 9 0 , 9 ( 3 
O l I n N l CIO - 2 6 . 8 ( 3) 03 I n N l 02 - 6 1 . 9 ( 3 
03 I n N l 09 1 7 8 . 6 ( 4) 03 I n N l OlO 6 0 . 9 ( 3 
05 I n N l 02 1 3 2 . 7 ( 4) 05 I n N l 09 13.3 ( 3 
05 I n N l CIO - 1 0 4 . 4 ( 3) N l I n N4 03 - 3 0 . 5 ( 3 
N l I n N4 05 89 .7 ( 3) N l I n N4 013 - 1 4 8 . 5 ( 4 
N7 I n N4 03 - 1 1 1 . 9 ( 4) N7 I n N4 05 8 . 3 ( 3 
N7 I n N4 013 1 3 0 . 1 ( 4) 0 1 I n N4 03 1 5 . 1 ( 3 
0 1 I n N4 C5 1 3 5 . 3 ( 4) 0 1 I n N4 013 - 1 0 2 . 9 { 4 
03 I n N4 C3 9 0 . 8 ( 4) 03 I n N4 05 - 1 4 9 . 0 ( 4 
03 I n N4 013 - 2 7 . 1 ( 3) 05 I n N4 03 1 7 8 . 9 ( 4 
05 I n N4 05 - 6 1 . 0 ( 3) 05 I n N4 013 60 .9 ( 3 
N l I n N7 C6 - 1 1 2 . 3 ( 4) N l I n N7 08 7 . 5 ( 3 
N l I n N7 016 1 2 9 . 5 ( 4) N4 I n N7 06 - 3 1 . 0 ( 3 
N4 I n N7 C8 8 8 . 9 ( 4) N4 I n N7 016 - 1 4 9 . 2 ( 4 
O l I n N7 06 1 7 7 . 6 ( 4) 0 1 I n N7 08 - 6 2 . 5 ( 3 
O l I n N7 016 5 9 . 5 ( 3) 03 I n N7 06 13 .2 ( 3 
03 I n N7 08 1 3 3 . 1 ( 4) 03 I n N7 016 - 1 0 5 . 0 ( 4 
05 I n N7 06 9 0 . 2 ( 4) 05 I n N7 C8 - 1 4 9 . 9 ( 4 
05 I n N7 016 - 2 8 . 0 ( 3) N l I n 0 1 012 1 7 . 0 ( 3 
N4 I n O l C12 - 2 9 . 0 ( 3) N7 I n 0 1 012 8 8 . 2 ( 4 
03 I n 0 1 012 - 1 0 0 . 1 ( 4) 05 I n 0 1 012 1 6 5 . 5 ( 4 
N l I n 03 C15 8 9 . 7 ( 4) N4 I n 03 015 18 . 7 ( 4 
N7 I n 03 015 - 2 6 . 0 ( 4) 0 1 I n 03 015 1 6 7 . 8 ( 5 
05 I n 03 015 - 9 8 . 1 { 4) N l I n 05 018 - 2 2 . 8 ( 4 
N4 I n 05 018 9 2 . 7 ( 4) N7 I n 05 018 2 2 . 1 ( 4 
0 1 I n 05 C18 - 9 5 . 9 ( 4) 03 I n 05 018 1 7 0 . 2 ( 5 
I n N l 02 03 1 7 . 3 ( 3) 09 N l 02 03 1 3 1 . 0 ( 6 
CIO N l 02 C3 - 1 0 0 . 6 ( 5) I n N l 09 08 5 1 . 9 ( 3 
C2 N l 09 08 - 6 6 . 0 ( 5) CIO N l 09 08 1 6 4 . 8 ( 7 
I n N l CIO O i l 1 6 2 . 5 ( 5) I n N l OlO 012 3 3 . 1 ( 3 
C2 N l CIO O i l - 7 7 . 1 ( 5) 02 N l CIO C12 1 5 3 . 5 ( 6 
C9 N l CIO o i l 5 1 . 3 ( 4) 09 N l 010 012 - 7 8 . 1 ( 5 
N l 02 C3 N4 - 4 8 . 2 ( 4) 02 03 N4 I n 5 1 . 0 ( 3 
C2 C3 N4 05 - 6 7 . 9 ( 5) C2 03 N4 013 1 6 5 . 0 ( 7 
I n N4 05 06 1 6 . 7 ( 3) 03 N4 05 06 1 3 1 . 1 ( 6 
C13 N4 05 06 - 1 0 1 . 8 ( 6) I n N4 013 014 1 6 0 . 6 ( 6 
I n N4 013 C15 3 2 . 3 { 3) 03 N4 013 C14 4 8 . 8 ( 5 
C3 N4 013 C15 - 7 9 . 6 ( 5) 05 N4 013 014 - 7 8 . 5 ( 6 
05 N4 C13 C15 153 .1 ( 7) N4 05 C6 N7 - 4 8 . 2 ( 4 
C5 C6 N7 I n 5 1 . 8 ( 3) 05 06 N7 08 - 6 5 . 0 ( 5 
C5 06 N7 016 1 6 4 . 7 ( 7) I n N7 08 C9 1 8 . 4 ( 3 
06 N7 C8 C9 1 3 1 . 7 ( 6) C16 N7 08 C9 - 9 8 . 5 ( 6 
I n N7 C16 C17 1 6 1 . 6 ( 6) I n N7 016 018 3 1 . 2 ( 3 
C6 N7 C16 C17 5 0 . 4 { 5) 06 N7 016 C18 - 8 0 . 1 ( 5 
C8 N7 C16 017 - 7 9 . 6 ( 6) C8 N7 C16 018 1 4 9 . 9 ( 7 
N7 C8 C9 N l - 4 9 . 8 ( 4) N l CIO 012 O l - 2 2 . 9 ( 3 
N l CIO C12 02 1 5 9 . 2 ( 7) C l l CIO C12 0 1 - 1 5 2 . 7 ( 7 
O i l CIO C12 02 2 9 . 4 { 4) CIO 012 O l I n - 2 . 4 ( 2 
02 C12 0 1 I n 1 7 5 . 4 ( 6) N4 C13 015 03 - 2 0 . 3 ( 3 
N4 C13 C15 04 162 .0 ( 5) 014 013 015 03 - 1 5 0 . 5 ( 9 
C14 C13 C15 04 3 1 . 8 ( 5) 013 015 03 I n - 5 . 1 ( 3 
04 CIS 03 I n 1 7 2 . 4 ( 7) N7 016 018 05 - 1 6 . 6 ( 3 
N7 C16 C18 06 1 6 5 . 1 ( 9) 017 016 018 05 - 1 4 7 . 2 ( 9 
017 C16 018 06 3 4 . 5 ( 5)" 016 018 05 I n - 1 0 . 2 ( 3 
06 CIS 05 I n 1 6 7 . 9 ( 7) 
lOFo , lOFc , l O S i g ( F o ) f o r 0,5H24lnN306 x O.SHjO 90-39 Page 1 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 
0 , 0 , 1 6 406 411 3 6 1073 1124 5 2 177 206 5 
2 3054 3191 15 7 202 196 4 7 337 327 4 3 103 99 8 
4 272 291 3 8 926 919 5 8 962 955 5 4 244 258 5 
6 112 101 6 10 730 728 4 9 419 427 4 6 307 317 5 
8 1565 1603 7 11 171 163 7 10 932 924 4 7 255 253 5 
10 1262 1229 6 12 738 728 4 11 180 182 7 8 474 474 4 
12 1095 1087 5 14 273 267 6 12 805 806 4 9 263 269 6 
14 786 787 5 16 439 436 6 13 155 153 9 10 439 453 5 
16 371 364 6 18 547 550 6 14 466 474 5 11 153 165 8 
18 381 388 6 20 433 441 7 15 163 180 9 12 316 303 6 
20 191 179 10 0 , 4 , 1 18 255 265 8 13 204 203 7 
22 172 143 11 0 1971 1983 5 20 202 205 10 14 202 199 8 
0 , 1 , 1 1 511 506 2 0 , 7, 1 15 170 161 9 
2 412 407 2 2 145 184 5 1 128 144 5 16 299 291 7 
3 77 8 1 5 4 659 689 3 2 473 454 3 17 138 141 12 
4 1208 1192 5 5 95 93 6 4 271 263 4 18 247 255 9 
6 244 233 3 6 1044 1054 5 5 174 171 5 0, 10 , 1 
8 853 849 4 7 188 198 4 6 427 443 4 0 1011 998 5 
10 675 678 4 8 1439 1412 7 7 353 356 4 1 252 259 5 
11 102 109 10 9 591 575 4 8 268 271 5 2 942 970 5 
12 762 770 4 10 821 813 4 9 288 287 5 3 467 468 4 
13 151 162 8 11 295 303 5 10 314 316 5 4 925 942 5 
14 164 149 8 12 623 636 4 12 529 530 5 5 587 572 4 
16 441 432 6 13 164 179 9 13 192 207 8 6 670 653 4 
18 597 606 6 14 494 477 5 14 394 397 6 7 265 259 5 
20 456 463 7 16 217 224 8 15 178 193 9 8 380 373 5 
22 343 344 8 18 302 291 7 16 377 376 6 9 153 114 8 
0 , 2 , 1 20 174 175 11 17 205 225 9 10 315 318 6 
0 2689 2736 13 0 , 5, 1 18 321 321 7 12 478 480 5 
1 215 215 2 3 111 113 5 19 153 143 12 13 221 192 7 
2 1755 1780 4 4 177 189 4 20 314 298 8 14 352 355 6 
4 1824 1840 5 5 178 156 4 0 , 8, 1 15 210 218 8 
5 149 143 5 6 273 243 4 0 1183 1177 6 16 204 204 8 
6 1097 1102 6 7 158 151 5 1 288 308 4 17 146 125 12 
7 183 170 4 8 354 357 4 2 1002 1018 5 18 149 159 13 
8 635 645 3 9 428 432 4 3 350 350 4 0 , 1 1 , 1 
9 185 184 5 10 580 578 4 4 1078 1097 6 1 95 94 11 
10 9-45 949 4 11 187 172 6 5 491 500 4 2 88 58 12 
11 196 211 6 12 739 737 4 6 1087 1144 6 4 321 331 5 
12 927 952 5 14 348 363 6 7 233 222 5 5 180 197 7 
13 159 176 8 16 492 482 6 8 1010 1009 5 6 545 562 4 
14 772 764 5 17 216 246 8 9 216 235 6 7 218 215 7 
16 193 191 8 18 454 452 6 10 678 685 4 8 292 281 6 
18 363 360 6 19 202 207 9 11 150 156 9 12 185 178 8 
20 200 189 9 20 401 395 7 12 501 507 5 14 284 281 7 
22 139 145 14 0 , 6, 1 13 160 162 9 15 159 167 11 
0 , 3 , 1 0 737 782 4 14 340 360 6 16 288 291 8 
1 258 248 2 1 548 544 3 16 264 270 7 17 171 162 10 
2 1545 1495 5 2 753 789 4 18 258 261 8 18 203 207 10 
3 129 142 5 3 311 309 3 20 206 190 10 0 , 12 , 1 
4 90 85 7 4 1357 1356 6 0 , 9, 1 0 698 686 4 
5 73 63 8 5 418 424 3 1 172 173 5 1 559 538 4 
l O F o , lOFc , l O S i g ( F o ) f o r Ci5H24lnN306 x O.9H2O 90-39 Page 2 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 
0 , 12 , 1 13 175 190 11 1 , 1 , 1 15 134 151 11 
2 702 696 4 14 132 137 14 1 1082 1083 4 16 474 484 6 
3 457 455 5 0 , 16 , 1 2 356 344 2 18 483 492 6 
4 462 476 5 0 176 165 8 3 260 248 3 20 339 349 7 
5 311 306 5 1 123 113 11 4 1099 1088 5 1 , 4 , 1 
6 239 223 6 2 267 263 7 6 772 762 4 0 1672 1701 5 
7 173 151 8 3 236 229 7 7 280 274 4 1 387 385 3 
8 187 172 7 4 345 330 6 8 457 453 3 2 1466 1448 6 
9 198 176 7 5. 303 284 7 10 461 475 4 3 238 254 3 
10 318 305 6 6 305 285 7 12 636 630 4 4 1478 1485 6 
1 1 249 261 7 7 247 246 8 13 237 213 6 5 120 119 6 
12 389 391 6 8 250 254 8 14 541 545 5 6 1644 1632 7 
13 298 293 7 9 201 187 9 15 204 214 8 7 171 185 5 
14 283 284 7 10 206 213 9 16 587 598 5 8 1149 1170 6 
15 217 231 9 11 171 173 10 17 296 303 7 9 199 197 6 
16 156 168 12 12 155 154 12 18 562 562 6 10 879 900 4 
17 154 143 12 0 , 17 , 1 20 361 348 7 11 335 333 5 
0 , 13 , 1 8 136 131 12 1 , 2 , 1 12 741 734 4 
1 108 80 11 11 111 114 16 0 1547 1533 4 13 205 213 8 
2 160 167 8 0 , 18 , 1 1 160 139 4 14 659 665 5 
3 167 166 8 0 160 158 11 2 1137 1160 5 15 202 216 8 
8 143 145 10 1 229 205 9 4 1963 1966 6 16 379 374 6 
9 111 62 11 2 184 182 10 5 82 77 8 18 359 359 7 
10 251 245 7 3 176 158 10 6 1590 1604 7 20 264 249 8 
11 124 114 12 4 188 194 10 7 309 306 4 1 , 5, 1 
12 210 200 8 5 178 170 10 8 1059 1053 5 0 397 382 3 
13 174 153 9 6 162 181 11 9 83 89 10 1 106 99 6 
14 225 215 9 7 215 214 9 10 757 768 4 2 173 172 4 
15 142- 124 13 8 173 169 11 11 351 351 5 3 239 225 3 
16 223 247 10 9 171 173 12 12 867 867 4 4 192 198 4 
0 , 14 , 1 1 , 0 , 1 13 177 178 8 5 381 370 3 
0 415 414 5 0 2482 2523 12 14 622 621 5 6 372 366 3 
1 312 311 6 1 102 57 4 16 285 277 6 7 143 141 6 
2 356 359 6 2 1624 1620 5 18 291 284 7 8 530 518 4 
3 316 295 6 3 187 198 4 20 236 234 9 9 202 177 6 
4 271 266 6 4 778 791 4 21 114 126 16 10 545 546 4 
5 310 302 6 5 468 459 3 1 , 3, 1 11 176 196 8 
6 300 282 6 6 1097 1133 6 0 410 390 2 12 477 481 5 
7 289 290 6 7 370 380 3 1 312 308 3 13 243 247 7 
8 339 327 6 8 891 899 4 2 951 940 5 14 402 391 5 
9 259 264 7 9 112 136 8 3 86 90 7 16 441 431 6 
10 292 284 7 10 934 961 5 4 246 243 3 17 156 146 10 
11 221 227 a 11 124 136 9 5 310 287 3 18 424 430 6 
12 244 264 8 12 806 802 4 6 832 827 4 19 129 153 14 
13 171 168 10 13 363 366 5 7 144 125 5 20 318 319 8 
14 205 212 10 14 597 602 5 8 773 764 4 1 , 6, 1 
0 , 15, 1 15 122 134 13 9 199 206 5 0 1679 1672 6 
7 142 151 10 16 179 157 8 10 577 565 4 1 860 845 4 
8 140 145 11 18 246 225 7 11 188 179 7 2 1275 1271 6 
9 153 138 10 19 191 212 9 12 537 533 5 3 323 315 3 
10 164 173 10 20 197 183 9 13 222 231 7 4 914 981 5 
11 172 150 10 2 1 119 147 16 14 355 373 6 5 272 266 4 
l O F o , lOFc , l O S i g ( F o ) f o r Oi5H24lnN306 x O.9H2O 90-39 Page 3 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc s i g 
1 , 6, 1 18 245 229 8 11 177 179 8 11 171 169 10 
6 876 896 4 19 145 127 12 12 271 261 7 12 200 192 9 
7 183 185 6 1 , 9 , 1 13 183 179 9 13 104 118 16 
8 896 904 4 0 289 293 4 14 319 310 7 14 141 142 13 
9 318 321 5 1 202 208 5 15 124 120 12 15 137 116 13 
10 714 733 4 2 147 170 6 16 296 285 ,8 1 , 15 , 1 
11 265 252 6 3 181 189 6 17 218 200 9 0 128 151 10 
12 691 699 4 4 162 191 7 18 211 212 11 1 127 147 11 
13 229 228 7 5 207 200 6 1 , 12, 1 6 93 97 15 
14 520 539 5 6 194 192 6 0 612 610 4 8 140 118 10 
15 138 144 11 7 221 220 6 1 375 380 5 9 168 141 9 
16 328 331 6 8 345 345 5 2 591 616 4 10 157 163 11 
17 101 101 15 9 268 283 6 3 233 232 7 11 184 178 10 
18 285 275 7 10 500 503 5 4 555 547 5 13 157 158 12 
20 198 193 10 11 231 251 7 5 192 189 7 1 , 16, 1 
1 , 7 , 1 12 426 419 5 6 495 479 5 0 172 155 9 
0 433 430 3 13 242 259 7 7 250 249 7 1 255 272 7 
1 320 315 3 14 323 315 6 8 452 438 5 2 245 235 7 
3 246 242 4 15 111 69 13 9 329 332 6 3 301 310 7 
4 189 177 5 16 335 333 7 10 401 406 6 4 281 287 7 
5 119 109 7 17 128 120 13 11 225 220 7 5 314 314 7 
6 230 258 5 18 328 312 8 12 355 358 6 6 257 234 7 
7 279 294 5 19 164 145 12 13 165 163 10 7 254 249 7 
8 316 331 5 1 , 10 , 1 14 236 235 8 8 212 195 8 
9 470 472 4 0 773 763 4 15 127 143 14 9 168 168 11 
10 484 466 5 1 423 432 4 16 205 189 10 10 171 168 10 
11 321 310 6 2 795 773 4 1 , 13 , 1 12 123 122 15 
12 523 518 5 3 337 336 5 0 96 101 13 1 , 17, 1 
13 176 172 8 4 734 737 4 1 148 140 9 5 102 86 14 
14 389 403 6 5 387 394 5 2 260 285 6 10 113 104 15 
16 440 431 6 6 717 726 4 3 190 191 8 1 , 18 , 1 
17 111 99 13 7 472 481 5 4 224 230 7 0 179 165 10 
18 377 363 7 8 541 547 5 5 109 112 11 1 244 246 8 
19 130 123 13 9 344 353 5 10 146 134 10 2 182 180 10 
20 298 288 8 10 407 398 5 11 169 147 9 3 218 219 9 
i , 8, 1 11 246 245 7 12 214 195 8 4 151 158 12 
0 1081 1095 5 12 338 332 6 13 146 166 11 5 214 187 9 
1 617 620 3 13 174 172 9 14 219 219 9 7 170 165 11 
2 910 921 5 14 329 328 7 15 142 133 13 8 142 128 12 
3 406 408 4 16 260 263 8 16 208 200 10 2 , 0 , 1 
4 774 784 4 18 204 204 10 1 , 14 , 1 0 73 102 8 
5 398 414 4 1 , 1 1 , 1 0 372 364 5 1 156 148 5 
6 890 867 4 1 230 230 6 1 330 326 6 2 1343 1349 6 
7 317 318 5 2 285 310 5 2 384 382 5 3 555 536 3 
8 749 738 4 3 192 167 7 3 294 294 6 4 1633 1643 7 
9 394 406 5 4 337 344 5 4 350 347 6 5 576 542 3 
10 520 515 5 5 135 138 9 5 265 275 6 6 1735 1708 7 
11 309 309 6 6 244 260 6 6 378 373 6 7 148 136 6 
12 426 424 5 7 275 270 6 7 316 323 6 8 1002 1027 5 
13 183 167 8 8 143 160 9 8 382 395 6 10 926 913 4 
14 365 375 6 9 124 141 11 9 283 293 7 12 801 791 4 
16 330 355 7 10 187 176 8 10 292 313 7 14 449 449 5 
l O F o , l O F c , l O S i g ( F o ) f o r C,5H24lnN306 x 0.9H2O 90-39 Page 4 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 
2 , 0 , 1 3 744 718 4 14 468 478 5 4 822 822 4 
15 241 257 7 4 561 540 3 15 262 266 7 5 368 376 4 
16 325 322 7 5 598 568 3 16 406 415 6 6 852 850 4 
17 165 177 10 6 622 627 3 17 160 157 11 7 306 299 5 
18 287 262 7 7 612 590 3 18 415 416 7 8 648 631 4 
19 177 179 10 8 283 289 5 20 324 325 8 9 292 283 6 
20 257 249 8 9 214 220 6 2 , 6, 1 10 520 506 5 
2 1 131 131 15 10 573 580 4 0 1519 1500 7 11 290 306 6 
2 , 1 , 1 11 355 365 5 1 337 342 3 12 460 459 6 
0 181 181 4 12 478 482 5 2 1383 1386 6 13 200 203 8 
1 851 811 4 13 260 239 6 3 254 263 4 14 359 362 6 
2 234 245 4 14 498 514 5 4 746 745 4 16 299 297 7 
3 372 373 3 15 156 151 10 5 194 191 5 17 155 126 11 
4 519 509 3 16 457 464 6 6 848 860 4 18 219 202 9 
5 738 716 4 17 140 142 11 7 233 235 5 19 152 129 12 
6 311 323 4 18 445 433 6 8 785 777 4 2 , 9 , 1 
7 772 748 4 20 340 344 8 9 253 251 6 1 156 164 6 
8 183 159 6 21 136 141 14 10 590 595 4 2 202 226 6 
9 126 110 8 2 , 4 , 1 11 273 259 6 3 105 126 10 
10 536 540 . 4 0 896 910 5 12 446 447 5 4 146 151 7 
12 645 642 4 1 132 134 5 13 142 141 10 5 138 129 8 
13 108 128 12 2 1554 1553 6 14 410 407 6 6 254 263 6 
14 720 740 5 3 395 383 3 16 352 360 6 7 180 176 7 
15 214 204 8 4 1560 1542 7 18 279 268 8 8 219 212 7 
16 493 511 6 5 673 659 3 19 175 169 11 9 196 212 7 
17 185 189 9 6 1314 1270 7 20 168 192 13 10 327 322 6 
18 374 364 7 7 348 347 4 2 , 7 , 1 11 254 254 7 
20 271 270 9 8 681 660 4 1 607 597 3 12 326 320 6 
2 , 2 , 1 10 604 603 4 2 697 685 3 13 181 175 9 
0 1484 1478 6 11 90 92 14 3 114 95 7 14 328 334 7 
1 286 290 3 12 605 593 5 4 509 502 4 15 149 141 11 
2 1390 1434 6 13 246 242 7 5 198 188 5 16 310 316 7 
3 413 407 3 14 490 492 5 6 265 253 5 17 130 152 14 
4 954 901 5 15 294 321 7 7 224 220 6 18 329 318 8 
5 370 360 3 16 418 422 6 8 158 179 8 2 , 10 , 1 
6 1675 1573 7 17 160 136 9 9 281 279 5 0 431 440 4 
7 337 325 4 18 368 361 7 10 384 382 5 1 389 397 5 
8 1302 1299 6 20 241 237 9 11 237 229 7 2 541 557 4 
9 231 231 5 2 , 5, 1 12 332 335 6 3 310 309 5 
10 800 788 4 0 458 451 3 13 114 108 12 4 655 650 4 
11 293 294 5 1 786 766 4 14 365 378 6 5 359 352 5 
12 544 548 5 2 321 313 3 15 118 116 13 . 6 821 806 4 
13 191 196 8 3 900 885 4 16 419 416 6 7 364 376 5 
14 466 474 5 4 716 705 4 17 142 158 12 8 671 683 5 
15 290 286 7 5 595 575 3 18 392 375 7 9 266 274 6 
16 453 462 6 6 780 767 4 19 122 102 15 10 471 481 5 
18 343 332 7 7 325 310 4 20 280 269 8 11 247 246 7 
20 255 228 8 8 289 296 5 2 , 8, 1 12 287 301 7 
2 , 3 , 1 10 338 352 5 0 745 746 4 13 259 251 7 
0 491 479 3 11 308 302 5 1 308 313 4 14 306 292 7 
1 510 501 3 12 351 358 6 2 869 877 4 15 161 148 10 
2 483 480 3 13 287 311 6 3 336 335 4 16 258 255 9 
l O F o , lOFc , l O S i g ( F o ) f o r Oi5H24lnN30|5 x O.9H2O 90-39 Page 5 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc s i g 1 kFo Fc S i g 
2 , 10 , 1 0 291 279 6 5 188 181 11 8 1032 1038 5 
18 185 180 11 1 327 326 6 6 147 131 13 9 223 232 7 
2 , 1 1 , 1 2 346 347 6 7 140 151 15 10 720 731 4 
0 83 86 14 3 242 238 7 3, 0 , 1 11 265 266 6 
1 251 228 6 4 402 396 6 0 359 400 3 12 489 477 5 
2 194 192 7 5 224 228 8 2 1031 1024 5 13 345 345 6 
3 149 127 9 6 338 333 6 3 313 294 4 14 378 380 6 
5 149 144 9 7 230 224 7 4 1424 1456 7 15 271 284 7 
7 167 167 9 8 235 227 8 5 168 159 6 16 467 490 6 
8 228 223 7 9 172 193 10 6 1193 1207 6 18 269 272 8 
9 266 265 6 10 177 173 10 7 121 105 9 20 121 126 15 
10 332 333 6 11 151 168 11 8 996 999 5 3, 3, 1 
11 274 288 7 12 140 128 12 9 158 172 8 0 120 82 6 
12 290 288 7 13 166 168 11 10 704 711 4 1 487 498 3 
13 178 203 9 14 129 148 15 11 368 378 5 2 640 633 3 
14 309 307 7 2 , 15 , 1 12 643 643 5 3 565 565 3 
15 181 171 10 1 171 182 9 13 329 338 6 4 450 456 3 
16 272 263 8 2 105 100 13 14 408 406 6 5 432 417 4 
17 193 186 11 3 124 138 11 15 204 205 9 6 288 302 5 
2 , 12, 1 4 156 165 10 16 466 489 6 7 451 470 4 
0 474 448 5 5 119 106 11 18 291 288 8 8 324 325 5 
1 351 342 5 6 126 150 12 19 173 159 11 9 369 369 5 
2 509 489 5 7 118 98 12 20 222 210 10 10 536 544 5 
3 271 266 6 8 184 171 9 3, 1 , 1 11 386 389 5 
4 457 459 5 9 178 165 9 0 221 222 4 12 438 426 5 
5 293 303 6 10 145 153 12 1 266 278 4 13 124 139 12 
6 524 543 5 11 131 142 14 2 216 223 4 14 406 424 6 
7 332 338 6 12 101 95 17 3 537 554 3 15 210 207 8 
8 469 474 5 2 , 16 , 1 4 265 260 4 16 422 415 6 
9 281 289 6 0 239 244 8 5 655 653 4 18 356 372 7 
10 388 378 6 1 283 308 7 6 294 306 5 19 185 185 11 
11 228 226 7 2 258 252 7 7 868 852 4 20 359 368 8 
12 272 264 7 3 265 264 7 8 369 352 5 3, 4 , 1 
13 177 181 10 4 265 264 7 9 506 511 4 0 874 896 4 
14 226 201 8 5 220 215 8 10 563 562 5 1 382 377 3 
16 152 144 12 6 227 232 8 11 397 379 5 2 1121 1135 6 
2 , 13, 1 7 166 167 10 12 451 442 5 3 543 533 3 
1 89 95 14 8 157 149 11 14 415 426 6 4 1085 1097 6 
3 182 169 8 9 138 120 11 15 275 268 7 5 623 621 4 
4 115 139 12 10 115 103 14 16 360 366 7 6 859 858 4 
5 261 278 6 11 126 114 15 17 235 251 8 7 380 389 5 
6 163 178 9 12 128 106 14 18 347 328 7 8 695 688 4 
7 248 250 7 2 , 17 , 1 19 166 176 11 10 511 528 5 
8 163 163 9 2 94 104 15 20 402 390 7 12 481 473 5 
9 205 220 8 4 121 123 13 3 , 2 , 1 13 282 289 7 
10 149 140 10 7 104 131 17 0 1227 1220 6 14 323 316 7 
11 204 177 8 2 , 18 , 1 1 480 477 3 15 336 334 6 
12 245 230 7 0 187 172 10 2 1316 1317 6 16 320 335 7 
13 144 143 12 1 232 221 8 3 107 113 7 17 152 166 11 
14 247 246 9 2 211 186 9 4 698 717 4 18 173 173 11 
15 157 138 11 3 205 208 10 6 987 1008 5 19 129 136 15 
2 , 14 , 1 4 186 176 10 7 307 290 5 3, 5, 1 
l O F o , lOFc , l O S i g ( F o ) f o r C,5H24lnN306 x O.9H2O 90-39 Page 6 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc s i g 1 kFo Fc s i g 1 kFo Fc S i g 1 kFo Fc S i g 
3 , 5, 1 11 226 222 7 4 559 554 5 5 280 290 7 
0 238 223 4 12 335 316 6 5 256 241 6 6 173 175 9 
1 524 508 3 13 190 166 8 6 459 452 5 7 213 238 8 
2 202 200 5 14 398 404 6 7 235 234 7 8 225 233 8 
3 654 639 3 15 293 290 7 8 410 419 6 9 169 167 9 
4 383 379 4 16 375 365 7 10 389 406 6 10 203 214 9 
5 419 413 4 17 200 210 10 11 178 190 9 11 166 165 10 
6 533 513 4 18 265 244 9 12 351 361 6 12 190 174 10 
7 262 254 5 3 , 8, 1 13 244 236 8 14 180 142 11 
8 336 342 5 0 .762 768 4 14 269 286 8 3, 14, 1 
9 201 178 7 1 220 218 6 15 203 199 10 0 366 362 6 
10 340 318 5 2 844 850 4 16 165 153 12 1 307 305 6 
11 243 247 7 3 214 223 6 17 157 156 13 2 345 349 6 
12 436 429 5 4 826 818 4 3 , 1 1 , 1 3 290 290 7 
14 498 503 6 5 287 289 5 0 120 120 10 4 368 363 6 
15 228 239 8 6 654 653 4 1 151 139 9 5 257 270 7 
16 431 416 6 7 380 372 5 2 175 180 8 6 282 273 7 
17 214 220 9 8 491 489 5 3 190 201 8 7 220 211 8 
18 276 266 9 9 110 107 12 4 193 195 7 8 228 210 8 
19 160 171 .12 10 499 496 5 5 358 360 6 9 184 176 9 
3 , 6, 1 11 159 141 9 6 168 169 9 10 201 192 9 
0 1022 1031 5 12 488 503 6 7 329 327 6 11 248 243 8 
1 436 427 4 13 222 220 8 8 289 293 6 12 224 211 9 
2 1031 1047 5 14 394 408 6 9 194 188 8 13 205 205 10 
3 522 518 4 15 245 241 8 10 317 334 7 3, 15, 1 
4 859 878 4 16 265 256 8 11 216 204 8 0 117 111 13 
5 433 433 4 17 182 173 11 12 250 256 8 1 203 211 9 
6 807 816 4 18 174 179 12 13 222 214 8 2 108 99 13 
7 434. 445 4 3, 9 , 1 14 169 167 11 3 121 115 12 
8 718 710 4 1 257 260 6 15 196 207 11 7 115 133 13 
9 223 234 7 2 246 268 6 16 167 160 11 8 151 134 11 
10 582 581 5 3 393 385 5 3 , 12 1, 1 10 129 145 14 
11 196 216 8 4 312 309 5 0 479 492 5 11 135 108 13 
12 476 478 5 5 387 374 5 1 289 288 6 12 138 127 14 
13 160 160 10 6 328 323 5 2 382 380 5 3, 16, . 1 
14 332 323 6 7 305 319 6 3 374 375 6 0 339 338 6 
15 183 167 9 8 278 271 6 4 320 308 6 1 200 218 9 
16 251 241 8 9 343 357 6 5 362 375 6 2 251 245 7 
17 225 231 9 10 185 164 8 6 297 302 6 3 165 176 10 
18 166 168 12 11 349 351 6 7 339 355 6 4 190 175 9 
19 225 244 10 12 230 215 8 8 323 338 6 5 188 177 9 
3 , 7 , 1 13 206 200 9 9 235 208 7 6 227 221 9 
1 344 356 4 14 271 266 8 10 311 313 7 7 176 164 10 
2 316 325 5 15 227 229 9 11 196 183 9 8 235 250 9 
3 404 403 4 16 275 260 8 12 251 237 8 9 114 140 17 
4 347 341 5 17 178 183 11 13 180 183 10 10 188 172 11 
5 440 457 4 18 247 242 10 14 187 182 10 3, 17, 1 
6 260 257 6 3, 10 , 1 15 144 153 14 2 132 120 12 
7 498 499 4 0 503 488 5 3 , 13 , 1 3 145 142 12 
8 229 219 6 1 295 308 5 2 154 178 9 4 106 125 16 
9 234 241 7 2 491 484 5 3 191 210 8 5 153 132 12 
10 270 256 6 3 293 283 5 4 174 157 8 3, 18, 1 
l O F o , l O F c , l O S i g ( F o ) f o r 0,5H24lnN306 x O.9H2O 90-39 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
Page 7 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 
3 , 18 , 1 10 486 480 5 2 188 182 7 16 253 259 9 
1 142 141 13 12 497 502 6 3 476 471 4 17 191 196 11 
2 131 129 13 13 242 243 8 5 478 479 4 4 , 8, 1 
3 149 118 12 14 384 374 7 6 125 119 10 0 703 720 4 
4 , 0 , 1 15 237 244 8 7 407 408 5 1 298 305 6 
0 353 333 4 16 363 354 7 8 391 405 5 2 593 588 4 
1 99 87 9 17 233 257 10 9 490 485 5 3 157 156 8 
2 810 821 4 18 166 189 13 10 464 461 5 4 479 470 5 
3 199 217 6 19 201 212 11 11 326 328 6 5 150 145 9 
4 1041 1039 5 4 , 3 , 1 12 423 410 6 6 289 293 6 
6 874 892 5 0 189 201 6 13 268 263 7 7 308 314 6 
7 310 308 6 1 631 634 4 14 380 376 6 8 369 365 6 
8 554 557 5 2 246 248 5 15 266 277 8 9 250 227 7 
9 483 486 5 3 638 649 4 16 323 313 7 10 371 380 6 
10 381 380 6 4 264 265 5 17 201 201 10 11 261 264 7 
11 261 267 7 5 500 512 4 18 237 213 10 12 370 365 6 
12 351 353 6 6 361 363 5 4 , 6, 1 13 286 288 7 
13 186 199 9 7 269 272 6 0 785 786 4 14 283 294 8 
14 347 348 7 8 336 332 6 1 99 83 11 15 246 250 9 
16 356 366 7 9 499 501 5 2 753 747 4 16 172 184 12 
17 239 237 9 10 307 316 6 3 227 238 6 17 137 139 15 
18 235 224 9 11 425 437 6 4 712 723 4 4 , 9 , 1 
19 278 273 9 12 323 331 7 5 278 273 6 0 141 132 9 
4 , 1 , 1 13 321 335 7 6 556 548 5 1 527 535 5 
1 688 704 4 14 377 372 6 7 359 359 5 2 126 111 10 
2 160 163 7 15 247 250 8 8 573 583 5 3 445 449 5 
3 661 659 4 16 369 375 7 9 262 256 7 4 157 173 9 
4 195 168 6 18 285 267 9 10 584 572 5 5 279 278 6 
5 556 565 4 4 , 4 , 1 11 219 217 8 6 173 174 9 
6 451 438 5 0 1024 1024 5 12 500 482 6 7 192 198 8 
7 377 392 5 1 124 134 9 13 215 211 8 8 280 298 7 
8 416 425 5 2 1007 1006 5 14 269 276 8 9 271 274 7 
9 577 596 5 3 246 255 5 15 200 202 9 10 271 263 7 
10 248 265 7 4 796 786 4 16 143 139 14 11 283 288 7 
11 361 378 6 5 290 284 5 17 157 165 13 12 210 194 8 
12 209 214 8 6 650 656 4 4 , 7 , 1 13 198 185 9 
13 250 238 7 7 326 336 5 0 241 255 6 14 138 132 12 
14 344 363 7 8 690 684 4 1 302 290 5 15 139 148 14 
15 224 243 9 9 178 179 8 2 251 255 6 16 171 186 12 
16 373 371 7 10 650 655 5 3 552 559 4 4 , 10 , 1 
17 166 156 11 11 128 135 12 4 255 246 6 0 612 637 5 
18 262 253 9 12 539 525 5 5 595 598 5 1 364 370 6 
4 , 2 , 1 13 255 250 8 6 276 268 6 2 464 484 5 
0 785 785 4 14 383 355 6 7 370 355 5 3 260 281 6 
2 918 925 5 15 218 216 9 8 427 426 5 4 327 330 6 
3 196 175 6 16 246 249 9 9 251 247 7 5 182 179 8 
4 1068 1056 5 17 202 198 10 10 379 386 6 6 257 261 7 
5 254 257 5 18 115 103 17 11 263 258 7 7 213 206 8 
6 674 692 4 19 176 177 12 12 323 332 7 8 355 352 6 
7 447 442 5 4 , 5, 1 13 281 295 7 9 183 173 9 
8 601 580 5 0 447 456 4 14 258 259 8 10 351 338 6 
9 297 311 6 1 436 455 4 15 285 292 8 11 246 240 8 
lOFo, lOFc, lOSig(Fo) f o r 0,5H24lnN306 x O.9H2O 90-39 Page 8 
Columns are lOFo lOFc lOSig, * f o r I n s i g n i f i c a n t 
. 1 kFo Fc s i g 1 kFo Fc S i g 1 kFo Fc s i g 1 kFo Fc S i g 
4 , 10 , 1 3 232 222 8 6 159 147 10 4 465 469 5 
12 251 264 8 4 274 254 7 7 179 164 9 5 300 319 6 
13 225 218 9 5 222 231 8 8 252 269 7 6 425 421 5 
14 197 215 11 6 215 219 9 9 458 453 6 7 210 211 7 
15 211 189 9 7 207 222 9 10 299 309 7 8 507 505 5 
16 189 166 11 8 201 189 10 11 363 351 6 9 360 356 6 
4 , 1 1 , 1 9 132 140 14 12 280 300 8 10 474 485 6 
1 236 244 7 10 194 185 10 13 363 355 7 11 282 271 7 
3 317 323 6 11 128 147 15 14 357 338 7 12 311 298 7 
4 169 163 9 4 , 15 , 1 15 230 232 9 13 249 227 8 
5 325 340 6 0 169 170 10 16 235 220 9 14 222 215 9 
6 129 142 12 1 181 192 9 17 141 149 14 15 137 154 14 
7 217 229 8 2 168 166 9 5, 2 , I 16 223 210 10 
8 222 207 8 3 116 120 13 0 597 598 4 17 190 190 11 
9 179 169 9 4 158 147 11 2 719 732 4 5, 5, 1 
10 235 232 8 5 130 124 13 3 186 183 7 0 155 154 8 
11 195 200 9 6 102 117 17 4 714 698 4 1 371 371 5 
12 189 190 10 7 171 186 11 5 258 254 6 2 241 246 6 
13 143 162 .13 8 121 116 15 6 573 568 5 3 393 392 5 
4 , 12 , 1 9 173 190 11 7 474 473 5 4 207 197 7 
0 486 486 5 4 , 16 , 1 8 430 418 6 5 466 463 5 
1 239 243 7 0 213 230 9 9 241 246 7 6 110 117 13 
2 397 373 6 1 178 157 10 10 464 463 6 7 484 488 5 
3 212 223 8 2 161 157 11 12 320 332 7 8 196 211 8 
4 327 325 6 3 146 144 12 13 275 274 7 9 609 621 5 
5 266 269 7 5 148 178 13 14 272 275 8 10 305 303 7 
6 311 300 6 6 130 106 13 15 261 250 9 11 362 372 6 
7 310 311 7 7 195 205 10 16 268 250 8 12 261 277 8 
8 346, 342 6 4 , 17 , 1 17 198 200 12 13 286 274 7 
9 179 170 9 2 106 113 17 5, 3 , 1 14 254 261 8 
10 273 262 7 5, 0 , 1 0 120 130 10 15 207 221 11 
11 121 105 13 0 693 695 4 1 680 685 4 16 228 223 10 
12 197 191 10 2 680 696 4 2 228 231 6 17 148 145 14 
14 184 182 11 3 245 268 7 3 608 620 4 5, 6, 1 
4 , 13 , 1 4 721 710 4 4 256 247 6 0 402 394 5 
0 109 102 13 5 115 125 13 5 419 430 5 1 183 191 8 
1 2-24 235 8 6 603 612 5 6 174 177 8 2 489 483 5 
2 148 151 10 7 448 453 6 7 227 210 7 3 325 338 6 
3 211 207 8 8 537 541 5 8 183 180 8 4 507 523 5 
4 166 180 10 9 358 382 6 9 573 578 5 5 241 257 7 
5 205 204 8 10 439 429 6 10 290 276 7 6 516 525 5 
6 160 154 10 12 311 286 7 11 457 471 6 7 274 280 7 
7 217 225 8 13 221 210 8 12 317 333 7 8 479 469 5 
8 199 201 9 14 261 249 8 13 380 385 7 9 341 342 6 
9 243 242 8 15 217 209 9 14 366 371 7 10 360 364 6 
10 196 200 10 16 293 279 8 15 231 229 9 11 230 236 8 
11 197 219 10 17 225 210 10 16 258 254 9 12 235 235 8 
12 168 150 12 5, 1 , 1 17 148 150 14 13 188 205 10 
4 , 14, 1 1 863 878 4 5, 4 , 1 14 195 189 10 
0 314 305 7 2 106 98 12 0 740 747 4 15 150 152 13 
1 208 202 8 3 776 773 4 2 622 629 4 16 180 187 12 
2 264 261 7 5 545 532 5 3 130 129 10 5, 7, 1 
l O F o , l O F c , l O S i g ( F o ) f o r Oi5H24lnN305 x O.9H2O 90-39 Page 9 
Columns a r e lOFo lOFc l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo Fc s i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 
5, 7, 1 1 284 297 7 9 151 172 13 5 207 215 8 
0 120 130 11 2 402 393 6 10 156 136 12 6 443 444 6 
1 336 322 6 3 319 334 6 5, 14 , 1 7 230 240 8 
3 460 466 5 4 301 296 7 0 180 197 11 8 386 384 6 
4 194 201 8 5 264 272 7 1 136 117 12 9 228 221 8 
5 437 446 5 6 295 291 7 2 201 195 9 10 348 343 7 
6 233 243 7 7 226 211 8 4 192 181 10 11 229 218 9 
7 308 326 6 8 338 341 7 5 153 140 12 12 229 218 9 
8 263 256 7 9 191 186 9 6 157 154 12 13 278 277 9 
9 398 409 6 10 296 292 7 5, 15 , 1 14 207 183 10 
10 221 218 8 11 174 178 11 0 108 95 14 15 225 226 11 
11 283 300 8 12 203 206 10 3 116 127 16 6, 3 , 1 
12 184 164 9 13 164 167 12 4 153 119 12 0 140 145 10 
13 222 237 9 14 174 160 12 5 143 136 14 1 645 626 5 
14 200 184 10 5, 1 1 , 1 6 127 141 16 2 121 111 11 
15 202 200 10 0 229 243 8 5, 16 , 1 3 560 548 5 
16 202 206 11 1 362 365 6 0 124 120 14 4 158 155 9 
5, 8, 1 2 193 191 9 6, 0 , 1 5 401 394 6 
0 384 380 5 3 363 386 6 0 404 416 5 6 126 127 12 
1 242 254 7 4 176 164 9 2 431 425 5 7 406 398 6 
2 444 440 5 5 318 316 7 4 460 440 6 8 162 148 11 
3 252 244 6 6 153 153 10 6 494 499 6 9 507 511 6 
4 452 449 5 7 250 247 8 7 289 283 7 10 181 174 10 
5 145 149 11 8 165 169 11 8 429 436 6 11 378 372 7 
6 425 419 6 9 229 228 9 9 272 275 8 12 193 204 10 
7 181 184 9 10 179 177 11 10 397 384 7 13 233 235 9 
8 400 406 6 11 191 180 10 11 192 184 10 14 240 250 10 
9 225 235 8 12 181 169 11 12 201 194 10 15 230 237 10 
10 334 343 7 13 164 168 13 13 230 242 10 6, 4 , 1 
11 232 225 8 5, 12 , 1 14 195 184 11 0 449 446 5 
12 255 251 8 0 233 212 8 15 279 262 9 1 205 205 8 
13 182 177 11 1 192 213 9 6, 1 , 1 2 464 455 5 
14 190 184 11 2 281 271 7 1 686 683 5 4 426 403 6 
15 141 155 15 3 230 229 8 3 640 647 5 6 389 376 6 
5, 9 , 1 4 311 321 7 4 105 107 14 7 191 186 9 
0 335 343 6 5 221 217 8 5 452 456 6 8 290 276 7 
1 572 588 5 6 283 274 7 6 157 136 10 9 290 287 7 
2 267 270 7 7 188 180 9 7 358 351 6 10 286 271 7 
3 369 376 6 8 207 172 9 8 250 259 8 11 267 235 8 
4 186 171 8 9 124 147 14 9 477 478 6 12 206 191 10 
5 .234 235 7 10 134 128 14 10 274 282 8 13 215 212 10 
6 135 127 11 11 165 153 11 11 413 406 7 14 222 198 10 
7 284 282 7 5, 13 , 1 12 215 203 9 15 216 202 11 
8 185 171 9 0 153 126 10 13 290 307 9 6, 5, 1 
9 307 322 7 1 257 260 8 14 218 225 10 0 158 177 9 
10 190 202 10 2 104 122 15 15 249 239 10 1 373 367 6 
11 216 203 9 3 173 184 10 6, 2 , 1 2 157 170 9 
12 179 176 10 4 112 116 14 0 429 424 5 3 472 479 5 
13 203 190 10 5 170 152 10 1 93 122 15 4 192 184 8 
14 230 197 9 6 176 168 10 2 422 419 5 5 507 520 5 
5, 10 , 1 7 193 188 10 3 148 168 10 6 138 133 11 
0 460 470 6 8 180 176 11 4 442 453 5 7 490 483 6 
l O F o , l O F c , l O S i g ( F o ) f o r Ci5H24lnN306 x O.SHoO 90-39 Page 10 
Columns a r e l O F o l O F c l O S i g , * f o r I n s i g n i f i c a n t 
1 kFo F c S i g 1 kFo F c S i g 1 kFo F c S i g 1 kFo F c S i g 
6, 5, 1 6, 9, 1 7, 0, 1 6 179 171 10 
8 112 110 15 0 213 218 8 0 472 491 6 7 198 193 10 
9 449 439 6 1 382 364 6 2 387 386 6 8 207 201 10 
10 151 136 12 2 184 186 9 4 350 342 7 9 182 180 11 
11 269 257 8 3 386 392 6 5 149 139 12 10 235 237 11 
12 180 166 11 4 183 188 10 6 227 231 9 11 163 154 14 
13 206 193 11 5 357 353 6 7 182 184 11 7, 5, 1 
14 204 191 10 6 159 162 10 8 208 208 10 0 229 253 8 
6, 6, 1 7 343 331 7 9 176 173 12 1 475 465 6 
0 293 286 6 8 142 144 13 10 205 203 11 2 179 198 10 
1 312 315 6 9 281 283 8 11 135 167 17 3 545 551 6 
2 380 380 6 10 158 141 12 12 177 175 13 5 477 477 6 
3 201 196 8 11 235 219 9 7, 1, 1 7 367 363 7 
4 462 470 6 12 231 214 10 1 398 387 6 8 181 185 12 
5 138 136 11 6, 10, 1 3 507 499 6 9 246 238 9 
6 431 437 6 0 250 233 7 5 503 510 6 10 176 161 12 
7 211 207 8 2 257 246 7 6 129 124 14 11 213 222 11 
8 265 249 7 4 225 204 8 7 546 540 6 7, 6, 1 
9 255 258 8 5 140 164 12 8 203 182 9 0 184 195 10 
10 142 138 12 6 205 201 10 9 443 430 7 2 205 194 9 
11 168 173 12 7 165 169 11 10 145 134 14 3 146 172 12 
12 171 144 11 8 179 190 11 11 351 361 9 4 228 220 8 
13 210 209 10 9 193 200 11 7, 2, 1 5 199 193 9 
14 226 220 11 10 188 194 11 0 415 419 6 6 210 214 9 
6, 7, 1 11 161 139 12 1 98 113 15 7 156 149 12 
0 144 139 10 6, 11, 1 2 332 321 7 8 225 192 9 
1 385 367 6 0 160 156 10 3 107 122 15 9 158 144 12 
2 147 139 10 1 262 271 8 4 292 281 7 10 177 167 12 
3 478' 483 6 2 154 155 11 5 124 101 12 7, 7, 1 
4 185 186 9 3 300 305 7 6 222 204 8 0 204 196 9 
5 441 438 6 4 162 150 12 8 203 213 10 1 447 437 6 
6 209 223 9 5 284 268 8 9 187 186 11 2 187 171 9 
7 387 394 6 6 153 149 12 10 249 259 10 3 459 449 7 
8 181 177 9 7 250 241 9 11 224 228 10 4 134 127 13 
9 364 373 7 9 236 223 9 12 228 215 10 5 379 380 7 
11 268 263 8 6, 12, 1 7, 3, 1 7 341 345 8 
12 144 131 14 0 144 104 12 0 155 153 10 8 210 213 10 
13 190 176 11 2 173 171 11 1 461 466 6 9 273 274 9 
6, 8, 1 3 115 133 16 2 109 86 13 7, 8, 1 
0 229 209 8 4 212 216 9 3 490 493 6 0 262 256 8 
1 165 196 10 5 139 126 13 5 479 465 6 2 221 216 9 
2 306 312 7 6 238 225 9 7 472 482 6 3 169 170 11 
3 230 242 8 7 104 88 17 8 132 145 14 4 190 192 10 
4 377 367 6 8 199 177 . 11 9 374 364 7 5 172 165 11 
5 192 208 9 6, 13, 1 11 251 269 10 6 183 198 11 
6 336 339 7 1 224 221 9 12 162 172 15 7 115 121 17 
7 159 148 10 3 207 211 10 7, 4, 1 8 239 221 9 
8 239 246 a 4 161 151 8 0 291 287 7 7, 9, 1 
9 194 201 10 5 199 184 10 2 238 226 8 1 275 235 8 
10 201 204 10 6, 14, 1 3 107 119 15 2 107 128 16 
11 141 143 13 0 144 152 14 4 238 220 8 3 342 348 7 
12 217 177 10 1 157 146 11 5 203 198 9 4 127 135 15 
lOFo, lOFc, l O S i g ( F o ) for C,5H24lnN306 x O.SHjO 90-39 Page 11 
Columns are lOFo lOFc lOSig, * for I n s i g n i f i c a n t 
1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 1 kFo Fc S i g 
7, 9, 1 8, 0, 1 0 271 280 8 4 188 172 11 
5 336 349 8 0 313 332 8 2 214 216 10 5 132 146 15 
6 147 139 13 2 238 235 9 4 158 148 12 6 147 165 14 
7 325 304 8 4 146 141 14 8, 3, 1 8, 5, 1 
7, 10, 1 8, 1, 1 1 430 428 7 1 472 462 7 
0 205 210 10 1 456 438 7 3 406 403 7 3 359 376 8 
2 226 223 9 3 426 437 7 4 176 172 12 4 155 137 12 
3 124 124 15 4 124 113 15 5 409 407 7 5 307 302 9 
4 190 203 11 5 425 432 8 6 169 167 13 8, 6, 1 
7, 11, 1 6 133 136 15 8, 4, 1 0 106 121 17 
1 206 197 10 7 410 416 8 0 173 168 11 2 127 110 15 
2 118 116 16 8, 2, 1 2 149 148 13 3 131 151 16 
T a b l e F i n a l A t o m i c C o o r d i n a t e s (xlO"*, x l O ^ f o r I n ) and 
8iso (-^  ) w i t h e . s . d . ' s i n p a r a n t h e s e s . 
X y z 8iso 
I n .02357 ( 4) .24234 2) .24128 2) 2.32( 1 
N l .2560 ( 6) .2538 [ 3) .3352 2) 2.2 ( 2 
C2 .4055 (1 0 ) .3208 4) .3143 4) 2,9 ( 3 
C3 .3293 ( 9) .3803 3) .2506 4) 3.0 ( 3 
N4 .2424 ( 9) .3326 3) .1844 3) 2.3 ( 2 
C5 .3979 (10) .2829 4) .1404 3) 2 . 8 ( 3 
C6 .3327 [10) .1905 4) .1267 3) 2.4 ( 3 
N7 .2561 ( 8 ) .1476 3) .1977 3) 2.1 ( 2 
C8 .4130 ( 8 ) .1368 3) .2581 4) 2.8 ( 3 
C9 .3460 10) .1660 4) .3372 3) 2.6 ( 3 
CIO .1413 8 ) .2738 4) .4072 3) 3.1 ( 3 
C l l .2571 (10) .2580 6) .4806 3) 5.4 ( 4 
C12 -.0663 9) .2297 4) .4061 3) 3.3 ( 3 
C13 .1216 10) .3898 4) .1330 4) 3.1 ( 3 
C14 .2232 (14) .4733 5) .1094 5) 5.2 ( 4 
C15 -.0894 12) .4056 5) .1677 4) 3.2 ( 3 
C16 .1428 10) .0666 4) .1806 3) 2.9 ( 3 
C17 .2519 (13) .0053 5) .1284 5) 4.6 ( 4 
C I S -.0712 (13) .0859 5) . 1550 4) 3.5 ( 3 
O l -.1403 ( 6) .2093 3) .3403 2) 3.2 ( 2 
0 2 -.1518 ( 7) .2189 3) .4671 2) 5.1 ( 3 
03 -.1515 ( 6) .3510 3) .2182 2) 3.4 ( 2 
04 -.1889 ( 9) .4658 3) . 1449 3) 4.6 ( 3 
OS -.1428 ( 7) .1617 3) .1689 [ 2) 3.1 ( 2 
06 -.1628 ( 9) .0279 4) .1246 ( 4) 5.4 ( 3 
o w l .6084 (21) .0378 9) -.0069 10) 8 . 7 ( 1 .0 
0W2 .6840 (31) .4704 46) .0005 [48) 1 5 . 1 ( 3 .9 
o c c . 
0.5 
0.4 
i s t h e mean o f t h e p r i n c i p a l a x e s o f t h e t h e r m a l e l l i p s o i d . 
Table Bond lengths (A) 
I n - N ( l ) 2 .258 (4) C(10) - C ( l l ) 1.512( 8) 
In-N(4) 2 .254 (5) C(10) -C(12) 1.547( 8) 
In-N(7) 2 .270(5) C(12) -0(1) 1.286( 7) 
I n - O ( l ) 2 .101(4) C(12) -0(2) 1.215( 7) 
In-0(3) 2 .094(4) C(13) -C(14) 1.522(11) 
In-0(5) 2 .094(4) C(13) -C(15) 1.552(10) 
N ( l ) - C ( 2 ) 1 .489(8) C(15) -0(3) 1.288( 9) 
N ( l ) - C ( 9 ) 1 .491(8) C(15) -0(4) 1.214( 9) 
N ( l ) - C ( I O ) 1 .498(7) C(16) -C(17) 1.503(11) 
C(2)-C(3) 1 .528(9) C(16) -C(18) 1.526(11) 
C(3)-N(4) 1 .486(8) C(18) -0(5) 1.296(10) 
N(4)-C(5) 1 .504(8) C(18) -0(6) 1.211( 9) 
N(4)-C(13) 1 .496(8) 0(4) . ..0W(2)(i) 2.65(8) 
C(5)-C(6) 1 .520(9) 0(4) . ..0W(2)(ii) 2.84(6) 
C(6)-N(7) 1 .491(8) 0(6) . ..0W(1)(i) 2.752(17) 
N(7)-C(8) 1 492 (8) 0(6) . . . O W ( i ) ( i i i ) 2.749(17) 
N(7)-C(16) 1 499(8) 0W(1) -OW(l)(iv) 1.20(3) 
C(8)-C(9) 1 514(10) 0W(2) -0W(2) (V) 0.92(14) 
Symmetry codes: 
( i ) x-1, y, z 
( i i ) x-1, -y+1, -z 
( i i i ) x-1, -y, -z 
( i v ) X, -y, -z 
(V) X, -y+1, -z 
Table Bond angles (°) 
N ( l ) - I n - N ( 4 ) 79. 7 (2) C(5)-C(6)-N(7) 113. 0 (5) 
N ( l ) - I n - N ( 7 ) 79. 7 (2) In-N(7)-C(6) 102. 7 (3) 
N ( l ) - l n - O ( l ) 77. 7 (1) In-N(7)-C(8) 108. 6 (4) 
N ( l ) - I n - 0 ( 3 ) 117. 3 (2) In-N(7)-C(16) 105. 4 [4) 
N ( l ) - I n - 0 ( 5 ) 147. 7 (2) C(6)-N(7)-C(8) 113. 0 [5) 
N(4)-In-N(7) 79. 3 [2) C(6)-N(7)-C(16) 112. 7 [5) 
N(4)-In-0(1) 148. 0 [2) C(8)-N(7)-C(16) 113. 5 [4) 
N(4)-In-0(3) 77. 0 [2) N(7)-C(8)-C(9) 113 . 4 [5) 
N(4)-In-0(5) 117. 0 [2) N ( l ) - C ( 9 ) - C ( 8 ) 111. 9 [5) 
N ( 7 ) - l n - O ( l ) 118. 1 [2) N ( l ) - C ( 1 0 ) - C ( l l ) 114. 1 [5) 
N(7)-In-0(3) 147. 3 [2) N ( l ) - C ( I O ) - C ( 1 2 ) 110. 9 [4) 
N(7)-In-0(5) 77. 0 [2) C ( l l ) - C ( I O ) - C ( 1 2 ) 113. 3 [5) 
0 ( 1 ) - I n - 0 ( 3 ) 93 . 6 [2) C(10)-C(12)-0(1) 117. 7 [5) 
0 ( 1 ) - I n - 0 ( 5 ) 93 . 9 [2) C(10)-C(12)-O(2) 118. 2 [5) 
0 ( 3 ) - I n - 0 ( 5 ) 94 . 1 [2) 0 ( 1 ) - C ( 1 2 ) - 0 ( 2 ) 124. 1 [6) 
I n - N ( l ) - C ( 2 ) 109. 9 f3) N(4)-C(13)-C(14) 115. 4 ;6) 
In-N(l)-C(9T 102. 8 [3) N(4)-C(13)-C(15) 110. 6 [5) 
I n - N ( l ) - C ( I O ) 105. 5 [3) C(14)-C(13)-C(15) 112. 0 [6) 
C ( 2 ) - N ( l ) - C ( 9 ) 112. 1 J4) C(13)-C(15)-0(3) 116. 9 [6) 
C ( 2 ) - N ( l ) - C ( I O ) 113 . 6 [5) C(13)-C(15)-0(4) 119. 4 [7) 
C ( 9 ) - N ( l ) - C ( I O ) 112 . 2 [4) 0 ( 3 ) - C ( 1 5 ) - 0 ( 4 ) 123 . 6 [7) 
N ( l ) - C ( 2 ) - C ( 3 ) 112. 1 [5) N(7) -C(16)-C(17) 114. 1 [6) 
C(2)-C(3)-N(4) 112 . 8 [4) N(7)-C(16)-C(18) 111. 4 (5) 
In-N(4)-C(3) 103 . 0 (4) C(17)-C(16)-C(18) 113 . 8 (6) 
In-N(4)-C(5) 110. 5 (3) C(16)-C(18)-0(5) 118. 0 (6) 
In-N(4)-C(13) 106 . 4 [4) C(16)-C(18)-0(6) 117. 0 (7) 
C(3)-N(4)-C(5) 112. 3 [5) 0 ( 5 ) - C ( 1 8 ) - 0 ( 6 ) 125. 0 (8) 
C(3)-N(4)-C(13) 112 . 0 (4) In-0(1)-C(12) 117. 8 (4) 
C(5)-N(4)-C(13) 112 . 0 (5) In-0(3)-C(15) 118 . 8 (4) 
N(4)-C(5)-C(6) 111. 6 (5) In-0(5)-C(18) 117. 5 (5) 
Table Bond angles (°). 
N ( l ) - I n - N (4] 79 72(18) C(5)-C(6)-N(7) 113. 0(5) 
N ( l ) - I n - N (7] 79 74(18) In-N(7)-C(6) 102. 7(3) 
N ( l ) - I n - 0 (1] 77. 70(15) In-N(7)-C(8) 108. 6(4) 
N ( l ) - I n - 0 (3) 117. 31(18) In-N(7)-C(16) 105. 4 (4) 
N ( l ) - I n - 0 (5) 147. 70(18) C(6)-N(7)-C(8) 113 . 0(5) 
N(4)-In-N (7) 79. 31(18) C(6)-N(7)-C(16) 112. 7(5) 
N(4)-In-0 (1) 148. 03(17) C(8)-N(7)-C(16) 113. 5(4) 
N(4)-In-0 [3) 77. 03(18) N(7)-C(8)-C(9) 113. 4 (5) 
N(4)-In-0 [5) 116. 98(18) N ( l ) - C ( 9 ) - C ( 8 ) 111. 9 (5) 
N(7)-In-0 [1) 118. 05(17) N ( l ) - C ( 1 0 ) - C ( l l ) 114. 1(5) 
N(7)-In-0 '3) 147. 31(17) N(l)-C(10)-C(12) 110. 9 (4) 
N(7) -In-0< '5) 76. 95(19) C ( l l ) - C ( I O ) - C ( 1 2 ) 113. 3(5) 
0 ( 1 ) - I n - 0 ( 3) 93 . 64(17) C(10)-C(12)-0(1) 117. 7(5) 
0 ( 1 ) - I n - 0 ( 5) 93 . 90(17) C(10)-C(12)-0(2) 118. 2(5) 
0 ( 3 ) - I n - 0 ( 5) 94 . 11(18) 0(1)-C(12)-0(2) 124. 1(6) 
I n - N ( l ) - C ( 2) 109 . 9(3) N(4)-C(13)-C(14) 115. 4(6) 
I n - N ( l ) - C ( 9) 102. 8(3) N(4)-C(13)-C(15) 110. 6(5) 
I n - N ( l ) - C ( 10) 105. 5(3) C(14)-C(13)-C(15) 112 . 0(6) 
C ( 2 ) - N ( l ) -•c( 9) 112. 1(4) C(13)-C(15)-0(3) 116. 9(6) 
C ( 2 ) - N ( l ) -•c( 10) 113 . 6(5) C(13)-C(15)-0(4) 119. 4(7) 
C ( 9 ) - N ( l ) -•c( 10) 112 . 2(4) 0(3)-C(15)-0(4) 123. 6(7) 
N ( l ) - C ( 2 ) -•c( 3) 112 . 1(5) N(7)-C(16)-C(17) 114. 1(6) 
C ( 2 ) - C ( 3 ) --N( 4) 112 . 8(4) N(7)-C(16)-C(18) 111. 4(5) 
In-N(4)-C(3) 103 . 0(4) C(17)-C(16)-C(18) 113. 8(6) 
In-N(4)-C(5) 110. 5(3) C(16)-C(18)-0(5) 118. 0(6) 
In-N(4)-C(13 ) 106. 4(4) C(16)-C(18)-0(6) 117. 0(7) 
C(3)-N(4)- C( 5) 112 . 3(5) 0(5)-C(18)-0(6) 125. 0(8) 
C(3)-N(4)- C( 13) 112 . 0(4) I n - O ( l ) - C ( 1 2 ) 117. 8(4) 
C(5)-N(4)- C( 13) 112. 0(5) In-0(3)-C(15) 118. 8(4) 
N(4)-C(5)- C( 6) 111. 6(5) In-0(5)-C(18) 117. 5(5) 
